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Background: Pain affects most people approaching the end of life and can be severe for some.
Opioid analgesia is effective, but evidence is needed about how best to support patients in managing
these medicines.
Objectives: To develop a self-management support toolkit (SMST) and delivery strategy and to test the
feasibility of evaluating this intervention in a future definitive trial.
Design: Phase I – evidence synthesis and qualitative interviews with patients and carers. Phase II –
qualitative semistructured focus groups and interviews with patients, carers and specialist palliative
care health professionals. Phase III – multicentre mixed-methods single-arm pre–post observational
feasibility study.
Participants: Phase I – six patients and carers. Phase II – 15 patients, four carers and 19 professionals.
Phase III – 19 patients recruited to intervention that experienced pain, living at home and were treated
with strong opioid analgesia. Process evaluation interviews with 13 patients, seven carers and
11 study nurses.
Intervention: Self-Management of Analgesia and Related Treatments at the end of life (SMART)
intervention comprising a SMST and a four-step educational delivery approach by clinical nurse specialists
in palliative care over 6 weeks.
Main outcome measures: Recruitment rate, treatment fidelity, treatment acceptability, patient-reported
outcomes (such as scores on the Brief Pain Inventory, Self-Efficacy for Managing Chronic Disease Scale,
Edmonton Symptom Assessment Scale, EuroQol-5 Dimensions, Satisfaction with Information about
Medicines Scale, and feasibility of collecting data on health-care resource use for economic evaluation).
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Results: Phase I – key themes on supported self-management were identified from evidence synthesis and
qualitative interviews. Phase II – the SMST was developed and refined. The delivery approach was nested
within a nurse–patient consultation. Phase III – intervention was delivered to 17 (89%) patients, follow-up
data at 6 weeks were available on 15 patients. Overall, the intervention was viewed as acceptable and
valued. Descriptive analysis of patient-reported outcomes suggested that interference from pain and
self-efficacy were likely to be candidates for primary outcomes in a future trial. No adverse events
related to the intervention were reported. The health economic analysis suggested that SMART could be
cost-effective. We identified key limitations and considerations for a future trial: improve recruitment
through widening eligibility criteria, refine the SMST resources content, enhance fidelity of intervention
delivery, secure research nurse support at recruiting sites, refine trial procedures (including withdrawal
process and data collection frequency), and consider a cluster randomised design with nurse as
cluster unit.
Limitations: (1) The recruitment rate was lower than anticipated. (2) The content of the intervention was
focused on strong opioids only. (3) The fidelity of intervention delivery was limited by the need for ongoing
training and support. (4) Recruitment sites where clinical research nurse support was not secured had
lower recruitment rates. (5) The process for recording withdrawal was not sufficiently detailed. (6) The
number of follow-up visits was considered burdensome for some participants. (7) The feasibility trial did
not have a control arm or assess randomisation processes.
Conclusions: A future randomised controlled trial is feasible and acceptable.
Study and trial registration: This study is registered as PROSPERO CRD42014013572; Current Controlled
Trials ISRCTN35327119; and National Institute for Health Research (NIHR) Portfolio registration 162114.
Funding: The NIHR Health Technology Assessment programme.
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Plain English summary
Pain affects most people approaching the end of life and can be severe for some. Opioid pain medicines(such as morphine) are effective, but evidence is needed about how best to support patients who are
approaching the end of life in managing these medicines.
By reviewing published research and interviewing patients, carers and health-care professionals, we
designed a self-management support toolkit (SMST). This consisted of factsheets, a pain diary, medication
chart and a goal-setting sheet. We trained clinical nurse specialists in palliative care to deliver the tool
using a four-step coaching process [the Self-Management of Analgesia and Related Treatments at the end
of life (SMART) intervention]. We then asked the trained nurses to trial the SMART intervention with a
group of patients over a 6-week period. The purpose of this trial was to see what patients, their carers
and nurses thought of the SMST and to decide if it was possible to run a larger trial.
Many patients were unable to take part because they were not prescribed strong enough painkillers or
were too unwell. We approached 37 patients, and 19 took part. The SMART intervention was acceptable
and valued by patients and nurses. In general, the study nurses delivered the intervention as planned.
We were able to collect information from patients on a regular basis and that this was not too much for
them. We interviewed the nurses at the end of the trial and this showed that we need to make some
refinements to the study: allowing patients on more types of painkiller to be included and providing more
training support to nurses. Based on these findings we have concluded that a larger study in the NHS is
feasible. This will determine whether or not SMART can provide cost-effective benefits to patients who are
approaching the end of life.
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xxi
Scientific summary
Background
Between 45% and 56% of patients with advanced cancer experience pain of moderate to severe intensity
before they die, and pain is frequently reported in patients approaching the end of life. Patients at the end
of life report that their preferred place of care and death is home. Poorly controlled pain at the end of life
can have a negative impact the quality of life for both patients and carers. Patients and their carers face
daily dilemmas on the best way to balance pain relief with adverse effects of analgesia and the consequent
impact of both on daily activities. One important influence on the quality of pain management for patients
at home concerns the information and understanding that they have regarding their pain and their
analgesic medication. Addressing the concerns and knowledge of patients leads to improvements in pain
control and this process relies on specific contexts that support behavioural change in patients, carers and
health-care professionals (HCPs).
Aim and objectives
We aimed to develop an intervention that enables patients approaching the end of life and their carers to
more confidently manage medications for pain (specifically strong opioids), nausea, constipation and
drowsiness at home. We then aimed to test the feasibility of evaluating this intervention in a future
clinical trial.
Phase I objectives
l Understand self-management needs and capabilities of patients and carers related to strong
opioid medication.
l Define the content of a prototype self-management intervention and a delivery strategy.
Phase II objective
l Refine the prototype intervention and delivery strategy.
Phase III objectives
l Assess acceptability and uptake of the intervention in a mixed-methods observational study involving
patients, informal carers and HCPs from four palliative care services.
l Assess the feasibility of obtaining outcome data for a larger definitive trial.
Methods
Phase I: development
Phase I described the intervention development process and consisted of exploratory mixed methods using
literature scoping searches and semistructured qualitative interviews.
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Initial qualitative work to develop a contextual framework of self-management within
palliative care
Semistructured interviews were conducted with patients and carers to identify medicines and
self-management needs at the end of life and explore perceived barriers to and facilitators of managing
medicines at home.
Scoping the literature
Evidence synthesis exercises were conducted to:
l evaluate the content and form of previous self-management interventions
l identify key systematic reviews of support self-management in long-term conditions and factors that
enable HCPs to support patient self-management
l identify existing public guidance on supporting pain and analgesia self-management in end-of-life
context.
A theoretical underpinning of supported medicines self-management was developed through literature
searches and informed by key learning points from previous studies conducted by the research team.
Initial contextual work and evidence synthesis activities defined the content and form of a prototype
self-management intervention and delivery strategy.
Phase II: refining and optimisation
Refining the intervention
Qualitative semistructured focus groups and interviews with patients, carers and specialist palliative care
health professionals (including service managers and commissioners) were conducted to refine the content
of the intervention resources and delivery strategy by exploring concepts of supported self-management
and defining patient, carer and health professional roles within the context of end-of-life care. This process
ultimately generated a prototype version of the Self-Management of Analgesia and Related Treatments at
the end of life (SMART) intervention.
Optimising the intervention
The prototype SMART intervention was further developed and refined through an iterative process of focus
groups and interviews. Findings from the focus groups and interviews were mapped to the prototype
intervention components, resulting in the self-management support toolkit (SMST) resources and an
educational approach to delivering these resources within the context of community palliative care services.
The SMST resources were reviewed by the patient and public involvement panel members, specialists
palliative care HCPs and a specialist in health literacy.
Phase III: feasibility testing
We conducted a multicentre mixed-methods single-arm pre–post observational feasibility study. The
feasibility study was conducted in four community palliative care services: two in Yorkshire and the
Humber and two in Hampshire. Within each community palliative care service, between two and four
community-based clinical nurse specialists (CNSs) were trained in the delivery of the SMART intervention,
and there were 12 overall (referred to as study nurses). Study nurses attended a half-day training
workshop facilitated by an expert nurse educator to enable them to deliver the intervention.
Patients were identified by screening study nurses’ caseloads and were eligible if they were aged
> 18 years, lived at home, were prescribed strong opioid analgesia, were cared for by specialist community
palliative care services, were considered by the clinical team likely to survive beyond 6 weeks of follow-up
and had the capacity to consent.
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Eligible patients who provided written informed consent (hereafter referred to as participants) were seen
by a study nurse who delivered the intervention to them. Study nurses delivered the SMART intervention
each time they visited their participants (and a carer when appropriate) during the 6-week study period
(each visit was referred to as a ‘SMART visit’). Study nurses were asked to visit participants a minimum of
three times during this 6-week period (i.e. at least once a fortnight). During each visit study nurses were
required to use a conversational approach to go through the educational delivery approach and provide
the resources from the SMST as required.
Data were collected from participants by researchers at baseline and at the 2-, 4- and 6-week follow-up
time points. Data were collected using self-reported outcomes measures for pain [Brief Pain Inventory
(BPI)]; self-efficacy [Self-Efficacy for Managing Chronic Disease Scale (SES)]; common end-of-life symptoms
[Edmonton Symptom Assessment Scale (ESAS)]; quality of life [EuroQol-5 Dimensions (EQ-5D)]; and
satisfaction with medication information [Satisfaction with Information about Medicines Scale (SIMS)].
Final data collection from participants’ health records was carried out at the end of the study to capture
patients’ health-care resource use and analgesic prescription during the 6-week follow-up period.
Results
Phase I
This early development phase contextualised a framework of supported self-management within palliative
care services. Qualitative interview identified five key themes, which were used to shape early thinking
about the dimensions of the intervention. The literature scoping exercises resulted in a theoretical
underpinning of supported self-management at the end of life and a description of the potential
components of self-management intervention and a nurse-led educational approach to delivery within
community palliative care services. The intervention components were further developed to generate a
preliminary model of supported self-management and the content and form of the prototype intervention.
Phase II
A total of 38 patients, carers and palliative care HCPs were recruited from hospice- and hospital-based
palliative care services in Hampshire and Yorkshire. The results highlighted the ever-changing process of
self-management enacted on a continuum of behaviours that were dependent on the responsibility taken
by the patient, carer and specialist nurse. The model of supported self-management was tested within the
context of end-of-life care, and the roles of patients, carers and CNSs were defined.
Mapping the findings from the focus groups and interviews onto the prototype intervention component
ultimately generated the SMART intervention that comprised both a SMST and a four-step educational
delivery approach. The SMST included eight factsheets, a pain diary, a medication chart and goal-setting
sheets. The four-step educational approach consisted of a needs assessment, information provision,
goal-setting and regular review and coaching of self-management progress.
The intervention was designed to be delivered via a feasibility study to patients by community-based
palliative care CNSs. The approach to delivery involved nesting the intervention in a clinical encounter
(nurse–patient consultation) and was enacted through a conversational process.
Phase III
Study nurse training
Prior to starting recruitment, the 12 study nurses attended a training workshop to enable them to deliver
the SMART intervention. Responses to the reflective style of the workshop were mixed, but the nurses
generally felt that the four-step educational delivery approach mirrored normal practice and they valued
the training materials supplied during and after the training workshop. Regular fortnightly contact was
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maintained between study nurses and the research team to provide additional training materials and
support throughout the study period.
Participant recruitment
Of the 417 patients assessed for eligibility in 4 months, 103 (25%) were screened eligible and 19 (5%)
were recruited to participate. Seventeen participants (89%) received the intervention and 15 (79%)
completed 6 weeks’ follow-up. Four participants withdrew from the study (two died, one withdrew from
researcher follow-ups and one was admitted to a nursing home). Baseline characteristics were similar
across the four recruitment sites: the median (range) age was 66 (48–88) years, 58% were female and
18 out of the 19 participants had advanced cancer.
SMART intervention fidelity and acceptability
Ten participants (53%) received the intervention as planned (i.e. started within 7 days of baseline data
collection, received at least a minimum of three SMART study nurse visits, received tailored staged
information provision, goal-setting and regular review and coaching). A further four participants (21%)
received all of the factsheets on their first SMART study nurse visit, although all other elements of the
intervention were delivered as planned. Three participants (16%) received the SMST resources but did
not receive the minimum three SMART study nurse visits and two participants (10%) did not start
the intervention.
End-of-study interviews with participants and carers revealed that the SMST resources (the factsheets,
pain diary, medication chart and goal-setting sheets) were universally seen as acceptable and were
perceived as beneficial as they addressed relevant fears and concerns and stimulated participants to ask
further questions and seek additional help. The goal-setting sheets were particularly valued and seen as
beneficial by participants and carers. The study nurses universally perceived the goal-setting and regular
review process as acceptable and deliverable. They identified the goal-setting as a core component of the
intervention and perceived value in it because it formalised and evidenced their specialist practice.
The end-of-life context provided a complex set of circumstances within which study nurses had to deliver
the intervention. Consequently, not all participants were able to fully engage with all elements of the
intervention; however, overall, the four-step educational approach appears to have been acceptable and
was adhered to by the study nurses.
Feasibility of collecting participant self-reported outcome data
The level of missing data from the self-reported outcome measures was extremely low. There was no
change in average pain scores; however, there was a slight reduction in interference from pain [–1.6, 95%
confidence interval (CI) –2.8 to –0.4] and a modest increase (0.7, 95% CI 0.3 to 1.2) in self-efficacy scores.
There was no overall change in the intensity of common end-of-life symptoms (ESAS), health-related
quality of life (EQ-5D) or satisfaction with information about medicines (SIMS). The number of participants
with clinically meaningful reduction in average pain and pain interference were summarised. These data
show that, at follow-up weeks 2 and 6, there were more responders based on pain interference than on
average pain intensity. The results suggest that the SES and BPI pain interference scale are the most
responsive to change and should be considered for the primary outcome for a definitive trial. Participants
generally found the outcome measures to be acceptable.
Feasibility of conducting a cost-effectiveness evaluation of SMART
An economic evaluation was conducted to assess the feasibility of estimating cost-effectiveness of SMART
compared with usual care in patients at the end of life who receive opioids. The costs of developing and
implementing the SMART intervention were relatively modest. The SMART intervention led to cost savings
and yielded incremental quality-adjusted life-years (QALYs) in a base case and many of the deterministic
sensitivity analyses. These QALY gains are small, although this is to be expected as this population has a
limited survival time in which to benefit. In general, the results are robust to one-way parameter changes
and SMART appears to be cost-effective compared with standard care alone. The feasibility aspects of this
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study suggest that conducting a cost-effectiveness evaluation in a definitive trial setting should be possible.
Furthermore, the results indicate that a low-cost intervention, such as SMART, could be cost-effective in
this population even if the impact on pain and side effect management were modest and suggest that
further research is warranted.
Conclusion
We have shown that the evaluation of a supportive self-management intervention for patients requiring
analgesia, and who are approaching the end of life, is feasible. We have demonstrated that our research
process, study nurse training schedule and intervention delivery strategy are feasible and acceptable within
a sample of community-based individuals approaching the end of life, their carers and palliative care CNSs.
Our success criteria were largely met and, for those that were not, we have identified clear means to
succeed within a future trial through a detailed process evaluation of our feasibility study. The key
considerations in the design of future definitive trial have been identified, and we believe that this is now
feasible to undertake.
Study and trial registration
This study is registered as ISRCTN35327119; PROSPERO CRD42014013572; and National Institute for
Health Research (NIHR) Portfolio registration 162114.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the NIHR.
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Chapter 1 Supporting self-management of
analgesia and related treatments at the end of life
Summary of Health Technology Assessment brief
In October 2012, the Health Technology Assessment (HTA) published a commissioning brief entitled
‘Self-management of pain relief, nausea and constipation for patients approaching the end of life’.
Applicants were asked to address the research question of whether or not a patient support tool could
improve the self-management of medication for pain, nausea and constipation in patients approaching the
end of life. This call was based on the recognition that:
Enhanced patient-family health decision making can improve the overall quality of end of life care.
As life-limiting illnesses progress, the number of disease related symptoms typically increases.
Medication regimens can be complex and pain, nausea and constipation are among the common
symptoms that often fluctuate and may be appropriate for self-management by patients and their
family carers. Patient decision aids have been shown to be effective in facilitating informed decision
making and it may be that a self-management aid could help patients and their families to manage
their medication regimens to improve pain, nausea and constipation symptom control. A feasibility
study is needed to develop a support aid and to assess its acceptability.
This report contains the research conducted in response to this brief (see Appendix 1 for full HTA brief).
Summary of current evidence and policy context
Approximately 160,000 people die from cancer each year in the UK, a number that is expected to rise to
193,000 by 2030.1 Evidence suggests that 45–56% of patients with advanced cancer (72,000–89,600 each
year in the UK), experience pain of moderate to severe intensity before they die.2,3 Detailed information on
pain in patients approaching the end of life with non-cancer diseases is less widely available.
Since 1986, the focus of pain treatment for patients approaching the end of life has been the use of
strong opioids based on the World Health Organization’s ‘analgesic ladder’.4 Initial studies suggested that
this approach could control pain in around 73% of cancer patients.5,6 Despite widespread availability of
strong opioids in the UK, at least 32% of patients with cancer are undertreated for their pain.3,7
Patients at the end of life report that their preferred place of care and death is home.8 The National Survey
of Bereaved People (VOICES) has evaluated the perceptions of the care given to recently deceased persons
(not just those with cancer) since 2011.9 In 2015, only 18% reported that pain was controlled ‘completely,
all the time’ at home, compared with 38% in hospital and 63% in hospice. Not surprisingly, uncontrolled
pain is the most frequent reason for community-based cancer patients to contact out-of-hours primary
care services.10
Although there is evidence that improved pain management for patients with advanced disease is
associated with involvement of palliative care, the evidence base is not consistent in reflecting significant
methodological heterogeneity.11 Little is known about the service constituents that are responsible for
improved pain management.
In 2008, the Department of Health published a strategy for end-of-life care as it recognised that many
people did not have what could be described as a ‘good death’: being treated as an individual with dignity
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and respect, being without pain and other symptoms, being in familiar surroundings and being in the
company of close family and/or friends.12 A National Institute for Health and Care Excellence (NICE) quality
standard was subsequently issued in 2011 to define and support high-quality end-of-life care, specifically
including pain management.13
In 2016, the British Medical Association interviewed 269 members of the public and 237 doctors regarding
the provision of end-of-life care by the NHS.14 For both the public and doctors, pain was the most feared
aspect of dying, echoing the findings of the national VOICES survey and underlining the importance of
good pain control at the end of life.
A succession of key reports have emphasised the urgent need to improve end-of-life care services in the NHS
because of unacceptable variation in access to and experience of care.15 The Leadership Alliance for the Care
of Dying People’s One Chance to Get it Right – Improving People’s Experience of Care in the Last Few Days
and Hours of Life16 recognised that pain and symptom control should be among the five key priorities of care
in the NHS. In 2015, NHS England led Ambitions for Palliative and End of Life Care: A National Framework
for Local Action 2015–2020,17 which described access to care and maximising comfort as two of its six
ambitions for improving services. The Parliamentary Health Committee on End of Life Care reported in 2015
that round-the-clock access to community nurses and specialist outreach palliative care for pain relief are
some of the actions that could facilitate a shift in quality of care.18
The Palliative and End of Life Care Priority Setting Partnership, led by the James Lind Alliance, undertook
a survey of 700 patients and carers and a similar number of professionals involved in end-of-life care,
regarding research priorities.19 Of the 83 shortlisted areas, one-third of the top 10 research priorities
related to symptom management, with pain specifically mentioned. In response to this, the National
Institute for Health Research (NIHR) undertook a themed review of palliative care research that it funds,
summarised in the NIHR report Better Endings.20
Overall, NIHR research has identified persistent inequalities and variations in care, with poorly co-ordinated
services and limited access to specialist palliative care. In addition, place of death may not be the most
important aspect of care for many; managing pain and other symptoms and the quality of care are key for
patients and their family, whatever the setting. These reports,12–15 all published in the last 2 years, serve to
highlight that although good-quality end-of-life care can be defined, currently within the NHS patients
experience poor pain control at home, the public remain understandably fearful of a painful death and
there is unacceptable variation in access to good care in the NHS. Providing better support to enable
patients to self-manage with more confidence is likely to be an important mechanism in improving
outcomes for patients with pain from advanced disease.21 Therefore, this research proposal was timely and
important in supporting NHS priorities and informing ways to improve the experiences of dying patients
and those that survive them.
Background rationale
One important influence on the quality of pain management for patients at home concerns the information
and understanding that patients have regarding their pain and their analgesic medication. Misunderstandings
by patients regarding opioids inhibit good pain control22 and we have found that this is particularly true for
older patients.23 Our own research has also shown that patients and their carers face daily dilemmas on the
best way to balance pain relief with the adverse effects of analgesia and the consequent impact of both on
daily activities.24,25 Attitudes and knowledge of health-care professionals (HCPs) towards opioids is likely to
influence the quality of information provided to patients26 and the increasing complexity of opioid choices in
end-of-life care may further reduce the confidence of non-specialist practitioners.27
However, addressing the concerns of patients leads to improvements in pain control,28 and this process
relies on specific contexts that support behavioural change in patients, carers and professionals.29–31
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Although education and self-management support are largely seen as nursing tasks rather than medical
tasks,30 our research suggests that pharmacists can make important contributions too.32,33
Despite there being a good understanding of patient and carer concerns regarding opioid analgesia and
related side effects, much less is known about the optimal means of addressing these concerns,34 which is why
they have been highlighted by NICE guidance.35 Simple information in the form of leaflets or video may help,36
but may be insufficient to make a tangible impact on patients’ perceptions of confidence to self-manage.
The research recommendation 4.1 from recent NICE guidance on the use of opioids in palliative care calls
for clinically effective and cost-effective methods of addressing patient and carer concerns about strong
opioids, including anticipating and managing adverse effects.35,37 Moreover, the NICE guidance indicates
that as well as constipation and nausea, drowsiness is one of the most common side effects of pain
medication and one that bothers patients most. All three side effects need to be addressed for optimal
pain management and we therefore extended the scope of the HTA brief to incorporate drowsiness in
the intervention.
Feasibility study aims and objectives
We aimed to develop an intervention that enables patients approaching the end of life and their carers
to more confidently manage medications for pain (specifically strong opioids), nausea, constipation and
drowsiness at home. We designed this project with a patient-centred approach at the heart of our
development plan, nested within a theoretically informed behaviour change framework. The expected
benefits of the intervention for patients were improvements in symptom relief, feeling empowered with
increased knowledge and skills to recognise worsening symptoms or adverse effects, being able to self-
initiate therapeutic adjustments and knowing how and when to access help from the health-care system.
We defined our intervention as a set of materials and coaching procedures that deliver knowledge,
facilitate the generation of specific action plans and enhance the user’s skills to monitor and reflect on
their actions. We judged that our intervention would be optimally delivered by clinical nurse specialists
(CNSs) who work within specialist palliative care teams. We thought that patients would be most likely to
benefit from the intervention if they were adults (aged > 18 years), approaching the end of life, suffering
from significant pain and being cared for in their own home, being treated with, or due to start treatment
with, opioids for pain, and experiencing (or anticipating) adverse effects of these medications. We were
particularly keen to embed the principles of experience-based co-design into the development, modelling
and testing of our prototype intervention, and to evaluate this within a theoretical framework for
characterising and designing behaviour change interventions.38,39
Our objectives were divided into three distinct phases, which is in line with the Medical Research Council
framework on developing and evaluating complex interventions.40 We also planned to use the explanatory
models of normalisation process theory to evaluate factors that will support implementation.41 This would
offer a clear path for implementation into the wider NHS should the effectiveness of the intervention be
established in a future definitive randomised controlled trial (RCT).
Phase I: development objectives
l Establish a patient and public involvement (PPI) panel.
l Establish the content of a prototype intervention and a manualisation strategy that includes a protocol
to standardise (1) the training of HCPs and (2) the delivery of the intervention by HCPs to patients
and carers.
l Understand self-management needs and capabilities of patients and carers related to strong
opioid medication.
l Define usual care.
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Phase II: modelling objectives
l Refine the prototype intervention and manualisation strategy.
Phase III: feasibility assessment objectives
l Assess acceptability and up-take of the intervention in a mixed-methods observational study involving
patients, informal carers and HCPs from four palliative care services.
l Assess the feasibility of obtaining outcome data for a larger trial.
Patient and public involvement
We have had sustained PPI throughout all stages of the Self-Management of Analgesia and Related
Treatments at the end of life (SMART) study. PPI has been an integral part of all our study processes from
inception and development of the research ideas, development of the funding application, through to
delivering the research project and interpreting the study findings. We have engaged with PPI in a number
of ways. First, through a PPI coapplicant (JG), we benefited from expert PPI input to help prioritise the
research question and ensure that the delivery of the intervention is undertaken in a way that is
meaningful and relevant to patients approaching the end of life and their carers. Second, in the first phase
of the project we established a dedicated PPI panel that informed and helped refine the content and
delivery strategy of the SMART intervention as well as review patient study materials (i.e. information
sheet, consent form, patient questionnaire). Last, we recruited an independent PPI representative to be
part of the Steering Committee, which has oversight and responsibility for the project, and gave the study
team insight and direction throughout the design, delivery and completion of the project.
Success criteria
Ultimately, we aimed to establish the acceptability and uptake of our prototype self-management support
toolkit (SMST) and determine the feasibility of evaluating this intervention within a larger trial. In order
to judge whether or not we had achieved our aims, we agreed our success criteria beforehand to be
as follows.
Phase I
l Establishment of a PPI panel and assessment of members’ support and training requirements.
l Development of a usual-care protocol based on literature review and clinical practice observations.
l Development of prototype intervention materials, manualisation strategy and usual care protocol.
Phase II
l Establish members of focus groups.
l Development of refined intervention materials and manualisation strategy.
Phase III
l Sampling strategy: recruit three patients per month at each site within 4 months.
l Feasibility of data collection: key clinical and health economic measures, and health-care resource
measures, have sufficient complete data to estimate primary study end points.
l Trial experience: patients and carers reporting acceptable and sustained use of intervention materials.
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Chapter 2 Development of the SMART intervention
Phase I: overview of initial contextual work
This chapter describes the intervention development process. First, it summarises the literature scoped to
inform the development of the intervention. Second, it recounts the exploratory activities undertaken with
specialist palliative care health professionals, patients and carers, to derive a concept of self-management
of analgesia (opioids) and related treatments (for nausea, constipation and drowsiness) at the end of life.
Through this development process it was possible to generate a preliminary model of self-management
that was then tested further through interviews and focus groups with patients, carers and HCPs. This
chapter will also describe how this model was then used to specify and inform the components, including
content and form, of the SMART intervention. This process aligned with the theoretical modelling phase of
the Medical Research Council framework for complex interventions.42,43
Initially, contextual work was performed to frame self-management within the field of palliative pain
management. Much is written about self-management, but the focus is predominantly on long-term
condition management.44 However, a survey of 90 cancer patients living at home receiving community-
based palliative care identified three key factors associated with successful pain management.45 The first
factor is maintaining a sense of control over managing medicines by modifying the schedule of taking
medicines around daily routines and planned activities. The second factor is negotiating a balance
(trade-off) between symptom control and the impact of medicines’ side effects on cognitive and physical
functioning. Furthermore, Hansen et al.46 identified that 40% of end-of-life patients regularly do not use
analgesia despite reporting moderate to severe pain and indicating an awareness that regular medication
was the most effective self-management behaviour for controlling pain. These authors concluded that
patients were making important trade-offs between pain relief and the side effects of medications and
this helped maintain a sense of control. The third factor associated with successful pain management
identified by Bennett et al.45 is a broad base of support. Community palliative care nurses and community
pharmacists were seen as key HCPs supplemented by support from a carer (family member or friend).
The authors concluded that a community-based intervention that is flexible and responsive to patients’
needs, involving carers and community-based HCPs, is most likely to be successful.
Information provision has been identified as a fundamental component of interventions in advanced
disease.37,47 Tailored information provision equips patients and carers with the necessary skills and confidence
to drive behaviour change.39,48 However, on its own it is insufficient to drive significant improvements in
patient-reported outcomes, such as pain and quality of life. Contextual factors associated with successful
pain management are the development of a trusting relationship with health-care providers, having
dedicated time to focus on medicines management and confidence in exerting self-control over a daily
analgesic routine.47,49 Identifying patient and carer needs was recognised by NICE as the basis for delivering
tailored support in its guidance on improving supportive and palliative care for adults with cancer.37
Therefore, in addition to information provision, regular assessment and review of patient needs is a key
component in supporting self-management of pain medication in this context.37,47
In order to understand the context more fully, six semistructured interviews were initially undertaken with
patients and carers recruited from a palliative care outpatient service. Interviews focused on identifying the
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need to self-manage medicines at the end of life and exploring perceived barriers to and facilitators of
managing medicines at home. This led to the delineation of five themes:
1. communication and understanding
2. addressing fears and concerns
3. information requirements
4. carer-specific needs
5. making trade-offs.
These themes were used to shape early thinking about the dimensions of the intervention, which were
further refined in later phases, as described below.
Evidence synthesis
Scoping of the literature
Scoping of the literature was undertaken following the preliminary work described above. The objective of
this exercise was to examine:
1. the content and form of previous interventions effective in improving pain management by patients
(see Appendix 2)
2. key systematic reviews of what can be done to support self-management across a range of long-term
conditions of relevance to this particular application at the end of life
3. key literature and reviews that identify factors that enable HCPs to support patient self-management
4. existing public guidance based on NICE clinical guideline 140 – Opioids in Palliative Care (Box 1)
5. description and potential components of self-management at the end of life (Box 2).
Theoretical underpinning of the intervention
The literature-scoping work informed the selection of theory focused on self-efficacy and behaviour change
to best suit the developing intervention. Self-efficacy is a key component of Bandura’s social cognitive
theory.54,55 The theory of social cognition states that knowledge acquisition can be directly related to
observing others within the context of interactions and experiences. According to this theory, self-efficacy
is the belief in an individual’s capabilities to organise and carry out courses of action to manage situations.
Bandura states that behavioural techniques can be used to target the four sources of self-efficacy: mastery
experience, role modelling, verbal persuasion and the regulation of physiological and affective states.
Michie et al.39 undertook a systematic search and consultation with behaviour change experts to identify
frameworks of behaviour change interventions. These were then evaluated for comprehensiveness,
coherence and a clear link to a model of behaviour. A new framework was subsequently developed to fully
meet all these criteria: the behaviour change wheel. The wheel characterises behaviour change interventions
around nine intervention functions aimed at addressing deficits in one or more of three essential conditions
for behaviour change: Capability, Opportunity and Motivation (termed the COM-B system). The behaviour
change wheel identifies three main target constructs (sources of behaviour), which are capability (physical
and psychological), motivation (automatic and reflective) and opportunity (social and physical). Around these
target constructs are nine intervention functions (education, persuasion, incentivisation, coercion, training,
enablement, modelling, environmental restructuring and restrictions), which represent ways to address
deficits in one or more of the target conditions.
Key learning from studies conducted by the team
The intervention development was also informed by key learning from two studies undertaken by
members of the research team. These were Cancer Carer Medicines Management (CCMM),56 funded by
Dimbleby Marie Curie Cancer Care, and Improving the Management of Pain from Advanced Cancer in the
Community (IMPACCT), a programme grant funded by the NIHR (RP-PG-0610-10114).
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BOX 1 Existing public guidance
Guidelines reviewed
l NICE (2012) information for managing pain with the strong opioids in people with advanced progressive
disease – information for the public.37
l All Wales Medicines Strategy Group: Opioids in Palliative Care – Patient Information Manual.50
Information covered
Managing pain with strong opioids: some treatments may not be suitable depending on your circumstances,
definition of palliative care and its purpose of alleviating pain and discomfort to improve quality of life.
Information about taking strong opioids: if you are offered strong opioids, HCPs should explain when and why
strong opioids are used to treat pain; how effective they are likely to be at relieving your pain; about taking
strong opioids for background pain and breakthrough pain, including how, when and how often to take them;
how long pain relief should last, possible side effects and signs to watch out for that might mean there is too
much of the medication in your system; and how to store strong opioids safely.
Discussing your concerns: if you are worried about addiction and side effects, your HCP should reassure you
that addiction is very unlikely and that you will be monitored for side effects. Strong opioids can be offered at
different stages and doing so does not necessarily mean that you are close to the end of your life.
Starting treatment with opioids: different forms, short acting vs. slow release, no standard dose.
If you have trouble swallowing: if pain is stable you should be offered a patch.
Reviewing pain control: need for regular reviews especially at the beginning.
Continuing treatment: sustained-release form.
Treating breakthrough pain: immediate-release form, advice from specialist if uncontrolled.
Managing side effects
Constipation: definition and statement that it affects nearly everyone who takes strong opioids. You should be
offered laxatives and a description of how laxatives work; they can take time to work so take them as advised
and your HCP may change the type of opioid if your constipation is severe.
Nausea: you may experience feeling sick when starting strong opioids or when the dose is increased, but this is
likely to last only a short time. If it persists, you should be offered anti-sickness medication.
Drowsiness: you may experience mild drowsiness or problems with concentration when starting strong opioids
or the dose is increased, but this is likely to last only a short time. Your HCP should warn you that having
problems might affect your ability to carry out some tasks, such as driving. If you have severe or long-lasting
problems and your pain is under control, your HCP may discuss the possibility of reducing the dose of opioid
with you. If your pain is not controlled, then your HCP may consider changing the opioid and if the problems
are not relieved by these changes then your HCP may seek specialist advice.
Questions to ask a HCP: tell me more about strong opioids for pain relief? Can you tell me about the side effects
associated with taking strong opioids? Will I become addicted to strong opioids? How long will it take for this
medication to work? What do I do if I am still in pain after taking strong opioids? What are my options for taking
some other type of pain relief? Can you give me some written material about strong opioid treatment?
Sources of more information: CancerHelp UK, Macmillan Cancer Support, British Pain Society and NHS Choices.
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BOX 2 Description and potential components of self-management at the end of life
Reference: Johnston et al.51
The above authors provided a definition (via concept analysis) of self-management support within the context
of palliative care:
. . . Assessing, planning, and implementing appropriate care to support the patient to be given the means
to master or deal with their illness or its effects.
The authors proposed eight potential professional roles to support self-management. These roles were undefined
but labelled as advocate, educator, facilitator, problem-solver, communicator, goal-setter, monitor and reporter.
References: Schumacher et al.52,53
These authors demonstrated that, for oncology patients (and their carers) in the USA, the practical experiences
of day-to-day management of pain medications could be both challenging and onerous. Navigating the
systems with complex webs of people and rules was a lengthy and tedious challenge causing frustration, effort
and added anxiety. These issues revolved around getting prescriptions, obtaining medicines, understanding,
organising, storing, scheduling, remembering and taking.
Understanding
Once patients and carers obtained medicines they were immediately faced with understanding the medicines
they had brought home. Lack of understanding led to uncontrolled pain. Many areas of confusion were
evident; keeping the purpose and names of medications straight was one. Medication names were ‘not in
English’ (i.e. plain English); many referred to medicines by appearance, and the use of abbreviations was seen
as confusing, as were drugs with similar names. Lack of understanding about maximum daily dose limits was
common (including not knowing that opioids do not have a dose ceiling). Understanding the meaning of
dosing intervals was an issue for some (e.g. every 3 days). Utilising the wide variety of information sources was
challenging and information printed on packs and inserts was too small for some to read.
Organising
Organising presented a host of issues because of the sheer number and various forms of medicines prescribed
for regular use, p.r.n. (as required) or both. Participants used a wide range of highly individual strategies:
elaborate daily rituals involving, for example, zip lock bags; differentiation of medicines by colour; lining up of
medicine bottles with magnifying glass; taking out pills and putting them into a glass. Lack of organisational
systems presented safety risks such as medicines sitting out in glasses:
Participants used their home environments for pain medication management in highly individualized ways.
Countertops, drawers, tables, windowsills, cabinets, boxes, bags, dishes, alarm clocks, whiteboards,
computers, and mobile devices were all used. Individuals and pets living in the home were taken into
account. Visitors were a consideration, especially visiting grandchildren.
Schumacher et al. p. 78753
Storing
This refers to putting medicines safely away. Hiding medicines from patients was a strategy used when carers
feared that the patient would get confused and take too much. Storing medication generally involved hiding
them and locking them up.
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The SMART intervention drew on carer needs for medicines management at the end of life identified from
the CCMM study (see Appendix 3), including needs for information about pain medicines and side effects,
changing beliefs about opioids and providing skills and opportunities for self-evaluation. The results of the
CCMM study also showed that a conversation-driven intervention, delivered by nurses in routine practice
and supported with a toolkit of resources, was acceptable to carers and to nurses and was compatible
with their existing practice. CCMM showed some evidence of benefit in influencing carers’ knowledge,
beliefs and behaviours related to management of pain medicines. Principles of the CCMM conversational
process (assessment, education and review), as well as elements of the toolkit (information leaflets,
medication chart, pain diary and contact details for local and national services), informed the development
of the SMART intervention.
Learning from the IMPACCT study was derived from a review of the optimal components of educational
interventions for advanced cancer pain, which was carried out as part of the study (see Appendix 4). In this
meta-review,57 the authors used Michie et al.’s39 behaviour change wheel as theoretical underpinning.
Mapping findings from six reviews and two papers led to identification of five out of the nine behaviour
change wheel intervention functions. These were considered essential for successful interventions:
1. education, for example providing written information about pain management, including analgesic and
non-pharmacological approaches
2. training, for example providing instruction, demonstration and coaching of new skills (techniques for
managing daily drug regimes, relaxation techniques)
3. enablement and persuasion, for example overcoming cognitive and emotional barriers to pain
management through addressing concerns about tolerance or addiction
4. environmental restructuring and resources, for example incorporating the delivery of education for
self-management into the usual care provided by specific health professionals, such as specialist nurses,
primary care practice nurses and community pharmacists
5. modelling, for example patients talking to other patients about their successful use of various pain
management strategies.
Scheduling
This refers to working out the best time to take medicines in relation to daily lifestyles. Some used pain as a
cue to take next regular dose earlier than scheduled, rather than take rescue medicines; this fitted with the
mindset of taking medicines only when pain is present.
Remembering
Remembering use of dosette boxes helped but this was not failsafe. All affected by fatigue, drowsiness
and confusion.
Taking
This was straightforward for most, but some experienced challenges (e.g. erroneously cutting sustained-
release pills).
BOX 2 Description and potential components of self-management at the end of life (continued)
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Phase II: refining and detailing the intervention
This section describes the work undertaken to refine and detail the intervention. In particular it describes
a series of interviews and focus groups conducted with patients, carers and HCPs. These data sources,
together with work described in the previous section, were used to derive the content and form of the
intervention for SMART.
Aim
The aim of this phase of the study was to refine and detail an intervention for self-management of
analgesia (opioids) and related treatments (for nausea, constipation and drowsiness) at the end of life.
Objectives
The literature scoping informed the objectives and these were to:
l explore views regarding the nature and components of supported self-management regarding
analgesia and related treatments at the end of life, and test our preliminary model of self-management
in this context
l introduce participants to, and ask for their views on, aspects of self-management in this context – in
particular our selected definition of supported self-management in palliative care (Johnston et al.51) and
practical difficulties regarding supply and medicines taking encountered by patients (Schumacher et al.52,53)
(see Table 2).
For HCPs, the objectives were to:
l reveal the self-management promoting activities and behaviours already used by specialist palliative
care HCPs and gain views on the professional supportive self-management roles proposed by
Johnston et al.51
l rehearse previous examples of interventions to test possible delivery modes and how these could link to
existing patterns of practice.
For patients and carers, the objectives were also to:
l understand what supported self-management at the end of life was for them
l explore patient and carer needs using the framework of Schumacher et al.’s52,53 commonly encountered
practical difficulties regarding supply and the taking of medicines
l gain views regarding potential options for the content, form and delivery of the intervention.
Approach to data collection
Focus groups and interviews were held in two geographical regions: Hampshire and Yorkshire. They were
conducted with patients, their carers and specialist palliative care health professionals (including service
managers and commissioners).
Inclusion criteria
Patients were included if they:
l were aged ≥ 25 years and considered to be in the last year of life
l were experiencing pain
l were being treated with, or starting, opioid analgesia
l were experiencing, or anticipating, adverse effects of nausea, constipation and drowsiness
l were living at home
l were being cared for by specialist community-based palliative care services in Hampshire or Yorkshire
l had capacity to consent.
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Carers were included if:
l they were the primary carer of a patient meeting the above inclusion criteria and
l the patient gave consent to their involvement.
Health-care professionals were included if they were:
l CNSs and doctors who were part of specialist palliative care teams or
l service providers or managers of specialist palliative care services or
l local commissioners of palliative care services.
Sampling strategy and recruitment
To access a range of individuals (HCPs, patients and carers), we aimed to recruit 35 participants via various
strategies across four hospices and two acute NHS trusts. The sampling and recruitment strategy is detailed
in Table 1.
TABLE 1 Sampling strategy and recruitment to interviews and focus groups
Hampshire
HCPsa
Acute trust 1+ hospice 1: eight hospital-based
CNSs, six consultants and one specialist
registrar were invited to participate. Of these,
two hospital-based CNSs attended the focus
group. 18 community palliative care CNSs
were invited to participate, five attended the
focus group that occurred at this hospice
Hospice 2: staff across the hospice
were invited to attend. Three
attendees participated in the focus
group at this hospice and a further
three travelled to attend the focus
group at the other hospice
Acute trust 2: one lead nurse/
commissioner was invited to
take part in an interview and
this took place
Patients and carersb
Acute trust: 17 patients were referred via a
hospital-based palliative care team, all except
four were approached by the researcher
(seven did not meet the eligibility criteria).
Two patients were recruited and interviewed
Hospice 1: 39 patients and carers
attending day hospice sessions were
informed about the study. Five
patients and two carers (who met
the eligibility criteria) approached the
researcher after these sessions and
four patients and two carers were
recruited (n= 6)
Hospice 2: six patients were
referred by day hospice staff as
meeting the study’s eligibility
criteria. All were spoken to by
the researcher and five patients
were recruited, with two carers
(n= 7)
Yorkshire
Focus groupsc
HCPs: an entire community palliative care CNS
team based at a hospice were invited to take
part in a focus group and all attended on the
day (n= 4). One palliative care consultant was
invited to take part in an interview and this
took place
Patients and carers: 10 eligible individuals were approached via a
hospice outpatient clinic. Of the 10, four attended the focus group,
four had agreed to participate but failed to attend, and two declined
a Two focus groups (at both hospices 1 and 2) were held in Hampshire for HCPs.
b At the point of recruitment, patients and carers were asked whether or not they would prefer to take part in a focus
group or interview. All stated a preference for interviews; therefore, no patient and carer focus groups took place
in Hampshire.
c Two focus groups, one for HCPs and another for patients and carers, were held in Yorkshire.
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Focus group and interview guides
Topic/interview guides (as well as supporting slide/card packs) were developed to meet the study objectives
(see Appendices 5–8). A number of tools were used to manage the interview and focus group discussions:
l a definition of supported self-management in the context of palliative care (Johnston et al.51)
l eight proposed professional roles to support self-management in the context of palliative care
(Johnston et al.48)
l the practical difficulties around supply and medicine taking encountered by patients and carers in the
work of Schumacher et al.52,53
l the content and form of previous interventions to improve pain management by patients.58–61
The interviews and focus groups were conducted by the study’s researchers. The focus groups were
conducted with a co-facilitator another researcher with expertise in the field, present to aid moderation.
Data analysis
The audio files from the interviews and focus groups were professionally transcribed. They were listened to
by the researchers alongside the transcripts to check for complete accuracy. Both study researchers
familiarised themselves with the data by reading and rereading the transcripts and identifying key issues,
concepts and themes. Initial coding took the form of indexing on the transcripts, and each research fellow
summarised the key themes from the data related to the sites in their regional area. The themes were
discussed for comparative purposes. Natasha Campling then coded the entire data set for all issues, aspects
and themes that were relevant to supported self-management in this field. Coding was performed in NVivo
(version 11; QSR International, Warrington, UK) utilising framework analysis.62
The development process
The process of intervention development is illustrated in Figure 1. The contextual work and literature
scoping informed a preliminary model of supported SMART. This model, a definition of self-management,51
practical difficulties related to supply and medicine-taking52,53 and the content and form of previous
interventions58–61 were used as tools within the focus groups and interviews to gain participants' views.
The result was development of a concept of self-management, to inform the required components
(including the content and form) of the intervention: a four-step educational approach and toolkit, plus
a training package to enable nurses to deliver the intervention within a feasibility study.
Findings from the intervention development interviews and focus groups
The sample
The sample was composed of 38 participants recruited via the two geographical regions of Hampshire and
Yorkshire (Table 2). The demographics for the HCPs and patients and carers are presented in Tables 3 and 4.
Concept of supported self-management in analgesia and related treatments at the end
of life
The development process, informed by the varied sources of learning outlined in Evidence synthesis,
enabled the generation of a preliminary model of supported self-management in analgesia and related
treatments at the end of life. The model was tested, within this specific context, through the interviews
and focus groups with patients, carers and HCPs. The model included the self-management definition,
professional roles outlined by Johnston et al.51 and the practical difficulties regarding medicines access,
supply and taking outlined by Schumacher et al.52,53
This process revealed new components of supported self-management within the end-of-life context. It
displayed an ever-changing process enacted on a continuum of behaviours dependent on the responsibility
taken by the patient, carer and specialist nurse. This was a complex web of behaviours, varying day by day,
if not hour by hour, within this context. With continual disease progression, there were frequent changes
in symptoms and side effects from both medication and palliative treatments, with behaviours profoundly
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affected. This context was complicated by the surrounding ‘swirl’ of what individuals and their families
were already striving to deal with, the wider context of psychological distress and high levels of carer
strain. Individuals in this context could be struggling to cope with a palliative care diagnosis and there was
anxiety and clinical depression of both patients and/or carers. Consequently, the capabilities of the patient
and carer fluctuated greatly, influencing supportive self-management roles and the required behaviours of
the specialist nurse.
Contextual work followed by literature scoping
Supported self-management definition and potential components at end of life
Content and form of previous interventions to fit practice
Content review of SMST with PPI group and
palliative care specialists
Review by health literacy expert
Modelled conversational process audio-recorded
(training resource for specialist nurses)
Development of training workshop for
specialist nurses
Further resources and support for specialist nurses
to promote engagement with trial processes
Intervention and training
package developed for
feasibility trial
A concept of supported self-management of analgesia and related treatments
at the end of life
Preliminary model of supported self-management of analgesia and related
treatments at the end of life
Focus groups and interviews with specialist palliative care health professionals,
patients and carers
(n = 38)
Four-step educational
approach underpinned by
conversational approach
with self-management
ethos and prompts
SMST: factsheets,
podcast films, charts and
goal sheets
Prototype SMART intervention
FIGURE 1 Intervention development process.
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The concept is presented here as it is key to understanding the development and form of the intervention.
The key components of the concept, the issues of responsibility and the supported self-management roles
of the patient, carer and CNS are outlined. Figure 2 is a diagrammatic representation of the concept.
Patient roles
Some study patients participated in managing their medicines almost entirely themselves; however, this
was the experience of a small minority. Those who had nurse specialist input and/or a carer who played a
role in supporting self-management enacted their own roles differently as a result, leading ultimately to a
change in their resulting behaviours. This was the experience of the majority of the patient sample. The
roles undertaken by patient participants are mapped to the roles to support self-management proposed by
Johnston et al.51 in Table 5.
TABLE 3 Health-care professional demographics
Demographic characteristic HCPs, n (N= 19)
Sex
Female 18
Male 1
Professional background
Nursing 17
Medicine 2
Main working environment
Hospice inpatient 4
Hospice education 1
Community 10
Hospital 2
Community and day hospice 1
Hospital, hospice and community 1
Length of time in current post
Years, mean (range) 7 (0.5–24)
Length of time in palliative care specialism
Years, mean (range) 13 (1–27)
TABLE 2 Intervention development interviews and focus groups sample
Patient and carer sample (n= 19) HCP sample (n= 19)
Yorkshire
1 focus group, n= 4 patients 1 focus group, n = 4 CNSs
1 face-to-face interview, n= 1 consultant
Hampshire
11 interviews, n= 11 patients, n = 4 carers 2 focus groups: n= 10, 9 CNSs + 1 specialist registrar; n = 3, 2 inpatient
unit nurses, 1 lecturer/practitioner
1 telephone interview, n= 1 lead nurse/commissioner
Overall total
38 participants
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The patients often played an advocacy role on their own behalf, for example requesting alternative
analgesics/opioids where they found the side effects unacceptable and they were unable to manage
them. They also educated their carer, if they had one, regarding their medicines so that if their condition
changed or they had a bad day then they could rely on them to safely administer their medications.
This often took the form of listing their medications, creating a simple timetable of what they took and
when and keeping this in a location within their home that could be easily referred to. This aided their
communicator role whereby they transferred relevant information regarding their medicines, their
effectiveness and their experience of side effects to HCPs [particularly general practitioners (GPs) and
CNSs]. Those patients who were under the care of a community palliative care CNS often set joint plans/
goals with their CNS, whereas others not under the care of a CNS made their own plans and goals and/or
negotiated these with their GP (e.g. coming off a neuropathic agent because of unacceptable side effects).
In addition, the patients facilitated relationships with their HCPs and carers so as to aid access to their
medicines. Patients worked at relationships with those who were key to managing their medicines and
supporting their self-management: CNSs and GPs, as well as community pharmacists. They often found
that knowing their pharmacist aided the supply and stocking of their medicines, resulting in them
obtaining their medicines quickly and without delays in the system. At times, pharmacists put in repeat
prescription requests for patients because of these relationships, meaning that the patient then just had
to arrange to collect the medications from the pharmacy or could use pharmacy delivery services,
when available.
TABLE 4 Patient and carer demographics
Demographic characteristic Patients, n (N= 15) Carers, n (N= 4)
Sex
Female 7 4
Male 8 0
Age
Years, mean (range) 66 (47–84) 69 (52–80)
Cancer site
Bile duct 1
Breast 1
Colon 1
Lung 4
Lung (pleural mesothelioma) 1
Oesophagus 1
Pancreas 1
Prostate 3
Skin (melanoma) 1
Uterus 1
Educational level
Degree level or above 4 2
Below degree level 6 2
No qualifications 5
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The role of facilitating/managing the practical issues related to supply and medicine-taking was frequently
an onerous one for patients. They had to get prescriptions, obtain the medicines, understand them once
they had been dispensed, organise the medicines at home to keep track of them, store them, schedule
them around their routine, remember to take them and, finally, actually administer them.
The patients played a problem-solving role navigating the difficulties in the medicines supply system.
They also problem-solved the side effects of their opioids, making decisions to appropriately balance the
benefits of pain control with a manageable level of side effects. This was an individual balance (e.g. titrating
laxatives on a daily basis to offset the common side effect of constipation). Others for whom nausea was an
issue titrated antiemetics on a daily basis. The side effect of drowsiness led some to delay doses or take
smaller doses to minimise this. Furthermore, at times a small minority of expert self-managers made complex
decisions regarding the dose of opioid to take when it was prescribed within a range.
•   Ever-changing issues: disease progression, treatment, symptoms, side effects
•   Fluctuating capabilities of both patient and carer
•   Acceptance of end-of-life diagnosis
•   Meaning of pain: continual reminder of disease and prognosis
•   Misconceptions and public perception of opioids
•   Previous experiences of opioids
•   Side effects of opioids
•   Pack inserts not tailored to medication usage at end of life
Expert/master
•   Responsibility chosen
•   Acceptance of risk, choice and autonomy
•   Complex decision-making
Transferred responsibilities
•   Reduced capabilities, competencies
     and engagement
•   Negatively affected by uncontrolled
     pain, side effects and depressions
•   Responsibilities transferred to
     another
Patient/carer roles
•   Advocate
•   Educator
•   Facilitator
•   Problem-solver
•   Communicator
•   Goal-setter
•   Monitor
•   Reporter
Manager of practical issues
•   Getting prescriptions
•   Obtaining medicines
•   Understanding medicines
•   Organising medicines
•   Storing medicines
•   Scheduling
•   Remembering
•   Administering
CNS roles
•   All roles underpinned by needs assessment
•   Advocate
•   Educator (information provision)
•   Facilitator
•   Problem-solver (pre-emptive role)
•   Communicator
•   Goal-setter
•   Monitor (and coach)
•   Reporter
Manager of practical issues
•   Getting/writing prescriptions
•   Obtaining medicines
•   Organising medicines
•   Storing medicines
•   Scheduling
End-of-life context
Opioid-related fears
Continuum of self-management behaviour
Roles undertaken
FIGURE 2 A concept of supported SMART.
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The patients monitored their symptoms, side effects and the effectiveness of their medicines, often
keeping their own records of this, particularly in relation to the administration of ‘as required’ doses for
breakthrough pain. This was facilitated by the input of community palliative care CNSs or GPs, who
prompted patients to consider how much were taking, when they were taking it and how they found it
(H2HCPfocusgroup). As a result, the patients were often in a position to accurately report their relevant
symptom and side effect experiences, and changes, to their HCPs.
Carer roles
The supportive self-management roles of the carer fluctuated in relation to changes in the competencies
and engagement of the individual patient. However, a few patients had always handed over responsibility
for medicines management to their carer: ‘she just always did it . . . I tend to be . . . not worried enough
about it you know. I basically need looking after that’s the truth of the matter’ (H1Pt004). The roles
undertaken by carer participants are mapped to the roles to support self-management proposed by
Johnston et al.51 in Table 5.
TABLE 5 Roles undertaken by patient participants
Johnston et al.51
roles to support
self-management
Intervention development interview and focus group participants
Patients Carers CNSs
Advocate For themselves (e.g.
requesting alternative opioids/
forms if side effects are not
acceptable)
Total advocacy role when
needed
Right type and route of drug
Educator Of carer if required,
anticipation of future changes
(i.e. planning for worsening
condition)
Of patient and CNS when
needed
Refining knowledge for
individuals, providing
instruction
Facilitator Of relationships/access to
medicines (e.g. GP, HCPs and
carer, carer and community
pharmacist)
Manager of the practical
supply and medicine-taking
issues when needed
Preparing for transitions, ‘home
feels like you have not got
someone to speak to just
around the corner’
Problem-solver Access to medicines and
navigating the supply system,
side effects management and
off-setting doses
Pre-emptive (e.g. regarding
stock management or
suggesting need for
breakthrough analgesia)
Best drug and side effect
profile for individual, sorting
out when supplies get in a
muddle, pre-emptive problem-
solving (‘always have a plan B’)
Communicator Of relevant information to
all – family and HCPs
‘Is it helping?’ Encouraging
discussion with patient
Picking style of communication
for individual, knowing the
family and patient (mediator as
well as communicator)
Goal-setter Self-planning, planning with a
GP or joint planning with CNS
Often in relation to getting
out and about (e.g. getting
out of the house for a
coffee, going to a favourite
place)
Proposing options and allowing
the individual to decide what
they would prefer and putting
a plan together
Monitor Writing down of
breakthrough doses and
noting effectiveness
Diary recording How much information has
been understood? Monitoring
involvement of patient in
decisions and reviewing
effectiveness of medicines
Reporter Of relevant symptom
experiences and side effects
Evaluation of the
effectiveness of the
medications
To wider palliative care team
and GPs
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Carers often took on an all-encompassing advocacy role for the patient, particularly when difficulties arose
with challenging side effects or poorly controlled pain. Advocacy took the form of working or facilitating
the supply system in relation to managing all the practical issues of getting prescriptions, obtaining the
medicines, understanding the medicines, organising the medicines in the home environment to keep stock
of them, storing them safely, scheduling them around the patient’s routine, remembering (i.e. reminding
the individual to take the medicines) and actually administering the medicines if required.
Facilitating and advocating on behalf of the patient in relation to obtaining the medicines was complex,
onerous and a hugely time-consuming process for many carers. One patient outlined his difficulties
(lengthy delays) in obtaining his fentanyl patches through a non-palliative care specialist pharmacy. This left
his wife needing to make in-person visits to speak to the pharmacist on his behalf, only for her to be
equally frustrated and leave the pharmacy without the patches, in tears, because she could not answer the
question ‘Who’s prescribed these?’:
H2Pt004: I’m not sure if it’s the chemist . . . when I rang through and said ‘Here look, what about these
patches?’ and the woman said ‘What are they?’ And then I said to her – and she said ‘Yes, well we have
got them down on the list, but I don’t know where they are.’ So in actual fact, on like that again . . .
Carer: If you lived alone, somebody very elderly . . .
Researcher: Yes, you need someone to work the system.
Carer: Yes! Yes!
As with the various roles of the patient and CNS, the carers’ roles were complexly interwoven.
The facilitator role for carers, as in the following example, was one of monitoring pain and the
effectiveness of medicines via a pain diary. In turn, this facilitated the administration of analgesia by the
carer to the patient, creating the end result of confidence and control over the situation:
. . . I would take an example actually it was quite difficult, as a facilitator it’s not quite between
health-care professionals and patient, it was actually between patient and carer. And it goes back to
what we were saying earlier on about carers being reluctant to give it [morphine] or patients being
reluctant to take it. And it’s where a diary was very useful ‘cos it actually empowered the carer to feel
that she was doing something useful to help with her spouse’s pain but also that she felt more in
control that she wasn’t giving it more often than she should do or she was writing that it had an
effect or didn’t have an effect and where they were going with it. And she was far happier to give it if
she was documenting things than just on his say so that ‘I’m in pain’, and he was saying that ‘I’m in
pain and she won’t give it to me’ . . . She admitted she wasn’t giving it because she was frightened
she was going to be giving too much and how would she know when to stop and the diary actually
facilitated being able to give [it], it was confidence . . .
H1HCPfocusgroup
Carers often played a monitoring role highlighting and watching for condition, symptom and side effect
changes. Indeed, their monitoring was often astute because of the acuity of observation by someone who
knew the patient best. As a result, carers could play an educator role of both the patient and CNS,
highlighting these changes as required. This linked closely with their communicator and reporting role, as
carers often aided the monitoring of the effectiveness of medicines by asking the patient simple questions
such as ‘Is it helping? Does that help?’:
. . . And every so often, I say to you don’t I? ‘How are you on the laxatives?’ And it seems ridiculous
doesn’t it, because . . . that’s the best [thing] that’s happened, is you’ve managed to get it [opioids vs.
constipation] at a level which is not a problem for you haven’t you . . . ?
Carer-H2Pt004
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Consequently, the carers encouraged discussion with the patient and could report this information to
HCPs, the CNS and GP as required.
The carers often took a lead in establishing small goals for the patient that they knew were of importance
to the individual. With effective medicines and side effect management, goals frequently set were in
relation to getting out of the house and continuing to visit favourite places for the individual.
The role of problem-solver was arguably the greatest of the roles played by the carer. In the words of one
carer, ‘I try and stop problems happening’ (Carer-H2Pt004). As with the CNS problem-solving role, this was in
the main pre-emptive carer role, resolving potential problems. This was particularly the case in terms of asking
the individual about their pain, so as to be able to administer ‘as required’ analgesia. Carers also pre-emptively
stock managed, requesting medicines before they ran out, and chased GP practices for prescriptions and
pharmacies if medications had not been dispensed as requested (e.g. in a different form or were missing).
Clinical nurse specialist roles
In order to evaluate which roles were required, and at what point, the nurses assessed the competencies
not only of the patient but also of the carer. The roles undertaken by the CNSs are mapped to the roles to
support self-management proposed by Johnston et al.51 in Table 5. It was recognised that nurses’ provision
of supportive self-management roles would fluctuate in relation to patient and carer needs and that at
times the roles would be challenging:
. . . I think all of these [roles] will probably peak in difficulty, at times depending on the situation.
As a professional, there could be a nightmare sometimes, in a person’s home advocating for that
patient, if . . . you have a family who have distinct feelings that are opposing the patient, that’s really
. . . difficult. The monitoring, there will be times when that, even on the inpatient unit, that’s got to be
a challenge at times, depending on the complexity of the patient, and the capacity of the staff, and
staffing levels . . .
H2HCPfocusgroup
Within this challenging context, the nurses emphasised the importance of ensuring that the individual
patient had the right drug via the right route. For them this was a clear role of advocacy:
HCP1 (H2HCPfocusgroup): I met a lady with head and neck cancer that was really compromising her
mouth and she was just starting on opiates, thought patch that’s going to be the best way to go . . .
Spoke to the GP who said fine, then they changed their minds and went back to the tablets because
someone in the practice had gone on a palliative care course and was told that MST [Morphine
Sulfate Tablets modified release] it’s cheap and cheerful start everyone on that. So then the relative rings
up we’ve just gone to collect the patches and it’s tablets so I’m like ‘Oh god’ ring up again, ‘there is a
reason why we said patches, I know they’re expensive but she can’t open her mouth’. So like ridiculous!
HCP2 (H2HCPfocusgroup): It’s about being that patient’s advocate isn’t it . . .
The supportive communicator role was vital to the nurses and they emphasised the complexity of
communicating well to ‘the agenda of the patient’ using language that would be understood, while
highlighting ‘what they need to know, because they might not be interested in all the things that you
want to say’ (H2HCPfocusgroup):
. . . I think you have to really pick your style of communication with each individual, this is what X was
saying about knowing your family, knowing your patient, ‘cos sometimes you are as much a mediator
as communicator. We can sometimes have a relative that just simply doesn’t believe in morphine . . .
they will withhold it from them . . . And then others where they will perhaps give a little too much,
then you have to sort of be kind in how you say these things, because they want to make it better . . .
Yes, so communication is quite hard; you have to get that right, don’t you . . . ?
H2HCPfocusgroup
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All the supportive roles of the CNS interlinked and overlapped, particularly that of communicator and
educator. This role of educator was viewed as one of providing ‘instruction and information regarding
medicines’ (H2HCPfocusgroup). The ever-increasing role of the internet as a source of information for
patients and their families was also recognised so that the supportive role of the nurses was often seen as
one of helping to ‘refine’ this knowledge for individuals. The need to provide education for carers specifically
was viewed as important, but it was argued that these supportive needs may not be met in practice:
. . . You get carers who the knowledge gap is so huge for them, they want to help they want to know
what to do and we need to be filling that knowledge gap for them appropriately . . . I think for the carer
what they want is the right information and we don’t currently meet that need I don’t think. We try . . .
H1HCPfocusgroup
In order to meet the informational needs of patients and their carers (within their educational role) the nurses
recognised that a number of issues needed to be identified and then addressed. In summary, they were:
l the starting point, working out how the individual best learns and then tailoring the information to
this; verbal information reinforced by written information (+ technological alternatives if possible) at the
right pace, via stepwise provision
l identifying the types of pain and which medications are best suited to the types of pain for that individual
l outlining each medicine, what it is, what it’s for and how to take it
l explaining the requirement to adjust medications on an ongoing basis and establishing this as baseline
understanding; highlighting that there are always alternatives if pain is uncontrolled or side effects are
viewed as intolerable
l informing on the side effects, the benefits versus the burdens and the likelihood of the individual
experiencing them
l outlining the need for laxatives and working out the balance between opioid dosage and laxatives
required for the individual
l discussing and revealing the individual’s fears, challenging and correcting opioid-related preconceptions
l explaining the lack of dosing ceilings for opioids and being clear regarding the relative lack of required
dosing intervals for ‘as required’ doses for breakthrough pain
l highlighting the importance of monitoring the effectiveness of the medications (especially in relation to
the pain experience); the need to record breakthrough doses so that regular opioid doses can be
increased/altered if required
l signposting the individual and carer to contacts for concerns/questions, outlining the most suitable
contacts for specific situations that the individual may encounter.
Within their problem-solving role, the nurses sought to work out the best drugs and dosages with the
most tolerable side effect profiles for the individual, recognising that this required fine tuning over time,
often in conflict with the end-of-life context. The nurses also assisted the patients/carers with problem-
solving in relation to the practical (supply and administration related) issues of getting prescriptions,
obtaining the medicines, organising the medicines at home, storing the medicines safely and scheduling
the medicines around their daily routines. For example:
. . . Getting prescriptions . . . we spend a lot of our time trying to sort that out, and you can
understand how patients really struggle with [it]. I mean one chap . . . it has taken so many phone
calls and so much of my time . . . a youngish intelligent chap and he has just really struggled with that.
I think the other issue is sometimes they get 28 tablets and then you change them, then that knocks
their whole sort of repeat prescription out of balance . . . When you’re wanting dosette boxes as well
they’re really difficult, they’ve already started, then you’re adding something in and changing them, to
add bits in, that’s really problematic . . .
H1HCPfocusgroup
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This could be a time-consuming role for nurses as medication supplies got ‘out of sync’ for patients with
any prescription alteration. For example, increases in dosage meant that supplies lasted for shorter periods
and ran out in advance of supplies of other medications.
The problem-solving role was often implemented in a pre-emptive way. This was referred to as
‘mind-reading’ or being ‘a problem-solver in advance’, which necessitated always having ‘a plan B’ (such
as knowing who to contact or consideration and education of the individual patient in relation to potential
crisis episodes, e.g. chest inflections or bowel obstruction):
. . . You’re anticipating, you’re pre-empting what might happen to be able to talk it through with that
patient and to that carer to be able to give them you know a toolkit of who to ring, when to ring and
why they might ring. How to deal with the uncertainties of do I ring now, do I ring later, but the
security of knowing that there is somebody to ring . . .
H1HCPfocusgroup
The professional participants stressed the imperativeness of this pre-emptive problem-solving role and the
fact that it mirrored the wider requirements of end-of-life care in general:
. . . The notion of the discussion about symptom control and analgesia and medicine things, the
pre-emptive nature of it links in with the much bigger picture, doesn’t it, I think of palliative and end
of life care now. The fact that all of it is about pre-empting and pre-planning, advance care planning,
you know the Gold Standard Framework; getting people on a register and pre-empting their kind of
deterioration, all of those things. It mirrors in a more distilled way the bigger picture of things . . .
H2HCPfocusgroup
Indeed, part of the pre-emptive problem-solving role within the context of end of life was the requirement
to prepare individuals and their carers for transition not only in terms of deterioration of condition, but also
in terms of transition between care settings, frequently between inpatient units/hospices and home. This
could also be seen as integral to the role of facilitator, whereby the nurses prepared the patients and their
carers for these transitions by enabling them to use inpatient stays ‘like a pit-stop’ where they could
initiate, develop or refine their information and knowledge of medication management. For example:
. . . So part of it before they go home is about talking through what our rationale has been for their
medicines and what type of pain we’re looking at to take for certain things. What we’ll have on the
discharge sheet that goes with them, there’s like a medication chart of what their drugs are and why
they take them, when they take them but you can be a little bit more distinct can’t we on the type of
pains so they’ve got some slight signpost, as to what to take, where when and how . . .
H1HCPfocusgroup
Another professional role was that of goal-setting. This was often about proposing different options
to the patient in relation to their medicines management, allowing the individual to decide between the
proposed courses of action and then putting a joint plan together based on the individual’s preferences.
These plans were then relayed and discussed with the wider palliative care team and GPs as needed (to
support medication changes) under the role of reporter. Furthermore, the CNS role of monitor intermeshed
in practice with the role of goal-setter (involvement in decision-making and shared responsibility where
possible). The nurses continually monitored ‘how much the patient has understood’:
. . . Whatever you do, if you are setting goals if you are solving a problem, or if you are educating,
whatever you are doing you have to check that . . . the message has arrived . . .
H2HCPfocusgroup
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. . . In terms of monitoring as well I think it’s about involving the patient in those decisions isn’t it so
you know having given them some education actually when you’re reviewing things you know saying
to them so are you happy then that we’re still on the same dose for now, you know they’ve got that
involvement in that haven’t they, it’s like an agreed shared sort of responsibility . . .
H1HCPfocusgroup
The monitoring role was seen as an imperative professional responsibility, particularly when starting
individuals on new medications. The nurses also emphasised the value of face-to-face monitoring in the
context of end of life. In the words of one:
. . . You can see people’s responses, you can work with them at their timing to answer questions.
I mean one gentleman I went into, I talked to him about his medication, and reading his bottles,
and actually I discovered he couldn’t read. And it was something as basic as that, making sure that . . .
I then put symbols on there that he felt represented like his water tablet, I put a droplet of water on a
little label on his bottle. So I think it’s a blended approach really, you know, just to phone them up,
say ‘How are you doing?’ and if you sense that this is not going . . . The things you are listening to
aren’t representative of somebody managing, then you actually go back and reassess them face to
face; there is nothing quite like eyeballing a patient . . . !
HCPW001
The continuum of self-management behaviours
The patient, carer and CNS roles outlined above were enacted on a far-reaching continuum. This
continuum of behaviours ranged from, at one end, expertise and mastery, with the individual taking full
responsibility for complex decision-making, accepting the associated risks, to, at the other end, transfer of
responsibility to another (the carer and/or CNS) because of patients’ and carers’ reduced capabilities and
engagement in self-management behaviours, sometimes negatively affected by uncontrolled pain, the side
effects of opioids (particularly drowsiness), clinical depression and memory loss:
HCP1 (H2HCPfocusgroup): I’ve seen both sorts . . . Obviously this is reflecting a distinct change in the
type of patient we are seeing as well. I would say the younger ones coming along are becoming
masters; they are gaining information from the internet, using every resource they have; they are
thinking outside of pure medication as being an option for their pain control, and yes, I have seen . . .
I can think now in my mind’s eye of a ‘master’. But prior to when I began in Hospice care, everybody
needed to be told, and there remains a little group of people, usually in the older age groups that still
need that and actually feel quite burdened by being expected to choose, and make decisions.
HCP2 (H2HCPfocusgroup): Very much so. There is a shift in people’s tendency. Before it was
‘You decide, you are the expert’, now it is ‘Wait a moment, I am the expert of my body and my
health, so I . . . give me the knowledge, give me the information so that I can make an
informed decision’.
Researcher (H2HCPfocusgroup): Is it something that you negotiate with patients, whether you expect
them to self-manage and master all these things? Or is it something that is sort of tacitly understood?
HCP1 (H2HCPfocusgroup): . . . You can tell, straight away when you start talking to them about what
they understand and what they want from us; that comes across very quickly, which group they are
going to fall into . . .
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All study participants highlighted the individual-level variation in the range of self-management
behaviours enacted:
. . . You’ll get some who don’t want anything to do with their medicines and you sort it out and then
people that want to know everything will want to do their own as much as they can . . .
H1HCPfocusgroup
Those patients who, when discussing the role they played in managing their medicines, reported feeling in
control, often referred to how relatively ‘lucky’ they were in terms of being able to ‘think about it and
work it out’. These individuals at one end of the continuum had accepted full responsibility for their role
and were in their eyes ‘doing it all’ themselves, but with backup strategies in place and knowledge of
whom to contact if anything changed.
The HCPs often spoke about those individuals at polar ends of the continuum but there was also wide
variation in behaviours and choices made by those individuals who were not at either end of the
continuum. Indeed, behaviours and choices were never static, but ever changing. In addition, there was
wide variation within the group of individuals assessed by their HCPs as ‘self-managing’ of their analgesia
and related treatments. For example, one professional discussed a patient who was managing his
medications, but without the adjustments that she ideally would have recommended:
. . . A man that’s really angry and frustrated, he’s young but he was diagnosed late. He’s had lots of
frustrations with chemo, and things like that. So he’s quite resistant to changes, and that’s fine, so
we’ve just left him [medication wise] as he is; he’s not managed quite properly, not adequately in our
eyes, but he is doing what he wants to do at the moment, so he’s doing it . . .
H4HCPfocusgroup
Where does the responsibility lie?
The competencies and engagement of the individual, and their acceptance of responsibility, affected their
enactment of self-management behaviours and, thus, the roles required of the carer and CNS. The CNSs
recognised the importance of assessing the individual’s ability to understand, their capabilities and their
potential engagement (what the individual was currently doing and what they would like to do):
HCP1 (H4HCPfocusgroup): . . . Asking them to go to through their medicines, some people haven’t
got a clue, and other people don’t even need to get the boxes or list out and they can tell you
absolutely everything they’ve had, and they’ve got lists and the diary, and it all written down. And
other people haven’t got a clue.
HCP2 (H4HCPfocusgroup): As well as trying to establish what level of understanding they’ve got, you
are using that information about how much they have engaged with their medicines and things to try
and determine the scope for them to self-manage . . .
For the nurses, it was about recognising that individuals make their own analgesia-related choices within
their home environments and that their autonomy to do so should be respected:
. . . I always say that it’s their pain and it’s up to them how they choose to manage it we can give
them the medications or the tools but you know ultimately if they’re happy to live with a certain level
of pain, they don’t want to use their medications, that’s their choice we’re there just to give them and
advise them how to use things but ultimately it’s up to them . . .
H1HCPfocusgroup
DOI: 10.3310/hta21760 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 76
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Bennett et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
23
Indeed, some patients made deliberate decisions to withhold or reduce doses of opioids to offset the side
effects that they were experiencing. These decisions were about balancing pain control against the things
that they wished to achieve:
. . . So if I’ve got pain, sometimes I won’t have that [oxycodone immediate-release formulation;
OxyNorm, NAPP Pharmaceuticals], and I choose not to, because I don’t want to get tired and sleepy as
I want to drive, or I want to do something, so I’ll manage it in a different way, not necessarily by
taking drugs . . .
H3Ptfocusgroup
The context of end of life
The overarching context of end of life had a profound influence on the supportive self-management
behaviours of the patient, carer and CNS. Within this context, there were ever-changing issues related to
continual disease progression and subsequent changes in symptoms and side effects from both medication
and palliative treatments. As a result, the behaviours were ever changing.
This context was further complicated at the end of life by the surrounding swirl of what individuals and
their families were already striving to deal with (the wider context), and of psychological distress and
anxiety as well as high levels of carer strain. Thus, individuals in this context may be struggling to cope
with a palliative care diagnosis and there may be anxiety and potential clinical depression of both patients
and/or carers. As a result, the capabilities of both the patient and carer fluctuated greatly, influencing the
supportive self-management roles and the required behaviours of the CNS in particular.
Opioid-related fears
The data demonstrated that patients’ and carers’ behaviours in relation to opioid management were
strongly affected by misconceptions and common public perceptions of these medicines. It was
commonplace for patients and their carers to hold fears or assumptions regarding opioids:
l fear that the individual taking them will become addicted to these medicines, ‘you hear of so many
people get[ting] addicted to certain things’ (H1Pt004)
l assumption that there is a ceiling dose for opioids as with other medicines
l fear of overdosing, even by taking just one extra dose
l fear that these medicines are ‘killers’ because of press accounts of abuse of opioids (H2HCPfocusgroup)
l assumption that the individual will develop a tolerance to the opioids and the pain will therefore not be
controlled as a result
l fear that death of the individual is imminent if they are started on opioids [i.e. ‘I’m dying’
(H1HCPfocusgroup)]
l fear that if the individual takes these medicines now then there is ‘nothing later’ for them to take in
the future ‘so I’ll avoid it if I can’ (H1HCPfocusgroup).
These fears and assumptions affected the self-management behaviours of patients. This was clearly
articulated by one focus group participant who required a hospice admission as a result:
. . . My self-management wasn’t terribly good, that’s why I ended up in here [the hospice] in the first
place. But it wasn’t to do with side effects, because I don’t actually suffer particularly bad side effects.
It’s more to do with the psychological attitude that I was taking morphine, and that I didn’t want to
over-take and the doctors kept saying to me ‘No we are giving you such small doses you can self-
medicate, you can up this to 5 mls, etc.’. So it was getting my head around that, because I’ve spent a
lifetime of being the sort of person that just carries on; never go to the doctors, that’s why I ended up
here! You know, I’ve never been one to take a lot of painkillers, and now I’m sitting here, I’ve got
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lower back pain, and I could do with some morphine! But I just thought ‘Oooh, I’ll just wait till after
this study [focus group]’, that’s the sort of person I am. So it’s been sort of, just ‘cos I’m strong, a
Yorkshire woman that doesn’t like to admit failure or weakness, I think that’s been the main issue
with me . . . At the time I was taking . . . morphine, and it was for pain relief. And I had the slow
release, and that was OK, every 12 hours. And then if I needed to have the little extra, you know,
I was the same as the other ladies, ‘Oh I don’t think I’ll be taking any of that!’ you know. Until
somebody did once say to me one day ‘You know you are on a very low dose you know’,
and I thought ‘Ooooh! How dare you!’ I thought I was a hard drug taker!
H3Ptfocusgroup
The HCP also highlighted that carer-held fears could be projected onto the patient, negatively affecting
self-management behaviours:
. . . sometimes the fears of the relatives project on to the patient. The patient might start out all right,
and then the minute they say to their nearest and dearest, or the next door neighbour ‘I’m on this
now’ and then they just get all these horror stories, and then you’ve got that to kind of circumvent as
well. So you know, it’s never black and white . . .
H4HCPfocusgroup
Arguably, the most common fears related to opioid usage were not the ones referred to above, but were
related to the side effects of the medicines themselves:
. . . I think probably the greatest fears are not so much the addiction but sedation or constipation and
again it’s a reluctance, ‘I won’t take it unless I need to ‘cos I don’t want those effects’ . . .
H1HCPfocusgroup
Patients referred to being reluctant to take opioids for fear of both constipation and drowsiness. The fear
of constipation and the subsequent difficulties in balancing doses of laxatives with opioid intake was
particularly troublesome for some. A number of the sample had accounts of faecal impaction requiring
admissions; as a result, the fear of constipation was profound:
My main concern is that if I get some pain, I take extra morphine. I’m on a patch at the moment,
so if I change the dose of the morphine, I have to change the dose that I take of the laxative. And of
course, the first time ‘oh yeah, OK, let’s bang it up by another one of the sachets’. And of course
I was then for the next 2 days on the loo! So ‘oh let’s cut it down’, by which time ‘Oh god I haven’t
been to the loo now for 2 days!’
H2Pt004
I’ve never before seen people so frightened of constipation, as he has been.
Carer
The SMART intervention
The development process and resulting conceptual work described above generated the SMART
intervention that comprised both a four-step educational approach and a SMST. The intervention was
designed to be delivered via a feasibility study to patients by community-based palliative care CNSs. The
approach to delivery involved nesting the intervention in a clinical encounter (nurse–patient consultation)
and was enacted through a conversational process.
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The four-step educational approach
The four-step educational approach was maintained from the study protocol, with data confirming that
such an approach was an appropriate way to proceed. Our contextual work had identified that needs
assessment, information provision and regular review were important components of a supported self-
management intervention that would potentially fit well into nurses’ usual practice processes. Goal-setting
(with associated action plans) was proposed following expert educational psychologist input (SM) as the
mechanism by which information provision could lead to behaviour change. In addition, a meta-review
of self-management interventions for long-term conditions identified that action plans for deteriorating
conditions were a key component of successful interventions.21 The approach was designed to sit alongside
the everyday practice of specialist nurses, with four cyclical steps to occur at each nurse–patient visit.
Step 1: needs assessment
A detailed assessment of patients’ needs is part of usual specialist practice and was intended to take place
at all SMART study nurse visits between the CNS and patient. The CNSs were to identify specific concerns
and needs related to self-managing opioid medicines at home, such as:
l fears and concerns related to taking opioids and their side effects
l self-management capabilities and issues preventing supported self-management of opioids at home
(e.g. getting prescriptions and obtaining medicines or dealing with breakthrough pain)
l relevant contact information for further advice and information.
Step 2: information provision
Verbal information reinforced by the provision of SMST resources. Following needs assessment, the CNSs
were to discuss any issues raised and use the SMST to provide tailored, staged and relevant educational
materials via the study resources (outlined below).
Step 3: goal-setting
Development of a self-management focused action plan. The third step aimed to guide patients towards
developing self-management focused goals at each visit. CNSs were to help patients identify goals that
were achievable through a set of actions that could be reviewed and modified at each visit.
Step 4: review and coaching
Review of the action plan and provision of support. The intent was for the trial CNSs to review patients’
self-management capabilities and progress at each visit and provide coaching and support to develop,
maintain and improve self-management behaviour. This was planned to involve the reviewing of
self-management goals and the evaluation of action plans. Nurses were also to focus on identifying
barriers for individuals to meet self-management goals or steps in their action plans, suitable supported
self-management strategies for the trial patient and/or carer and problem-solving techniques. Follow-up and
reinforcement of information and self-management strategies were planned to reflect usual patterns of and
forms of contact and review (i.e. face to face and via telephone).
The self-management support toolkit
The evidence from the data was mapped to components of the intervention (both the educational
approach and proposed SMST resources), resulting in the framework outlined in Table 6. The framework
also linked the intervention components to the target participant understanding and behaviour in relation
to self-management, including the behaviour source,39 the target supportive self-management roles of the
specialist nurse,51 the self-efficacy techniques to be used by the nurse54,55 and the intervention function,39
and served to ensure a theoretically modelled intervention.
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TABLE 6 Data mapping to intervention components and scope of toolkit resources
Target participant
understanding/behaviour
Target professional
self-management
rolea
Self-efficacy
techniqueb
Intervention
component Evidence from the data
Target
construct
(behaviour
source)c
Intervention
functiond
Willingness to self-manage
opioids and side effects
1, 2, 3 Verbal persuasion Recruitment and
consent process
pre-intervention
delivery;
educational
approach
Majority see it as part of their responsibility:
you’ve got to look after yourself quite a bit,
and then know who to turn to if you can’t
find the answer
Capability;
motivation
Education;
persuasion
Shared understanding of side
effects
2, 5 Mastery experience Educational
approach; factsheet
Importance of acknowledgement. Need for
‘normalisation’ to reduce fear. For patients,
opioid drowsiness not always perceived as
diminishing. Prescription of laxatives but ‘they
never said you will need it’. Lack of focus on
opioid nausea and drowsiness by HCPs
Motivation Education
Self-titration to negate side
effects (drowsiness and
constipation)
2, 4, 5, 6 Verbal persuasion;
mastery experience;
role modelling
Educational
approach; factsheet
Unmet need. Patients learn this through trial
and error, accounts of ‘crisis’ situations with
impaction, underdosing to control drowsiness
Capability Training;
incentivisation;
enablement
Misconceptions and
unnecessary fears regarding
opioids
2, 5 Verbal persuasion;
mastery experience;
emotional
regulation
Educational
approach; factsheet
Issues: holding back on medications (e.g. stock
piling for a rainy day); ceiling amount and as
needed 4-hourly dose; ‘I’m imminently dying’;
addiction; tolerance
Motivation Education;
persuasion;
enablement
Safe drug administration:
control of what taking, why
and when (+ safe storage and
not removing medicines from
boxes)
2, 3, 5, 7, 8 Verbal persuasion;
mastery experience;
role modelling
Information chart
(what, when,
rationale,
appearance);
dosette box if
required; podcast –
patient
Some unmet needs here: some ‘muddled’
patients not always aware of drug names or
purpose; using pet names for drugs, etc.;
confusion over millilitres vs. milligrams; literacy
level; need for removal of ‘old’ drugs;
information chart would be helpful for carers
too
Capability Education;
training;
modelling;
enablement
Recognition of pain patterns 2, 4, 5, 7 Verbal persuasion;
mastery experience
Educational
approach;
factsheet; pain
diary
Importance in order to control pain Capability;
motivation
Education;
persuasion;
incentivisation;
training
continued
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TABLE 6 Data mapping to intervention components and scope of toolkit resources (continued )
Target participant
understanding/behaviour
Target professional
self-management
rolea
Self-efficacy
techniqueb
Intervention
component Evidence from the data
Target
construct
(behaviour
source)c
Intervention
functiond
Monitoring the effectiveness
of the medicines
2, 3, 4, 5, 6, 7, 8 Verbal persuasion;
mastery experience;
role modelling
Educational
approach;
factsheet; pain and
side effect diary;
podcast – HCPs
Importance for HCPs to be able to goal-set
and manage symptoms effectively, shared
responsibility with patient
Capability;
motivation
Education;
persuasion;
incentivisation;
training;
modelling;
enablement
Control over practical issues:
checking stock, ordering,
collecting, etc.
1, 2, 3, 4, 5 Verbal persuasion;
mastery experience;
role modelling
Factsheet; podcast
– patient
Practical issues can be onerous, sapping energy
unnecessarily (physical journeys, lack of syncing
of supplies, etc.)
Capability;
motivation;
opportunity
– physical
Education;
incentivisation;
modelling;
enablement
Checking of dispensed
medicines
2, 7, 8 Verbal persuasion;
mastery experience
Educational
approach factsheet
Not always right: supplies may be missing or
not in correct form. Use community pharmacist
as resource
Capability;
motivation
Education;
persuasion;
training
Back up plans: knowledge of
who to contact, when, plus
out of hours
1, 2, 3, 4 Verbal persuasion;
mastery experience
Educational
approach; factsheet
Key message in patient/carer data – unmet
needs
Motivation Education;
enablement
Understanding of initial verbal
information giving reinforced
by additional resources
2, 3, 5 Verbal persuasion;
mastery experience;
role modelling
Factsheets;
podcasts; list of
good websites,
signpost where
to go
Patients and/or carers ‘bombarded’ with
information. Recognition that where
information is given in it is not always taken in
and that it needs to be reinforced by other
resources
Capability;
motivation
Education;
training;
modelling;
enablement
a 1, advocate; 2, educator; 3, facilitator; 4, problem-solver; 5, communicator; 6, goal-setter; 7, monitor; 8, reporter.51
b Self-efficacy technique: mastery experience, role modelling, verbal persuasion and the regulation of physiological and affective states.54,55
c Target construct (behaviour source): capability (physical and psychological), motivation (automatic and reflective), opportunity (social and physical).39
d Intervention functions: education, persuasion, incentivisation, coercion, training, enablement, modelling, environmental restructuring, restrictions.39
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As a result of this framework, the SMST resources were developed to address the evidence from the data.
The resources comprised eight factsheets, two podcasts, a pain diary, medication charts and goal-setting
sheets. The factsheets were drafted to encompass all the core themes and issues outlined by the patients,
carers and palliative care HCPs. They went through iterative cycles in the development process. The study
PPI group was asked to review the content of all the factsheets, as were specialist HCPs from two different
palliative care teams who were not going to be involved in the feasibility study (in order to prevent
potential issues of bias and/or contamination). The final stage of development was review of the factsheets
by an expert in health literacy (HB). The presentation and structure of the facts were recast with reference
to the evidence on how people make sense of illness and decisions about treatment.63,64 Factsheet content
did not change, but readability was improved (assessed using Simple Measure of Gobbledygook readability
formula65) by shortening sentences and eliminating some longer words (except drug names). The text
was subdivided in all the factsheets into small titled sections to facilitate review by patients, with spaces
provided for patients and carers to write notes or questions. These changes improved the factsheets’
health literacy and utility to support patients’ reasoning about treatment in the context of their experience
of illness and lifestyle.
The factsheets
1. Managing pain with opioid medicines.
2. Contacts for advice and further information.
3. Getting prescriptions and obtaining medicines.
4. Organising opioid medicines.
5. Fitting pain control into my daily routine.
6. Checking opioid medicines are managing pain.
7. Common concerns when taking opioid medicines.
8. Keeping on top of side effects.
The eight factsheets are reproduced in Appendix 9. Each factsheet was designed to be used as a
standalone educational resource or in combination to provide a set of educational materials relevant to the
trial patient. Only factsheet 2 (contacts for advice and further information) was a core factsheet resource
that the CNSs were asked to deliver to the respective trial patient on their first SMART visit.
The podcast films
The data demonstrated that individuals value resources being available in various forms to meet individual
need. Therefore, two audio-visual podcasts were developed as an alternative medium:
l ‘The Practical Issues of Managing Medicines’ – when a patient described the practical methods
(self-management strategies) they used to monitor their medication stock levels, order new medicines
and organise them at home.
l ‘Monitoring the Effectiveness of Medicines’ – two experienced palliative care specialists discussed
why monitoring the effectiveness of medicines is valuable in relation to self-management and why
specialists may ask individuals to do this.
Structured guides (see Appendices 10 and 11) were written from the data to guide filming and the films were
edited to produce two short 5- to 6-minute podcasts. This length of the podcast files was guided by the data,
which suggested that patients and carers would watch short films and could benefit from them. Furthermore,
it is known from existing resources (such as www.healthtalk.org/) that there is value that patients place in
hearing authentic voices recounting their experiences and strategies in dealing with health-related issues and
problems. Even when strategies are not ones that individual patients are likely to use themselves, it can help
them to consider alternative strategies that might work for them. The podcasts were designed to be delivered
to patients on a digital versatile disc (DVD) or memory stick (for computer use).
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The pain diary and medication chart
In order to develop versions of a pain diary and medication chart to suit this specific context, existing medication
charts and pain diaries used at the sites were requested and reviewed. In addition, a selection were sampled
from online sources (e.g. professional-focused medication administration records) and patient-focused booklets
(e.g. those produced by Macmillan Cancer Support). Two resource charts resulted in:
1. a pain diary to record and track pain which could be used by the patient (and their CNS) to monitor the
effects of opioid medication and any side effects (see Appendix 12)
2. a medication chart which could be used to help patients organise, remember and take their medicines
(see Appendix 13).
The goal-setting sheets
The final SMST resources, self-management-focused goal-setting sheets, were developed in consultation
with an expert educational psychologist (SM). They were entitled ‘Things I would like to achieve over the
next week’ (see Appendix 14) and were the second of two core resources of the SMST (the first being the
‘Contacts for advice and further information’ factsheet). The sheets were designed so that a trial patient
could set one or two key goals at each visit and then with the help of their CNS set an action plan with
small, practical steps to meet the goals. At the bottom of each sheet was space for the patient to review
with their CNS the progress, or otherwise, that had been made in meeting the goals so as to inform
development of the action plan where needed.
Training development
A training package was developed prior to the feasibility study to enable the study nurses to deliver the
intervention. The training package was developed from the following:
1. A philosophical standpoint and definition of self-management at the end of life derived from our
developing conceptual analysis (Evidence synthesis and Phase II: refining and detailing the intervention)
and drawn from the work of Johnston et al.51
2. To date, there has been a lack of specification in the literature about how self-management focused
conversations regarding analgesia and related treatments at end of life should be enacted – it is not known
what practitioners do and need to do to help support patients to self-manage. To illustrate the nature of a
conversation in this context, a conversation was modelled using ethno-drama from a real-life case exemplar,
by nurse educators for Masters students attending a module on cancer, palliative and end of life care.
3. Literature focused on the self-management of long-term conditions, such as systematic reviews and
practice guidelines (e.g. Canadian practice guidelines on self-management in chronic care66), which
emphasises the importance of action-planning was also used to inform the training development, as
were the delivery strategies of similar educational interventions by specialist nurses as part of complex
intervention studies.67
4. An awareness that those delivering the intervention would be both self-selecting and palliative care
nurses specialists with pre-existing expertise and skills.
The research team built on the four-step educational approach of needs assessment, information giving,
goal-setting and review and coaching to develop a training approach that modelled the four steps within a
therapeutic conversational process between the specialist nurse and patient. The educational approach and
conversational process were underpinned by recognition of the importance of:
l good communication skills, identifying concerns, clarifying and exploring
l not imposing solutions to professionally identified problems and being open to all patient-identified
concerns
l agreeing realistic goals and action plans and reviewing these at each visit – noting detail on whether or
not the action plan was followed and the patient’s ability to carry out the plan.
DEVELOPMENT OF THE SMART INTERVENTION
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A bespoke training package resulted, comprising a workshop session, combined with additional resources
for the study research fellows to deploy with the nurses over the course of the trial to reinforce nurses’
engagement in the study and support their delivery of the intervention. Further details regarding the
training package are given in Chapter 3, SMART intervention.
Conclusion
The work presented in this chapter was undertaken to define the concept of supported self-management
at the end of life and to develop the theoretical underpinning for the content of the intervention. This
work provided a basis on which to develop and refine the content of the intervention through interviews
and focus groups with patients, carers and HCPs. The findings from these activities resulted in the
development of a theoretically informed behaviour change intervention to enable study nurses to deliver
the intervention. We had planned to embed the principles of experience-based co-design within this phase
of the work, and to a large extent this was achieved. However, the constraints on working with a
population of very sick people meant that we used an iterative process and, where possible, sought views
and involvement in a number of different ways. In summary, the development process resulted in the
SMART intervention comprising a four-step educational approach and SMST, both of which are
summarised in Box 3. The intervention was to be delivered to the individual patient by their community-
based palliative care CNS using a conversational process, within the context of a clinical consultation.
Mechanisms of impact through which the SMART intervention is hypothesised to lead to a medicines
self-management behaviour change are summarised in a logic model (Table 7).
BOX 3 The SMART intervention
The four-step educational approach
(1) Needs assessment
Assess beliefs, behaviour and knowledge related to pain and pain medicines.
(2) Information provision
Provide specific information (discuss content of appropriate factsheets + podcasts).
Provide ‘contacts for advice’ factsheet at first visit.
(3) Goal-setting
Collaboratively set goals based on the patient’s needs (complete ‘things I would like to achieve . . .’
at each visit).
Complete ‘what I will do to help get me there’ to enable the goals to be met (small practical steps).
(4) Review and coaching
Plan follow-up (face-to-face visits and telephone calls).
Identify barriers, strategies, problem-solving techniques and support.
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The SMST
Factsheets
l Managing pain with opioid medicines.
l Common concerns when taking opioid medicines.
l Keeping on top of side effects.
l Checking opioid medicines are managing pain.
l Getting prescriptions and obtaining medicines.
l Organising opioid medicines.
l Fitting pain control into my daily routine.
l Contacts for advice and further information.a
Charts
l Pain diary.
l Medication chart.
Podcast films
l Monitoring the effectiveness of medicines.
l The practical issues of managing medicines.
Goal-setting
l Goal-setting sheets.a
a Core SMST resources that every patient received.
BOX 3 The SMART intervention (continued)
DEVELOPMENT OF THE SMART INTERVENTION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
32
TABLE 7 The SMART logic model of process evaluation of the SMART intervention
Problem Opportunity
Intervention
description Implementation Mechanisms of impact
Outcomes of
individual elements
of the intervention
Outcomes of the
overall intervention
Enhanced supported
decision-making can
improve overall quality
of end-of-life care.
People living with
advanced disease
often experience
fluctuating symptoms
that require complex
medication regimens.
Supporting self-
management could
help patients and their
family to manage
their medications to
improve pain and
related symptoms
Development of a
SMST that will be
delivered by nurses,
designed to help
patients improve their
knowledge, skills and
confidence to manage
medicines for pain,
constipation, nausea
and drowsiness
Four-step supported
self-management
process
Step 1, needs
assessment – identify
current medicines
management
behaviours, beliefs,
knowledge of pain
medicines
Step 2, information
provision – tailored
information specific to
identified concerns
which will positively
alter behaviour,
address beliefs
Step 3, setting
self-management
goals – realistic and
achievable plan that
responds to concerns
and has potential to
improve pain
management
Step 4, regular review –
set a date to review the
action plan and provide
additional information
and coaching
Nurse delivery: the four-step
educational approach will be
delivered by specialist palliative
care nurses working with
community-based patients
over a minimum of three
sessions. The first session
should be within 1 week
of baseline data collection.
Study nurses will assess
self-management needs,
provide tailored information
and plan pain management
goals (steps 1–3). Over the
6-week follow-up study,
nurses will provide at least two
additional follow-up meetings
to review self-management
needs, provide additional
educational resources and
review success with goals
(step 4)
Nurse training to deliver the
intervention: study nurses will
attend a half-day training
workshop that will cover
concepts and key features of
self-management; the
components of the
intervention and the
conversational process;
who will use the educational
resources with patients;
worked-examples and practice
using resources with patients;
ongoing support (peer-to-peer
support and support from
research fellows)
1. Needs assessment:
prioritisation of needs
that are most important
to the patient and,
therefore, most likely to
motivate engagement
with intervention, discuss
what roles and tasks are
required by each person
to engage patients and
their informal carer in
self-management and
encourage behaviour
change. This assessment
may also include a
discussion on barriers and
fears about self-management
and prioritising symptoms
to self-manage
2. Educational materials: this
information will present
benefits and burdens of
medications in verbal,
written and audio-visual
(podcast) formats and will
encourage a conversation
about the trade-offs
between symptom
management and side
effects and how the
consequences of these
compromises might be
dealt with. Specific
information on obtaining
and managing medicines,
allaying fears and concerns
about opioids, how to
get help
Clearly identified needs
and improved patient
and carer engagement
in self-management via
increased knowledge
of obtaining and
managing medicines
and how to access
support. Clearly
identified action plans
to support goal
achievement. Patients
empowered with
increased knowledge
and skills to recognise
worsening symptoms,
be able to self-initiate
therapeutic adjustments
and know how and
when to access help
from their local health-
care system
Reduced pain
intensity and reduced
interference from
pain in daily
activities. Reduced
need for out-of-hours
support. Improved
quality of life and
self-efficacy
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TABLE 7 The SMART logic model of process evaluation of the SMART intervention (continued )
Problem Opportunity
Intervention
description Implementation Mechanisms of impact
Outcomes of
individual elements
of the intervention
Outcomes of the
overall intervention
Resources to support nurse
training: nurses will also
receive the following resources
to support the training:
a diagrammatic representation
of the four-step SMART
intervention; the definition of
self-management in palliative
care and related professional
roles; self-management
conversational prompts to use
with patients; an audio-
recording of a modelled self-
management conversation;
summary sheet for making
action plans with patients
Ongoing support for duration
of trial: to support the study
nurses throughout the trial,
the research fellows will
meet with them regularly
(approximately once a week)
to support them to provide the
intervention to their patients
3. Goal-setting: actions
agreed with patient that are
realistic and achievable and
linked to needs assessment.
Identify and record the
self-management tasks
that are required with
patient and carer. Support
patients to develop their
self-management action
plan by balancing their
values and preferences
with the requirements of
medication management
alongside the possible
side effects.
4. Regular review: sustaining
behavioural change,
adapting goals, monitoring
progress; enhance the
patient’s capacity to
monitor and reflect on their
actions and understand
what is required of them to
fulfil this role and receive
support from a professional
Note
Patients living at home (with or without a carer) wishing to be more confident in self-management of medicines for pain, constipation, nausea and drowsiness. Patients and carers living
with fears about opioids (side effects of these medications) and the symbolism of opioids meaning a rapid and painful decline towards death. Patients experience fluctuating symptom
burden that can be unpredictable. Patients and carers dealing with multiple health-care systems – they do not experience a joined-up service where everyone knows about their situation
and needs.
D
E
V
E
L
O
P
M
E
N
T
O
F
T
H
E
S
M
A
R
T
IN
T
E
R
V
E
N
T
IO
N
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry
w
w
w
.jo
u
rn
a
lslib
ra
ry.n
ih
r.a
c.u
k
3
4
Chapter 3 A feasibility study assessing the SMART
intervention and trial processes
Introduction
This chapter focuses on Phase III of the SMART study: the feasibility study. As outlined in Chapter 2,
The SMART intervention, the SMART intervention is designed to support self-management of analgesia
and related treatments for patients approaching the end of life. It was developed with HCPs, patients and
carers to distil best practice, and reviewed by our dedicated PPI panel.
Aim and objectives
The aim of the feasibility study was to assess both the feasibility of undertaking a definitive RCT and the
acceptability of the SMART intervention. This aim was achieved by collecting data on the following
specific objectives:
l patient, carer and nurse eligibility, recruitment and follow-up rates
l fidelity of the SMART intervention delivery (see Trial outcomes for definition)
l patient, carer and nurse acceptability of the SMART intervention
l contamination of non-study nurses (i.e. the feasibility of blinding non-study nurses working within
study recruitment sites)
l completion rates, variability and suitability of patient-reported outcomes
l the extent of carer involvement.
The data from this feasibility study will be used to inform the design, intervention delivery strategy, sample
size, outcome measures and operational aspects of a definitive trial aimed at establishing the effectiveness
of the SMART intervention.
Design and setting
We conducted a multicentre mixed-methods single-arm pre–post observational feasibility study of the
SMART intervention in patients living at home with advanced pain recruited from four community palliative
care services.
The SMART intervention is an evidence-based supported self-management educational intervention
delivered by CNSs in partnership with patients (and carers when appropriate) living at home with pain
from advanced disease. The aim of the SMART intervention is to improve pain management and quality of
life by enabling patients and carers to better self-manage analgesia (specifically strong opioids) and related
treatments. The feasibility study was conducted in four community palliative care services: two in Yorkshire
and the Humber and two in Hampshire. Within each community palliative care service, between two and
four community-based CNSs were trained in the delivery of the SMART intervention (referred to as study
nurses hereafter), which was a total of 12 overall. In addition, two research fellows co-ordinated trial
recruitment and follow-up. Data were collected at baseline and at the 2-, 4- and 6-week follow-up
time points.
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Patient and public involvement
Specific engagement for this feasibility study took place via regular study meetings and individual
correspondence with PPI panel members. PPI panel members have been closely involved in the design and
delivery of this feasibility study. PPI representatives were involved with:
l reviewing the content and format of the SMART intervention materials and the nurse delivery strategy
l reviewing and feeding back to the study team on the draft patient study materials, including the
self-reported outcome measures included in the patient questionnaire, which led to the removal of one
questionnaire [Beliefs about Medicine Questionnaire(3)] as panel members felt the wording to be
inappropriate for the end-of-life context.
Ethics approval and research governance
Research ethics approval was sought in September 2015 from North West – Lancaster Research Ethics
Committee (REC). Provisional ethics approval was given on 10 October 2015 with a request for further
clarification on seven minor points (no changes to the protocol were requested). Favourable ethics opinion
was confirmed on 27 October 2015 (REC reference number 15/NW/0797). Following favourable ethics
opinion from the REC, management permission (research and development approval) was obtained from
University Hospital Southampton NHS Foundation Trust’s research and development department, as well as
local site approvals.
Amendments to protocol
There was one substantial amendment, which outlined three changes to the protocol. This was approved
on 23 November 2015 and the changes to protocol are summarised below.
1. Changes to patient-reported outcome measures: replacement of the Self-Management Ability Scale68
with the Self-Efficacy for Managing Chronic Disease Scale (SES)69 and removal of the Beliefs about
Medicines Questionnaire,70 because it was felt to be too burdensome for participants to complete.
2. Change to assessing fidelity of delivering the SMART intervention: study nurses would be asked to
audio-record the nurse–patient consultations when the SMART intervention was used.
3. Change to wording of ‘weekly’ to ‘regular’ review of patients’ progress with goal-setting review so that
the protocol reflects study nurses’ usual practice.
See Appendix 15 for communication with the REC.
Participants
Participants were adults with advanced disease living at home (with or without a carer) and prescribed
opioid medication and experiencing (or anticipating) side effects from these medications.
Eligibility criteria
Patients were eligible for participation if they:
l were aged ≥ 18 years
l had been prescribed strong opioid analgesia
l were living at home
l were being cared for by specialist community palliative care services
l were considered by the clinical team likely to survive beyond 6 weeks of follow-up
l had the capacity to provide informed consent.
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Patients were ineligible for participation if they:
l had insufficient literacy or proficiency in English to contribute to the data collection that was required
for the research.
Carers were eligible to take part in an end-of-study interview if:
l they were the primary carer of a patient meeting the above inclusion criteria
l the patient whom they cared for had consented to their involvement.
Recruitment procedures
Sites
Study nurses and patient participants (and carers, when appropriate) were identified from community
palliative care services at four hospices: two in Hampshire (site codes HANTS1 and HANTS2) and two in
Yorkshire and the Humber (site codes YKHB1 and YKHB2). Identifying patients from community palliative
care services offered the most efficient access to patients approaching the end of life who were living at
home. Hospital-based palliative care services were used as recruitment sites for the focus groups and
interviews described in the previous chapter. However, patients recruited from hospital-based palliative
care services were either inpatients or in transition between inpatient and community health-care services
and, therefore, not living in their own homes. Therefore, it was decided not to recruit from hospital-based
palliative care services for the feasibility study as the focus was to identify patients who were managing
pain in their own homes.
Nurse recruitment: identification and consent
At each recruitment site, between two and four community-based palliative care CNSs were identified by
contacting service team leaders; 12 CNSs (hereafter referred to as study nurses) were identified from the
four recruitment sites. An invitation was sent to all CNSs in the four community teams to attend a brief
presentation by the SMART study research team. Following this, CNSs interested in the study were invited
to attend a half-day workshop at which they received further information and training on the trial
procedures and delivery of the intervention.
All study nurses who were trained to use the SMART intervention were also invited to take part in a
one-off face-to-face interview at the end of the trial. Study nurses were given a recruitment pack (see
Appendix 16) by a researcher, who explained the purpose of the qualitative interview. Study nurses were
asked to provide written informed consent to take part in an interview with the research no less than
24 hours after receiving a recruitment pack and having had sufficient opportunity to ask any questions
about their participation.
Non-study nurses working with research active sites were identified by contacting community service-lead
CNSs. An e-mail was sent to lead CNSs with a link to an online survey and a request to circulate among all
palliative care CNSs within their teams.
Participant recruitment: eligibility, approach and informed consent
Potentially eligible patients were identified by screening all new referrals and existing patients on study
nurses’ caseloads against the eligibility criteria. Screening caseloads was done by a clinical research nurse
(CRN) or researchers with the study nurses. This activity was recorded on a screening log (see Appendix 17),
kept at each site. Before eligible patients were approached, their participation was discussed among the
study nurse, researchers and wider clinical team to consider patients’ capacity to participate.
Eligible patients were first approached face to face by their CNS, who gave a verbal explanation of the
study and provided them with a recruitment pack, consisting of an invitation letter, a patient information
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sheet and a consent form (see Appendix 17). At this point, patients not interested in participating were
thanked for their time and asked if they would say briefly why they refused participation and, if willing,
whether or not they thought the SMART intervention was acceptable in principle.
To identify carer participants, patients who were interested in the study were asked if they had a main
informal carer (family member or friend) who may also be interested in participating in an interview with a
researcher. If a main informal carer was identified, they were provided with a recruitment pack for carers
(see Appendix 17).
Patients (and carers) interested in knowing more about participating in the SMART study were asked to
provide their contact details and told that a researcher would contact them to discuss the study in more
detail and answer any questions that they may have about participation. At this point, all subsequent
recruitment and consent activities were completed by a researcher or CRN.
Patients were then contacted by telephone or face to face by a researcher to discuss the SMART study and
answer any questions they had about participation. At this point, patients who refused participation were
thanked for their time and asked if they would say briefly why they did not wish to participate.
Following provision of the recruitment pack, patients and their carers were given at least 24 hours to
consider their participation and were encouraged to discuss the study with their family/friends and
other HCPs.
Patients (and carers) willing to participate were asked to provide full written informed consent, following
which they were recruited into the trial, and hereafter are referred to as participants.
This study nurse-led approach to identification and introduction and researcher/CRN-led approach to
recruitment was the most efficient way to identifying eligible interested patients while keeping the burden
of recruitment to a minimum for the study nurses and separate from their clinical practice.
Recruitment schedule
We estimated that within a 4-month recruitment period approximately 450 new patients would be
referred to the four recruitment sites included in our study. We assumed that two-thirds of patients would
have pain (n = 300), of which 50% would be eligible (n = 150). Based on these assumptions, we
conservatively estimated that 20% of eligible patients would agree to participant (n = 30), which gave a
predicted recruitment rate of eight consented participants per month across all sites for 4 months.
The SMART intervention
Training of the clinical nurse specialists
A bespoke training package was designed (outlined in Chapter 2, Training development), comprising a
half-day workshop session. Following the training session, additional resource packs were developed for
the study researchers to deploy with the nurses over the course of the trial to reinforce their engagement
in the study and support their delivery of the intervention.
All 12 study nurses attended an initial SMART training workshop. The workshops were run in Hampshire
and Yorkshire, with nurses from the two hospices in each region attending the same workshop. Sessions
were facilitated by an expert Nursing and Midwifery Council-registered nurse educator who leads
postgraduate palliative and end-of-life care education provision. In attendance, and acting as co-facilitators,
were two study researchers. Sessions were experiential in approach, requiring reflection and demonstration
of practice, and were run using the SMART training plan (Table 8) and supported with resources developed
by the research fellows for the study nurses (see Appendix 3).
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TABLE 8 The SMART training plan
Time Activity Facilitator prompts
13.00–13.10 Thanks
Housekeeping
Overview of plan, setting scene of intervention and approach
to training (ask questions as go along, repeat things as needed,
centred on participants)
Introduction to each other and the things that they have been
thinking about in terms of getting ready to provide the
intervention
Facilitator to make a mental note of the things participants have been thinking
about as these will be good examples later of the importance to assess beliefs,
behaviours and knowledge
13.10–13.20 Warm-up exercise: the nature of self-management and
conversations
Ask participants to select one or two cards from a range of possibilities – cards are
pictorial, depicting wide variety of different scenes and patterns. Ask participants
to choose the card(s) that bring to mind the features of self-management present
in the clinical example they have been thinking about in preparation for the
session:
We asked you to think of an example from your practice that brought to mind
what self-management means in your practice. Keeping these features in your
mind, choose a card or couple of cards that best depict these features
Once everyone, including facilitators, have a card(s), ask participants to talk in pairs
about their cards and the features of self-management that they have in mind.
Allow 5 minutes per person
13.20–13.30 Identify key features of self-management Feedback to group: explain rules of feedback, each person asked to feedback.
Feedback not commented on, time for discussion afterwards, once everyone has
fed back. Ask each person to hold up their card(s) and explain the features of
self-management that the card brings to mind. Once everyone has fed back, the
facilitator summarises features that have been raised and integrates this with the
features of self-management emphasised within the intervention. Facilitator
emphasises that the intervention is designed to enhance pain management
through enhanced self-management of pain medications
continued
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TABLE 8 The SMART training plan (continued )
Time Activity Facilitator prompts
13.30–13.45 Introduce focus of conversational process: identify and build on
what the participants intrinsically know about conversations
Ask the participants to go back into their pairs and think back to the conversation
that they had about the cards, when they were explaining reasons for choosing
the selected cards. Ask the participants to describe the process of the conversation
that they had together: How did they start? How did the conversation develop?
How did it become focused? How did it finish? Facilitator lays out a conversational
process on the wall or floor or table using A4 sheets of paper in different colours
for each phase of conversation (four phases as above). The phases of conversation
are labelled on the coloured paper. Ask the participants to ‘walk through’ the
conversation they had together – this is best done by physically walking through
(walking along the process on the floor/along the wall). Facilitator draws out what
happened at each phase and makes a note on a Post-it® note (3M, Cynthiana, KY,
USA) of what happened and agrees with whole group where this Post-it note
belongs. When all pairs have completed this process, facilitator summaries the
process of conversation in terms of what the purpose is of each phase and frames
this in relation to the intervention (e.g. so this phase of the conversation is about
identifying a focus, a title for the rest of the conversation, this phase is about
transmitting understanding the focus and clarifying meaning, this phase of the
conversation draws the points together and shapes the next thing to happen – in
this case what you will feed back to group, in clinical practice what actions you
will take). Facilitator then links this conversational process with the SMART
intervention – we are going to use a similar conversational process in this
intervention, so one of the key points is that you already know the process we are
going to follow, the key thing is that this conversation needs to carry the things
that will make the intervention different from an everyday conversation
13.45–14.00 Outline conversational phases and components Facilitator walks participants through intervention conversational process
emphasising the four different components. Reinforce this process by providing a
diagram of the process. Go through process illustrated within the diagram, giving
examples of how the process would flow in clinical practice when discussing pain
medicines with a patient
14.00–14.15 Introduce next part of the session Next hour focused on the interventional process, going to put what we know
about self-management and conversational process into practice in relation to
supporting self-management of pain medicines. Facilitator models intervention
process with colleague – brief example
14.15–14.30 Break During break facilitator outlines an example on board which is going to be used
for the rehearsals
14.30 Welcome everyone back Facilitator summarises what has happened so far and plan for this part of the
session – to work closely through the process as a group, using the case outlined
on board, using forum theatre technique
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Time Activity Facilitator prompts
14.30–15.00 Participant-worked example Intervention-worked example – participants guiding facilitator in the interventional
process
15.00–15.10 Introduce next section – resources
Overview of resources available for use within the intervention
and principle of these being a toolkit
Short presentation of resources available and how these are intended to be used
15.10–15.25 Practice introducing and using resources Participants to work in pairs and practise how they would introduce a resource to
a patient and how they would shape this part of the conversation to encourage
self-management. Pairs to make a plan about what they need to do to get to
know the resources – ask them to write an action plan that follows what is
needed in a self-management plan – realistic, time orientated, outcome
orientated, etc. Then ask them to add an action around the whole intervention –
what they need to do to be able to provide intervention
15.25 Introduce last section of day – ongoing support Group discussion – facilitator introduces purpose of this last section – how to
support each other and how the researchers can support them to provide the
intervention. The process for eliciting this information will follow the intervention
thus allowing participants to model and reinforce the process and give them
additional vicarious experience of the intervention. Facilitator asks participants to
work in pairs, taking 10 minutes each to work through process of peer reflective
support – each taking role of peer supporter and peer discussant. Use intervention
process to shape reflective conversation:
1. ‘Can you tell me what concerns you about providing the intervention?’
2. ‘Which of these concerns is most pressing?’
3. ‘What is it about this concern that bothers you?’ ‘What could you do to help
with this concern?’
4. ‘When would it be good to review how you are getting on?’
Introduce review resources – capturing concerns, accessing information and
reviewing goals and support needs
15.45 Bring things together
Ask participants to summarise by explaining the intervention in
their own words
Finish round by asking researchers to summarise the
intervention in their own words
Close, thank participants, summarise plan for follow-up and
resources available
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During the workshop session, it became apparent that the nurses wanted further detail on the research
process, such as eligibility criteria, screening, approach and consent, before they felt able to give their
attention to intervention delivery itself. As a result, these processes had to be outlined by the co-facilitators.
This took time during the workshops, leaving no time to model the conversational process for and with the
nurses, or the goal-setting, in particular the process of effective action-planning once goals are set. To
respond to this, additional resource packs were created for the study nurses following the workshops. It was
the intention that these resources would be given to the nurses via weekly opportunities to reflect on
delivery of the intervention through face-to-face visits with the study researchers.
Additional resource packs comprised (1) a 30-minute nurse–patient modelled self-management-focused
conversation between two skilled nurse educators (one of whom was the workshop session facilitator),
which was supplied as an mp3 file on a memory sticks with an expectation that nurses would listen to the
‘model’ conversation; (2) self-management conversation prompts (see Appendix 18), outlining potential
questions mapped to the four steps of the educational approach; and (3) a ‘making action plans’ document
(see Appendix 19), outlining specific actions needed to help a patient meet their self-management focused
goal(s). The use of these resources enabled the researchers to provide ongoing coaching and support to the
study nurses during the trial and additionally helped to promote ongoing engagement of the nurses.
In order to help formalise and aid standardisation of the approach to ongoing nurse engagement, an aide
memoire for the researchers to use with the study nurses at site visits was developed, which prompted
questions related to the nurses’ experience of each step of the educational approach (see Appendix 20).
A related framework to standardise the documentation of these discussions via researcher field notes was
also developed (see Appendix 21).
Interventions details and schedule of delivery
Study nurses were asked to begin using the intervention with participants within 7 days of consent and
baseline data collection. As described in Chapter 2, The SMART intervention, the SMART intervention
comprised both a four-step educational approach and a SMST. In brief, the four-step educational approach
was designed to reflect the everyday practice of specialist nurses and included an assessment of participants’
needs, provision of information, goal-setting and review and coaching of self-management progress. The
SMST comprised eight factsheets, two podcast films, a pain diary, a medication chart and goal-setting sheets.
It was intended that the intervention would be delivered by study nurses each time they visited their
participants (and a carer when appropriate) over the 6-week study period (each visit was referred to as a
‘SMART visit’). Study nurses were asked to visit participants a minimum of three times during this 6-week
period (i.e. at least once a fortnight). During each visit, study nurses were required to use a conversational
approach to go through the four steps of the educational approach and provide the resources from the
SMST as required. As a minimum, study nurses were required to provide the factsheet ‘Contacts and
further information’ and the goal-setting sheets as core resources at their first SMART intervention visit.
Assessment and data collection
Screening data collection
Screening data were collected by a researcher or CRNs on all the patients on the study nurse’s caseload.
Data were collected on sex, age, referral status (existing patient or new referral) and eligibility.
Baseline data collection
The researcher or CRN completed the baseline case report form (CRF), which captured data on participants’
medical history (e.g. type of advanced disease, date of diagnosis), reason for referral to palliative care,
palliative treatments received (within the past month) and current medications for pain, nausea and
constipation. The baseline CRF also asked participants whether or not, in a future study, they would take
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part if they were randomised to receive either the intervention or standard care as usual (yes/no response).
This question was included to inform the acceptability of randomisation processes in a future definitive trial.
Participants were also asked to complete an outcome measure pack comprising five validated self-reported
outcome measures on pain, self-efficacy, common symptoms, quality of life and satisfaction with medicines
information. These outcome measures are described in Participant self-reported outcome measures.
Follow-up schedule
Participants were followed up for 6 weeks from the date of baseline assessment. Six-week follow-up was
chosen because the risk of short survival in this population meant that demonstrating early and sustained
improvements in self-management within a few weeks would be particularly important in this context.
During the 6-week follow-up period, participants were contacted by a researcher at three time points
post baseline:
1. week 2 (day 14)
2. week 4 (day 28)
3. week 6 (day 42).
The exact timing of follow-up visits was flexible to fit around participants’ medical and other appointments,
although efforts were made to keep follow-up visits within ± 2 days of the scheduled appointment date.
Follow-up visits were usually conducted face to face between the participant, their carer and a researcher.
Participants were offered a telephone follow-up if this was more convenient.
At each follow-up visit the researcher completed a follow-up CRF and asked the participant to complete
the outcome measure pack (as described above). The follow-up CRF captured data on any of the following
activities since the last follow-up (or baseline) visit:
1. which factsheets had been given to the participant
2. whether or not any self-management goals had been set (or reviewed)
3. whether or not the participant and/or carer had watched either of the video podcasts.
Participant and carer interview
As part of the final follow-up visit (week 6) participants (and carers, when appropriate) were asked to
take part in an audio-recorded face-to-face semistructured interview together with a study researcher.
Participants and carers were interviewed together. The topic guide for these interviews focused on two
broad areas. First, participants and their carers were asked what they thought about taking part in the trial
and how they were managing their medicines. These questions were intended to explore participants’
and carers’ acceptability of trial procedures, what they thought of the intervention itself and how it had
been delivered to them by their CNS. These questions were designed to understand the extent to which
participants and their carers were aware of the formalised educational process, the acceptability of the
SMST resources (i.e. what they liked and did not like about it), their continued use of the intervention and
whether or not their participation had any effect on their confidence with managing medicines. Interview
guides are reproduced in Appendix 22.
Study nurse interview
In addition to participant and carer interviews, all study nurses were invited to take part in an audio-recorded
semistructured interview after follow-up had closed for all participants at their site. These interviews covered
a range of topics designed to capture their experiences of participating in the research process (including the
training workshop), as well as their views on the acceptability of the intervention and whether or not they
felt that they could integrate it into their clinical practice. The topic guides for the study nurse interviews are
reproduced in Appendix 22.
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Final data collection
At each site, when the last participant had completed 6 weeks of follow-up (or had withdrawn from the
trial) a final data collection CRF was completed to capture the following data on all patients at that site:
l date of death or date last known to be alive
l place of death and preferred place of death (if known)
l health-care resource use over the 6-week follow-up period (these data are reported in Chapter 4 as
they relate to the health economic evaluation of the overall intervention)
l current medication prescribed for pain, nausea and constipation.
Adverse events
The intervention was evaluated within a patient population with advanced disease and who are
approaching the end of life. Thus, it was expected that episodes of acute illness or infection, new medical
problems and deterioration of existing medical problems would occur and could result in prolonged
hospitalisation, hospital readmission, significant or permanent disability or incapacity, or death. In
recognition of this, events fulfilling the definition of an adverse event or serious adverse event were not
reported in this study unless the event resulted from administration of any research procedure.
Non-study nurse data collection: assessing contamination
To inform the design of a future definitive trial, it was considered appropriate to evaluate whether or not
within individual sites the practice of non-study nurses was influenced as a consequence of working in a
team where their colleagues were using the SMART intervention. To assess contamination, an online
survey was sent to all non-study nurses working in the community palliative care teams at the four
recruitment sites. The survey captured data on:
l demographics (age, sex, grade/band)
l duration of palliative care experience
l whether or not they were an independent prescriber
l whether or not they were aware of the SMART study and what it was about
l whether they had discussed the SMART study with colleagues who were using the intervention
l if they were aware of the study or had discussed it with a colleague, whether or not this had
influenced their own practice supporting medicines management with their patients.
A copy of the online survey questions to non-study CNSs is reproduced in Appendix 23.
Participant self-reported outcome measures
Pain was measured using the short-form Brief Pain Inventory (BPI).71 Using a 0–10 numerical rating scale
(anchored 0, ‘no pain’, and 10, ‘pain as bad as you can imagine’), the BPI allows respondents to rate their
worst, least and average pain intensity during the past 24 hours, as well as present pain. The responses to
the four pain intensity items are reported separately. Using a 0–10 numerical rating scale (anchored 0,
‘does not interfere’, and 10, ‘completely interferes’), respondents are also asked to rate the extent to
which pain interferes with general activity, mood, walking ability, normal work, relations with other
people, sleep and enjoyment of life.
Self-efficacy was measured using the SES (adapted for palliative care).69 This scale contains six items that
assess an individual’s confidence with managing symptoms of illness and was adapted for a palliative care
context. Each item is measured on a 1–10 numerical rating scale, anchored 1, ‘not confident at all’,
and 10, ‘totally confident’.
Symptom burden was measured using the Edmonton Symptom Assessment Scale (ESAS).72 The ESAS is a
10-item tool designed to assess common symptoms in palliative care patients. Each item is measured using
a 0–10 numerical rating scale anchored 0, ‘no (symptom)’, and 10, ‘worst (symptom)’. The ESAS was
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originally developed in cancer patients but has been extensively used at end of life. The final item,
‘other problems’, was modified to represent drowsiness.
Health-related quality of life was measured using the EuroQol-5 Dimensions, five-level version (EQ-5D-5L),73
which is a standardised, generic measure of health-related quality of life. It provides a single index value
for describing and valuing health status calculated from a simple descriptive profile consisting of the
following five dimensions: usual activities, self-care, mobility, pain/discomfort and anxiety/depression.
The EQ-5D-5L index is reported not in this chapter, but in Chapter 4, as it relates to the health economic
evaluation of the overall SMART intervention. The EQ-5D-5L also provides an overall measure of health-
related quality of life by asking respondents to rate their present health state from 0, ‘worst health you
can imagine’, to 100, ‘best health you can imagine’, which is reported in this chapter.
Satisfaction with medicines information was measured using the Satisfaction with Information about
Medicines Scale (SIMS),74 which consists of 17 items about the types of information required to facilitate safe
self-management. For each item, respondents are asked to rate the amount of information they have
received using the following response scale: too much, about right, too little, none received or none needed.
Trial outcomes
For consistency, reporting of the feasibility study outcomes is presented in line with the trial aims
(see Aim and objectives): to assess the feasibility of conducting the trial procedures and the acceptability
and fidelity of the SMART intervention to participants, carers and study nurses.
Feasibility of conducting trial procedures
Process outcomes providing measures of the feasibility of study procedures included eligibility rates,
recruitment rates and follow-up rates at 2, 4 and 6 weeks; the fidelity of delivery (i.e. number of SMART
intervention visits delivered per participant); completion and acceptability of participant self-reported
outcome measures; completion of patient health-care records to collect outcomes; estimates of variability
in patient-reported outcome measures; the extent of contamination of non-study nurses working in
research-active teams; and level of carer involvement based on the number of carers willing to take part in
a face-to-face interview.
The feasibility of conducting the study procedures was also assessed through semistructured face-to-face
interviews with participants, carers and study nurses. Interview guides were developed (see Appendix 22)
to explore the feasibility of the trial processes.
Choosing a primary outcome measure for a definitive trial
The primary aim of a definitive trial would be to observe a reduction in average pain intensity (measured
using the BPI average pain intensity item) and is therefore a candidate primary outcome for a future
definitive trial. However, the complexity of symptom control within an end-of-life population may mean
that the average pain intensity scores do not improve over the course of the study period despite the
participant having received some benefit from using the intervention with their study nurse. It is recognised
that changes in pain interference (measured as a composite score of the seven interference items on the
BPI) and self-efficacy (measured on the SES), may be more responsive outcomes. As outlined in the logic
model presented in Chapter 2 (see Table 7), the SMART intervention is aimed at improving medicines
self-management behaviours; therefore, it is possible that participants may have experienced improvements
in self-efficacy and interference from pain (mediated via information provision, goal-setting and regular
review and couching) without any direct improvement on pain severity score. Indeed, stability in pain
severity score over the study period may indicate improvements in overall medicine self-management in
the context of declining health. Therefore, the BPI pain intensity, pain interference measure and the SES
self-efficacy score were assessed as candidate primary outcomes for a definitive trial.
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Fidelity of intervention delivery
Intervention delivery ‘as planned’ was defined as:
l initiation within 7 days of baseline
l a minimum of three SMART study nurse visits over the 6-week follow-up period
l assessment of participants’ self-management needs/requirements (step 1)
l tailored information resource provision from the SMST (step 2)
l self-management goal-setting and action-planning (step 3)
l regular review and coaching of self-management goals (step 4).
To assess whether or not the SMART intervention was delivered as planned, nurses were asked to record
the details of each SMART visit on a standardised CRF. This form captured information on:
l self-management needs identified and discussed
l intervention factsheets provided to participants
l self-management goals set or reviewed
l changes made to participants’ analgesic medication and who made the change
l details of any additional contact with participants between SMART visits.
The number of CRFs completed per participant was used as a proxy indicator of the number of SMART study
nurse visits each participant has received. When study nurse CRFs were missing, participants’ clinical records
were searched for evidence of a SMART visit having taken placed. To capture evidence of goal-setting, the
goal-setting sheets were printed on carbon copy paper: the top copy was kept by the participants in their
SMST folder, one copy was kept by the study nurses in the participant’s notes and one copy was collected
by the researchers (either from the study nurse or from the participant at each follow-up visit) as evidence of
goal-setting having taken place. When goal-setting sheets were missing, participants’ clinical records were
searched for evidence of goal-setting.
Fidelity of the intervention delivery was also assessed by the researchers. At each follow-up visit the
researchers completed a CRF capturing data on which SMST resources had been received by participants
since the previous follow-up, whether or not the participants had set or reviewed their self-management
goals, whether or not they had watched the video podcasts (if yes, which ones) and whether or not they
were still using the SMART intervention.
In addition to the above quantitative assessment of intervention delivery, fidelity was also assessed during
interviews with participants (and carers) after they completed 6 weeks of follow-up and with the study
nurses at the end of the trial. Interviews included questions focusing on the extent to which the
intervention had been delivered as intended as well as any barriers to or facilitators of delivering the
intervention or using the intervention.
Finally, in order to develop an ‘intervention delivery fidelity checklist’ to be used in a future national
multicentre definitive trial, study nurses were asked if they would be willing to audio-record their patient
consultations when they used the SMART intervention. It was intended that these audio transcripts would
be judged against a checklist of key elements required for intervention delivery.
Acceptability of the SMART intervention
Acceptability of the SMART intervention was assessed during recruitment by asking all patients who
received an information pack whether or not they thought the intervention was acceptable in principle
(yes/no response).
During the study period participants’ and carers’ acceptability of the intervention was assessed
quantitatively by evaluating the number of participants agreeing to use the intervention compared with the
number indicating that they were still using the intervention at each follow-up. Participant and carer
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engagement with the SMST was assessed at each follow-up visit by the question ‘Are you still using the
SMART toolkit?’.
The end-of-study interviews with participants, carers and study nurses (described above) also assessed
acceptability and usage of the SMART intervention. Interview guides (see Appendix 22) were developed to
explore participants’, carers’ and study nurses’ experience of using the intervention.
Sample size
A practical approach was taken to recruit an adequate sample size to evaluate the feasibility of conducting
a definitive trial. Browne75 suggests that when previous data sets are not available to estimate the sample
size required to achieve a planned power to conduct the necessary quantitative evaluations, a pilot sample
of 30 participants per arm is sufficient to estimate the population standard deviation (SD). A sample size of
30 patients would allow the 95% confidence interval (CI) around the proportion of patients with at least a
30% reduction in average pain intensity on the BPI to be calculated within 0.164 degrees of precision,
assuming a 30% response rate (participants with ≥ 30% reduction, 0.3 ± 0.164).
Analysis plan
The overarching approach to data analyses (for both qualitative and quantitative outcomes) was informed by
the recommendations of Moore et al.76 regarding process evaluation of complex interventions. The logic
model presented in Chapter 2, Conclusion, establishes the causal assumptions underpinning the mechanisms
of action of the SMART intervention. The qualitative and quantitative analyses described here focus on
developing this understanding by evaluating the data in terms of its mechanisms of actions and the
consequences that will trigger behaviour change.
Qualitative data: analysis of interview data
The audio files from the interviews were professionally transcribed. They were listened to alongside the
transcripts by the researchers (NC and MM) to check for complete accuracy and ensure data familiarity.
The data were coded utilising framework analysis62 by indexing transcripts for all issues relevant to the
feasibility of conducting the trial processes (i.e. deliverability), acceptability and usage of the intervention,
perceived benefits and any potential disadvantages of both the research design and the intervention.
The interview data were analysed within a framework designed for the study based on the recommendations
of Moore et al.76 regarding process evaluation of complex interventions. The analysis framework, and the
ultimate higher level of analysis, focuses on the mechanisms of action, the participant, carer or study nurse
responses to the research design or intervention, the mediating factors and the consequences.
The analyses of qualitative findings are presented in full in Appendix 24. These analyses focus on the
feasibility and deliverability of the trial processes, acceptability and usage of the intervention, perceived
benefits and possible disadvantages of both the research design and the intervention itself, including the
four-step educational approach and the SMST.
Quantitative data
Unless otherwise stated, all percentages were calculated using the total number of participants (or forms
completed) within the relevant population, which was the denominator (i.e. excluding all participants with
missing data for that variable). All percentages, means, medians, interquartile ranges (IQRs), ranges, SDs,
standard errors and 95% CIs will be rounded to one decimal place (or two significant figures for numbers
< 0.1). To account for the variation in the amount of intervention received by participants, all calculations
and analyses were performed on an intention-to-treat basis (i.e. based on all consented participants). This
pragmatic approach to include all consented participants was taken as it more closely reflects the real-life
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situation in which the amount of palliative care support received by patients varies. All calculations and
analyses were carried out using Stata® version 12 (StataCorp LP, College Station, TX, USA).
Assessing feasibility of conducting trial procedures
Recruitment and retention
The feasibility of the recruitment strategy was evaluated by summarising the screening, eligibility, approach
and consent processes and included the numbers of participants involved at each stage and reasons for
non-participation. A recruitment flow diagram depicts the course of participants throughout the screening
and recruitment process. A recruitment graph presents monthly and cumulative recruitment figures.
These data were summarised overall and by recruitment site.
Demographic characteristics for consented participants are presented overall and by research site. The
number/proportion of participants with a carer and consenting carer was summarised, as were carer reasons
for non-participation and the details of the consenting carer. Participant retention during follow-up,
including the number of participants withdrawing or who were lost to follow-up (hereafter referred to as
dropouts), together with the timing and reason for dropouts, is presented overall and by recruitment site.
Acceptability of randomisation
Participants’ acceptance of being randomised to either standard care or SMART intervention was assessed
by summarising the number/proportion of participants indicating that they would agree to be randomised.
Participant self-reported outcome data
Completion rates of all participant responses to the questionnaire packs as well as missing item-level
data were summarised at each time point. In this section of the analysis, missing data were classed as a
category in their own right, and all percentages were calculated using the total number of participants or
forms expected in the relevant population as the denominator (i.e. including participants with missing
data for that variable). As outlined in our initial grant application, we had hoped to explore the impact
of potential confounders, such as disease state, age, sex, level of support and recruitment site, on the
potential for participants to benefit from the intervention. However, owing to the small number of
participants taking part, statistical analysis was not conducted to explore potential confounders.
Summary statistics and corresponding 95% CIs are reported for participant self-reported outcomes at
each time point and mean differences were calculated between baseline and 6-week follow-up time point.
The number and proportion of participants with a meaningful reduction in average pain intensity and pain
interference were summarised as recommended by Dworkin et al.:77 a decrease in BPI pain intensity of
≥ 2.0 points or ≥ 30%; and a decrease in BPI pain interference of ≥ 1 point at each follow-up time point
compared with baseline.
To evaluate the performance of candidate primary outcomes (described in Trial outcomes) for a definitive
trial, statistical and contextual factors were taken into consideration. These included the proportion of
missing data, any evident floor or ceiling effects, precision (variability) of the outcome measures based on
95% CIs (around mean responses at each time point, mean difference score between baseline and 6-week
follow-up and the SD of responses) and responsiveness to change based on the observed effect size and
the distribution of change by 6 weeks.
Survival following study entry
To understand how close to the end of life participants were, the number of days between study entry
and date of death were calculated for participants with a known date of death (i.e. who died during the
follow-up period or after follow-up but before the final data collection). For participants known to be alive
at the end of the study, the median (range) number of days between baseline and the date the patients
were last known to be alive was summarised.
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Derivation of participant self-reported outcomes
For the four pain intensity items on the short-form BPI71 (pain at its ‘worst,’ ‘least,’ ‘average,’ in past
24 hours and pain ‘now’), the mean item response was calculated with scores ranging from 0 to 10, with
higher scores indicating greater pain intensity. A pain interference score was obtained by calculating the
mean of the responses to the seven pain interference items (where four or more of the seven items were
completed). Scores ranged from 0 to 10, with higher scores indicating greater interference from pain.
For the SES,69 a summary scale score was obtained by calculating the mean of the six items (where four or
more items were completed). Scores ranged from 0 to 10, with higher scores indicating higher self-efficacy.
For the ESAS,72 a summary score was obtained by calculating the mean of the nine symptom items
(pain, tiredness, nausea, depression, anxiety, drowsiness, appetite, well-being and shortness of breath),
which were summed at each time point to give the mean scale score representing the extent of symptom
burden. Scores ranged from 0 to 10, with higher scores indicating increased symptom burden.
A measure of health-related quality of life was derived by summing the present health state item on the
EQ-5D-5L73 at each time point. The item is scored from 0 to 100 and then divided by 100. Item scores are
reported between 0 and 1, with higher scores indicating better health status.
Responses to the 17 items on the SIMS74 were summed (responses too much, too little and none received
are scored 0; responses about right and none needed are scored 1), to give a total satisfaction score at
each time point. Scores range from 0 to 17, with higher scores indicating higher satisfaction with
information received about medicines.
Fidelity and acceptability of the SMART intervention
Intervention delivery and fidelity
The uptake and retention rate of the intervention were evaluated by summarising the number of SMART
visits each patient had from a study nurse during the 6-week study period. These data were summarised
as the mean number of SMART visits received by all participants. The analysis was evaluated within the
context of total screening and eligibility rates, as well as the number of participating CNSs, to provide an
indication of overall capacity to deliver the intervention per protocol. The average length of time for each
intervention SMART visit was also summarised, together with the number (and proportion) of participants
receiving at least three SMART visits.
Adherence to the SMST delivery strategy for the education resources (the factsheets, the pain diary, the
medication chart, podcast films and goal-setting sheets) was assessed by summarising which resources
were present in participants’ SMST folders at each follow-up visit. The number/proportion of patients
indicating that they had watched the podcast films at each follow-up visit was also summarised.
Acceptability
Acceptability of the SMART intervention was assessed, primarily summarising data from the qualitative
semistructured interviews with participants, carers and study nurses. Quantitative evaluation of participants’
acceptability was achieved by first summarising responses to the ‘acceptable in principle’ question, and
then by comparing the SMART intervention uptake rate with the number of participants reporting that
they are still using the intervention at 6 weeks follow-up. For all participants, reported use of the factsheets
and DVD podcasts, as reported at the follow-up visits with the study researcher, will be summarised.
Data accuracy
To evaluate the accuracy of data input, a random check of 20% of the data entered into the trial database
was carried out prior to data cleaning and analysis. This process identified that data entry accuracy was
very high: > 99% across all the questionnaire and study CRFs.
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Missing data
Attempts were made to retrieve missing data via a thorough data cleaning process, including a 10% check
of all data entered by hand. Every effort was made to obtain complete dates for all key data. Completion
rates of all participants’ responses to the outcome measures packs as well as missing item-level data were
summarised at each time point. Within this section of the analysis, missing data were classed as a category
in their own right and all percentages were calculated using the total number of participants or forms
expected in the relevant population as the denominator (i.e. including participants with missing data for
that variable).
Participant recruitment, retention and characteristics
Participant flow
Figure 3 presents the Consolidated Standards of Reporting Trials (CONSORT) flow diagram of participant
recruitment from screening through consent and intervention delivery to follow-up completion. In total,
417 patients were screened against the eligibility criteria (Figure 4), of whom 103 (24%) were eligible.
Of the eligible patients, 37 (36%) were approached, of whom 22 (59%) were interested and 19 (51%)
consented and were recruited and are hereafter referred to as participants. Of the 19 consented
participants, 15 (79%) completed 6 weeks of follow-up. A total of 17 participants (89%) received
the intervention.
Over the 4 months of the trial, the recruitment rate was 4.75 consented participants per month. Figure 5
presents the weekly recruitment figures for each site (bars) and the weekly cumulative accrual rate against
target accrual rate (dotted line). The median (range) days between approach and consent was 7 (4–39) days.
Recruitment sites
HANTS1 and HANTS2 were the two community palliative care services in Hampshire; YKHB1 and YKHB2
were the two community palliative care services in Yorkshire and the Humber. Stacked columns in Figure 5
show the weekly recruitment rate by site. The dots and lines show target cumulative accrual rate (black
line) and the actual cumulative accrual rate (blue line).
Eligibility criteria
Table 9 summarises the screening activity undertaken across all sites and presents basic demographics for
patients screened. Based on previous studies undertaken by the research team, we had assumed that 66%
of screened patients would be ineligible for participation; however, 314 out of the 417 patients (75%)
screened were ineligible. The primary reason was not having been prescribed strong opioid analgesia
(Table 10). Our screening procedure did not stipulate rescreening of ineligible patients, which may have
identified patients who had subsequently been prescribed opioid analgesia. The researcher field notes
taken during the screening process identified that many patients were ineligible because they were not
prescribed strong opioids but were prescribed weak opioids for pain.
The interviews with study nurses revealed that the eligibility criteria were initially seen as acceptable by being
relatively broad. However, the study nurses were surprised by the lack of individuals who met the eligibility
criteria. Moreover, those who did meet the eligibility criteria often had complex end-of-life needs and would
have been ‘on their reserves to do it [very fatigued and only just able to participate]’ (H2CNS002). One study
nurse responded that ‘It’s interesting that . . . there’s quite a lot of patients that aren’t even on opioids’
(H1CNS002). Another study nurse indicated that ‘I was surprised in a way that I didn’t have any patients
that would be applicable for the study . . . maybe, that shows how complex the patients are that come to
us, and how quickly people who may possibly have been suitable deteriorated’ (H1CNS004).
A mediating factor in the low eligibility rate was the number of study nurses involved in the study. Across
the four sites there were 37 full-time equivalent CNSs, of whom 12 (33%) volunteered to take part in the
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SMART study. Consequently, the pool of patients available to screen was smaller than expected and those
who were ‘eligible’ often had very complex needs that were not captured by the broad eligibility criteria.
Patient referral rate
We had assumed that approximately 450 new patients would be referred to the four community palliative
care services during the recruitment period (a rate of 112 per month). As we recruited only 12 nurses to
take part in the study, the actual number of new referrals from these 12 study nurses over 4 months of
recruitment was 202 (a rate of 50 per month).
Completed 6-week
follow-up
(n = 15, 79%)a
Intervention delivery
and follow-up
Screened for eligibility
(n = 417)
Eligible
(n = 103, 24.7%)
Approached
(n = 37, 36%)
Interested
(n = 22, 60%)
Consented and
 recruited
(n = 19, 86.4%)
Screening
Enrolment
Did not consented
(became unwell)
(n = 3, 13.6%)
Consent
Not eligible
(n = 314, 75.3%)
Not approached
(n = 66, 64%)
Not interested
(n = 15, 40%)
Dropped out between
weeks 1 and 2
(n = 3, 17.6%)
Did not receive
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FIGURE 3 The CONSORT flow diagram of recruitment. a, Calculated as the proportion of consented participants.
DOI: 10.3310/hta21760 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 76
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Bennett et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
51
Screening and initial approach processes
The initial screen for eligible patients included screening all existing patients on the study nurses’
caseloads. Subsequent caseload screening was of new referrals (see Figure 4). Consequently, 54%
(n = 227) of all patients were screened within the first 3 weeks of recruitment, resulting in 70% (n = 72) of
all eligible patients being identified within the same 3-week period. Given that study nurses’ appointments
with patients were usually weekly, fortnightly or ‘as required’, they had to prioritise which patients they
approached first based on the next appointment date. This meant that many eligible patients identified in
the first 3 weeks of the trial were not approached (reasons described below), or by the time the study
nurses were able to see them had become ineligible because of declining health (i.e. they were not
anticipated to survive more than 6 weeks).
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TABLE 9 Demographic data of screened patients
Variable
Recruitment site, n (%)
All HANTS1 HANTS2 YKHB1 YKHB2
Screened 417 (100) 148 (35.5) 57 (13.7) 148 (35.5) 64 (15.4)
Sex
Male 118 (45.3) 60 (40.8) 28 (50) 71 (48) 29 (45.3)
Female 227 (54.7) 87 (59.2) 28 (50) 77 (52) 35 (54.7)
Age (years) 73 (22–97) 72 (37–97) 76 (35–95) 74 (39–96) 69 (22–92)
Referral status
New 202 (48.4) 64 (43.2) 33 (57.9) 95 (64.2) 10 (15.6)
Existing 215 (51.6) 84 (56.8) 24 (42.1) 53 (35.8) 54 (84.4)
Eligible
Yes 103 (25.4) 24 (16.9) 18 (35.1) 39 (26.4) 22 (33.4)
No 314 (74.6) 124 (83.1) 39 (64.9) 109 (73.6) 42 (65.6)
Approacheda
Yes 37 (36) 9 (36) 10 (55.6) 13 (33) 5 (22.7)
No 66 (64) 15 (64) 8 (44.4) 26 (67) 17 (77.3)
Interestedb
Yes 22 (60) 7 4 7 4
No 15 (40) 2 6 6 1
Consentedc
Yes 19 (86.4) 6 3 6 4
No 3 (13.6) 1 1 1 0
a Denominator is the number of eligible patients.
b Denominator is the number of patients who were approached.
c Denominator is the number of interested patients.
Note
All data are presented as n (%) except age which is median (range).
TABLE 10 Reasons for screening failures and why patients were not approached
Reason for screening failures n (%)
Not prescribed strong opioid 168 (53.5)
< 6 weeks survival 61 (19.4)
Patient lacks capacity to consent 29 (9.2)
Patient not living at home 19 (6.1)
Discharge 18 (5.7)
Strong opioids for breathlessness 11 (3.5)
Other 8 (2.5)
All 314 (100)
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Just over one-third of eligible patients were approached and invited to participate in SMART (see Figure 3).
Reasons for the low approach rate were largely missing because of low CRF completion rates (71% missing;
Table 11); however, end-of-study interviews and researcher field notes provided more explanatory evidence.
Study nurses indicated during interviews that approaching eligible patients was not a problem in itself (i.e.
patients were not intrinsically opposed to finding out about the research). However, the often complicated
and rapidly fluctuating circumstances of the end-of-life context meant that it was often not appropriate to
approach eligible participants about participating. In addition, some patients had already been approached
about participating in other drug trials and study nurses felt that they ‘couldn’t burden them with something
else at that time’ (H1CNS002). Many eligible patients, as a result of their complex situation, were frequently
admitted to alternative care settings (hospital, hospice or nursing home) for symptom control or respite care;
therefore, study nurses found it challenging to find a relatively stable period during which to approach them
about participating.
Another factor affecting the screening and approach processes was the contact time between study nurses
and researchers or CRNs to undertake screening activity, which was not consistent across all sites due to
pressure on study nurses’ time and the size of their caseloads. The number of patients screened per CNS
varied from 17 to 68 (median 36). Maintaining weekly appointments with each CNS to screen new
referrals and review recruitment of eligible patients was challenging and, although the screening process
was seen as deliverable and acceptable by the study nurses, they were very aware that they (and
sometimes the CRNs) were not available when they had said they would be for screening appointments.
One that responded: ‘It was only tricky because of time’ (H1CNS002). Existing pressures on study nurses
and their often high caseloads meant that screening appointments frequently needed to be rearranged/
reattempted, with the result that screening was missed on some weeks. One study nurse stated she found
the screening onerous and two said they would have preferred to screen with just the researcher (rather
than screening with two people, e.g. the CRN and research fellow). Consequently, screening was
undertaken regularly, but not always on a weekly basis.
Participant recruitment
Despite the low approach rate, the proportion of patients interested in participating after reading the
information sheet was higher than expected (60%; see Figure 3). The majority of those who refused to
participate did so because they felt that they were too unwell at the time of being asked. Participant
interviews revealed two primary motivations for taking part:
1. It was an opportunity to give something back and to help others.
2. It was a way for them (and their carer) to learn something new that might help them to manage
their pain.
TABLE 11 Reasons eligible patients were not approached
Reason patients were not approached n (%)
Died 7 (10.6)
Discharged 3 (4.5)
Inpatient 4 (6)
Too unwell 2 (3)
Other 3 (4.5)
Missinga 47 (71)
All 66 (100)
a Data not recorded on CRF. Reason for not approaching patients was explored during interviews with study nurses to
identify bias that may have been introduced into the recruitment process.
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Of the 37 patients who were given an information sheet, 19 (51.4%) consented to participate (hereafter
referred to as participants), of whom nine (47%) also had a carer who consented.
Nurse recruitment
Across the four sites, 12 CNSs were trained to deliver the SMART intervention with their patients.
The demographic details of the 12 study nurses are summarised in Table 12. Eleven of the 12 nurses
completed an interview with a researcher at the end of the trial about their experiences of being part of
the trial and delivering the intervention.
Three study nurses (25%, two in Hampshire and one in Yorkshire and Humber) recruited no participants.
Three study nurses (25%) recruited one participant each, three (25%) recruited two participants each, two
(17%) recruited three participants each and one (8%) recruited four participants.
Study nurses were asked whether or not they would be willing to audio-record their consultations with
participants when using the SMART intervention to enable the research team to develop an intervention
delivery checklist to assess fidelity. This was generally met with apprehension by the study nurses, although
TABLE 12 Demographics of study nurses and non-study nurses
Variable
Nurses, n (%)
Study (N= 12) Non-study (N= 15)
Site
HANST1 4 (36.4) 4 (26.7)
HANTS2 2 (18.2) 3 (20)
YKHB1 3 (18.2) 4 (26.7)
YKHB2 3 (27.3) 4 (26.7)
Age
Median years (range) 53 (49–54) 51 (43–62)
Sex
Female 12 (100) 15 (100)
Band
6 2 (16.7) 4 (26.7)
7 10 (83.3) 9 (60)
8 0 (–) 2 (13)
Time working in palliative care
Median years (IQR) 8.2 (1–16.7) 10.5 (3.75–15.5)
Independent prescriber
Yes 6 (54.6) 4 (26.7)
No 5 (45.4) 11 (73.3)
Take part in an interview
Yes 11 (92)
No 1 (8)
Note
Data are presented as n (%) except for ‘age’ and ‘time working in palliative care’ which are presented as median (range)
and median (IQR).
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the majority agreed to do it. To allow study nurses time to get used to using the intervention it was
decided that they would start recording SMART intervention consultations with their second participant.
However, the completion rate for this part of the study was poor, primarily because half of the study
nurses recruited one participant or none. In the end, only two nurses (in Hampshire) audio-recorded their
SMART intervention consultations; however, this provided insufficient data to test an intervention delivery
checklist. For a future definitive trial, alternative methods should be considered.
Baseline participant characteristics
Participants’ baseline demographic factors and clinical characteristics were broadly similar across the four
sites (Table 13). Participants recruited from the two Hampshire sites had slightly lower (worse) Australia-
modified Karnofsky Performance Scale score than the two northern hospices. There was a range of disease
types, with the most common being breast cancer (26%), followed by liver or pancreatic cancer (16%).
One patient had a non-cancer diagnosis (liver cirrhosis). Although the study was open to patients with any
type of advanced disease, we found that most of those on strong opioids, and, therefore, eligible for the
study, were patients with cancer.
TABLE 13 Participant baseline demographic factors and clinical characteristics
Variable
Recruitment site, n (%)
All HANTS1 HANTS2 YKHB1 YKHB2
Participants recruited 19 (100) 6 (31.6) 3 (15.8) 6 (31.6) 4 (21)
Age (years) 66 (48–88) 68 (63–88) 68 (51–73) 60 (48–82) 59 (50–69)
Sex
Male 8 (42.1) 2 1 2 3
Female 11 (57.9) 4 2 4 1
Karnofsky score
Entry 60 (50–70) 55 (50–60) 50 (50–70) 60 (60–70) 70 (60–70)
Completion 60 (40–60) 60 (50–60) 50 (0–50)a 60 (40–70) 65 (30–70)
Primary disease
Breast cancer 5 (26.3) 1 2 4 1
Lung cancer 4 (21) 3 1 1 1
Bowel cancer 1 (5.3) 1 1 1
Gynaecological cancer 1 (5.3) 1 1
Pancreas/liver cancer 3 (15.8)
Liver cirrhosis 1 (5.3)
Bone cancer 1 (5.3)
Head/neck cancer 1 (5.3)
Metastatic sarcoma 1 (5.3)
Unknown primary 1 (5.3)
Time to referralb
Days 211 (17–414) 17 (9–570) 40 (12–292) 414 (211–505) 172 (19–330)
Weeks 30 (2–59) 2 (1–81) 6 (2–42) 59 (30–72) 25 (3–48)
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There were differences in the median time from diagnosis of advanced disease to referral to palliative care
services between the Hampshire and Yorkshire recruitment sites: the median (IQR) time between diagnosis
and referral in Hampshire was 4 (IQR 2–61) weeks compared with 38.5 (IQR 9–59) weeks in Yorkshire and
the Humber. The end-of-study interview data with the study nurses from both Hampshire sites emphasised
that late presentation at diagnosis (i.e. more advanced disease) meant that many patients referred to
palliative care services were close to the end of life and subsequently had limited exposure to specialist
palliative care services.
Across all four sites, the most common reasons for referral to palliative care services were for pain control
and psychological support. Just over half of participants (n = 10) were undergoing palliative treatment at
the time of enrolment. Six patients were receiving palliative chemotherapy and three were receiving
palliative chemotherapy plus radiotherapy.
TABLE 13 Participant baseline demographic factors and clinical characteristics (continued )
Variable
Recruitment site, n (%)
All HANTS1 HANTS2 YKHB1 YKHB2
Reason for referral
Pain only 8 (42.1)
Psychological support only 1 (5.2)
Pain + psychological support 6 (31.5)
Other symptoms 4 (21)
Pall treatments
Yes 10 (52.6) 0 2 4 4
No 9 (47.4) 6 1 2 0
Treatment types
None 9 (47.4) 6 1 2 1
Chemotherapy 6 (31.6) 0 2 3 2
Chemotherapy + radiotherapy 3 (15.8) 1 1
Ascites drainage 1 (5.3)
Carer recruitedc
Yes 9 (47.5) 4 2 1 2
No 10 (52.6) 2 1 5 2
Completed 6-week follow-up
Yes 15 (79) 5 2 5 3
No 4 (21) 1 1 1 1
a Completed Karnofsky score based on two participants due to one dropout.
b Time elapsed between advanced disease diagnosis and referral to community palliative care: data available on 15 of
19 participants.
c n= 8 spouse/partner, n = 1 friend.
Notes
Data for sex, primary disease, reason for referral, palliative treatments, carer recruited, completed 6-week follow-up are
presented as n (%). Data for age is presented as median (range). Data for Karnofsky score and diagnosis to referral
presented as median (IQR).
DOI: 10.3310/hta21760 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 76
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Bennett et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
57
At baseline, all participants were prescribed at least one strong opioid for pain relief (Table 14). Two
participants (10%) had one strong opioid prescription, 15 participants (79%) had two strong opioid
prescriptions (for background and breakthrough pain), one participant (5%) had three strong opioid
prescriptions [two background (tablets + patch) and one breakthrough] and one participant (5%) had five
strong opioid prescriptions. Of the 15 participants who received two strong opioid prescriptions, three
(16%) were also prescribed a weak opioid. Co prescribing rates of laxatives, antiemetics, neuropathic
analgesics and non-opioid analgesics were 74% (n = 14), 79% (n = 15), 68% (n = 13) and 74%
(n = 14), respectively.
Randomisation acceptability
During the baseline visit, participants’ general willingness and acceptability of randomisation was assessed
by asking the question, ‘If the study had been designed so that those taking part would be randomly
selected to receive either the intervention or standard care would you have taken part?’.
TABLE 14 Baseline medication summary
Variable All, n (%) (N= 19)
Strong opioid
None 0
1–3 18 (94.7)
≥ 4 1 (5.3)
Weak opioid
None 16 (84.2)
1–3 3 (15.8)
≥ 4 0
Non-opioid analgesic
None 5 (26.3)
1–3 14 (73.7)
≥ 4 0
Neuropathic analgesic
None 6 (31.6)
1–3 13 (68.4)
≥ 4 0
Laxative
None 5 (26.3)
1–3 14 (73.7)
≥ 4 0
Antiemetic
None 4 (21)
1–3 14 (73.7)
≥ 4 1 (5.3)
Note
All participants reported that they were taking at least one
strong opioid for pain relief.
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A total of 17 out of 19 participants (89%) responded to this question by saying that they would. One
participant did not understand the concept of randomisation and, therefore, preferred not to comment
either way. One participant–carer dyad indicated anxiety about the relinquishing of control associated with
randomisation and that maintaining control of ‘critical decisions in palliative care’ was important to them
and this was the reason why they would not have agreed to randomisation.
Researcher follow-up
All follow-up visits were conducted by one of two researchers, face to face at participants’ homes.
Overall, participant retention was high: of the 19 participants who consented, 15 (79%) completed
6 weeks of follow-up (see Figure 3). One participant completed all follow-up visits with a researcher but
did not receive the intervention because of complex pain management issues that prevented the study
nurse from devoting time within the consultation to initiating the use of the SMART intervention.
Therefore, of the 19 consented participants, 14 (74%) received the intervention and completed 6 weeks
of follow-up. However, an intention-to-treat analysis approach was taken to account for the variation in
the amount of SMART intervention received by participants; therefore, all consented participants were
included in the analysis. As such, the denominator at baseline was 19 and at all follow-up time points
was 15.
Withdrawals
The end-of-life context meant that many patients experienced uncontrolled symptoms (not just pain) and
infections during the course of the 6-week study period. Despite this, relatively few participants were lost
to follow-up. There were four dropouts, all associated with a rapid unexpected decline in health:
l One participant died 1 week after consenting, having received no SMART study nurse visits (only
baseline data obtained).
l One participant died between baseline and the 2-week follow-up, having received two SMART study
nurse visits (only baseline data obtained).
l One participant withdrew from researcher follow-up visits because of uncontrolled pain in week 2
(prior to week 2 follow-up), but continued to use the goal-setting element of the SMART intervention
with the study nurse on four more occasions (baseline data obtained + evidence of four goal-setting
sheets from the study nurse).
l One participant withdrew between baseline and the 2-week follow-up because of declining health and
was subsequently moved to a nursing home where they were no longer managing their medicines;
this participant received one SMART study nurse visit (only baseline data obtained).
In order to capture accurately why, when and from what participants withdraw, a future trial should
explicitly record what parts of the trial participants are withdrawing from (i.e. the research elements or the
intervention elements).
Acceptability of study length and frequency of follow-up visits
The 6-week study period was universally seen as ‘about right’ or ‘just right’ by the participants and their
carers: ‘I think it’s just about right actually, you probably need that length of time to get any results’
(H2Pt019) and ‘It seems to have gone quick’ (H1Pt001-C). The study nurses also appeared to agree on
the acceptability and deliverability of a 6-week study period.
In terms of the deliverability of follow-up appointments with researchers, Figure 6 shows that in the
majority of cases it was feasible to conduct three follow-up visits within a tight time frame of 2 days
either side of the scheduled fortnightly follow-ups. Nevertheless, it was not always possible to conduct
follow-up visits within this tight time frame (see Figure 6). This is not surprising given the complex nature
of participants’ homes.
Interview data revealed that participants and carers all stated that the frequency of researcher visits
(fortnightly) was acceptable, and some looked forward to these visits. Participants responded, ‘It’s been
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very nice you coming in’ (H2Pt019) and ‘It’s been lovely. I enjoy you coming . . . you’re so easy to talk to,
you ask the right questions’ (H1Pt009). These responses indicate that people approaching the end of life
valued taking part in a research study and that they saw the researcher as external to their care team and
were able to develop a positive relationship with them over the 6-week duration of the study.
Participant and carer interviews
Thirteen participants completed an interview with a researcher (Table 15). Although nine carers consented
at baseline to participate in an interview, only seven were available to complete an interview with
a researcher.
Survival following study entry
At the close of the study, three participants were known to have died. Two participants died during the
follow-up period at 21 days and 14 days following baseline assessment, respectively. One patient died
after the follow-up period, 71 days following baseline assessment. Two participants withdrew from the
study follow-up data collection for reasons of declining health; the number of days between study entry
and withdrawal was 14 days in one case and 27 days in the other. These data are summarised in Figure 7.
Fidelity and acceptability of the SMART intervention
Intervention delivery
To what extent was study nurse training provided as planned?
During the interviews, study nurses were asked to comment on the training workshop (described in
SMART intervention). Responses to the experiential, reflective style of the training workshops were mixed;
they varied widely from generally or overtly positive through to neutral and negative responses. The
reflective nature of the session appealed to some, whereas others found it challenging and preferred
alternative approaches (e.g. along the lines of advanced communications training, accompanied by a video
of a modelled conversation and then subsequent group discussion). However, critical reflection on existing
practice is necessary to stimulate change, which is fundamental to the intervention delivery.78,79 Nevertheless,
there was a general view that the sessions covered what the nurses needed to know in anticipation of their
study involvement.
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There was a mixed reception to the underpinning self-management ethos of the sessions. During the
workshops, the Johnston et al.51 definition of self-management support in palliative nursing was explored,
as well as the related eight professional roles from advocate to reporter (see Appendix 25). Some of the
study nurses appeared to readily understand the supported self-management ethos, whereas others were
more challenged by it. The self-management ethos of the study and the training sessions challenged the
professional behaviours and identity of some of the specialist palliative care nurses, whose therapeutic role
is often measured by their effectiveness to ameliorate pain. The nurse interviews also revealed that it was
harder for some nurses to adapt their practice from imposing their views (i.e. telling patients how to use
opioids) to collaborative discussion. Such discussion focused on the individual patient using and developing
their own self-management strategies as result of the information provided by the nurse.
There was feedback that the four-step educational approach was viewed as akin to usual specialist
practice, but some nurses felt that the workshop sessions made the four steps seem more complicated
than it actually was. The nurses generally felt that the four-step approach mirrored normal practice and,
consequently, was not viewed as being distinctive or novel. The study nurses reported that they valued
the training materials supplied during and after the training workshop (see Appendices 18 and 19, and
Figure 8). In particular, the nurses liked the figure illustrating the self-management conversation prompts
mapped to the four steps of the educational approach (see Figure 8). Despite this, there was variation in
the extent to which nursers referred to the training resources over the course of the study, with the
majority of use being at the start of the trial.
TABLE 15 Post-study participant interviews
Variable n (%)
Number of participant interviews completed 13 (68.4)
Previous (or current) occupationa
Manual worker 5 (38)
Health-care worker 2 (15)
Professional/managerial 4 (31)
Academia 2 (15)
Qualificationsa
None 4 (31)
Below university degree 6 (46)
University degree or higher 3 (23)
Number of carers presenta 7 (54)
Carer occupationb
Manual worker 2 (29)
Health-care worker 2 (29)
Professional/managerial 3 (42)
Carer qualificationb
None 1 (14)
Below university degree 5 (71)
University degree or higher 1 (14)
a The denominator is the number of participants who completed an interview (n = 13).
b The denominator is the number of carers who completed an interview (n= 7).
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There was insufficient opportunity during the training workshop for the study nurses to become familiar with
the research process, which led to some anxiety during the workshop. This had an impact on time available
for role modelling a conversation in practice. Therefore, a future definitive trial should consider providing an
opportunity to receive information and ask questions about the research process prior to any training.
Based on our finding of a mixed reception to the self-management ethos, it appears important that nurses
process the intervention and rehearse how they deliver self-management-focused conversations that fit
their own practice. There are likely to be different timelines regarding adoption of such a focus, and nurses
vary in how much they need to practise this before it becomes embedded. Therefore, some form of further
training and support for those involved in delivering the intervention is desirable and could be combined
with efforts to assure intervention fidelity.
The busy and time-pressured reality of clinical practice for these specialist nurses, who often managed
large caseloads, meant that the delivery of ongoing training and support during the course of the trial was
often problematic. These issues were captured in the researchers’ field notes and included difficulty
making appointments to meet the study nurses. Visits usually had to be made at the start of their working
day. However, not all the study nurses visited their office before going out to visit patients, and none
wanted to make appointments at the end of the day. Furthermore, visits to the study nurses were
1. Needs assessment
Assess beliefs, behaviour and knowledge
related to pain
2. Information
provision
Provide specific
information (discuss
content of appropriate
factsheets)
3. Goal-setting
Collaboratively set goals based on the
patient’s needs
4. Review and
coaching
Review: specify plan
for follow-up
(face-to-face visits and
telephone calls)
Coaching: identify
barriers, strategies,
problem-solving
techniques and
support
1.  List specific pain 
management-related
goals
2.  Develop action plans
that enable achievement 
of goals (list barriers and 
strategies to address them)
3.  Specify follow-up plan
(monitor progress
towards goals)
Personal action plan
FIGURE 8 Diagram of the SMART four-step educational process.
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complicated by nurses covering weekend working and, therefore, having days off in the week. Once
appointments were made, the study nurses were not always subsequently available (because of extended/
unexpected patient visits, over-running meetings, their own illness, etc.). Nonetheless, when they were
available, they were usually open to discussing their experiences of delivering the intervention (utilising the
four-step educational approach), but time devoted to this was always pressured or limited. Over the course
of trial, the study nurses were usually visited by the study researchers once a fortnight depending on their
availability, which was less often than the weekly frequency originally intended.
To what extent was the intervention delivered by study nurses as planned?
Table 16 summarises the pattern of the intervention delivery for each participant. Overall, there were 52
SMART study nurse visits across all participants, evidenced by completion of study nurse CRFs. When study
nurse CRFs were missing, evidence of a SMART intervention visit having taken place was gathered from
participants’ clinical records, the presence of a goal-setting sheet having been completed (with date) or
from researchers’ field notes. The final column in Table 16 groups the participants based on whether they
received the intervention as planned (group A), partially (groups B and C) or not at all (groups D and E).
Of the 19 participants who consented, 17 (89%) had a first SMART study nurse visit and started using the
intervention (see Table 16). From this point, 10 participants (53%) received the intervention as planned
(group A). One participant in group A decided not to have the factsheets after reading through them,
but did engage with the goal-setting. As the information provision was designed to be tailored to the
participants’ needs, this still met the criteria for this element of the intervention. Four participants (21%,
group B) received the minimum number of SMART study nurse visits, goal-setting, and review and coaching,
but the information provision was not staged as they received all the factsheet on their first SMART study
nurse visit. This does not necessarily represent inappropriate delivery of the intervention resources; however,
it was not clear whether all the factsheets were delivered on the first visit at the participant’s request (which
would satisfy the criteria for tailored provision of information) or whether the study nurses handed them all
over in one go. One participant in group B [identification (ID) 14 – YKHB1; see Table 16] withdrew from
researcher follow-ups because of uncontrolled pain but continued to engage with the goal-setting and
reviewing (steps 3 and 4 of the intervention). Three participants (16%, group C) did receive the intervention
materials and the goal-setting, but did not receive the minimum number of SMART study nurse visits.
However, in group C one participant died during the first 2 weeks of the study and one participant was lost
to follow-up because of rapidly declining health (see Table 16). Finally, two participants (10.5%, group D)
did not receive any elements of the intervention: one participant died within a week of giving consent and
the other did not receive the intervention (because of complex pain management issues that prevented the
study nurse from starting the SMART intervention), but did complete all researcher follow-up visits.
The timing of study nurse visits is summarised in Figure 9, which shows that participants generally
received a SMART study nurse visit once a week or once a fortnight. The average duration of SMART
study nurse visits was 57.2 minutes (SD 15.1 minutes), but this covers the whole consultation and not just
time spent using the SMART intervention. Interview data with study nurses revealed that they were able to
successfully deliver the SMART intervention during their visits and the pattern of delivery was acceptable
as it matched their normal visiting pattern. However, in relation to the acceptability of the length of the
SMART study nurse visits, the nurses were very conscious of the extra time required for study visits
(approximately 30 minutes for the first visit and 15 minutes for each further visit) and the impact this
had on their workload. One study nurse responded:
We [one study nurse and another study nurse] talked about timekeeping a lot, because in my first
couple of SMART study appointments they were really long, partly because the lady I had, it was quite
difficult to keep to time with them anyway.
H2CNS001
The study nurses managed to successfully accommodate this additional workload without changes to their
usual care patterns, except for one (part-time) study nurse who asked a colleague to follow up some patients
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TABLE 16 Pattern of SMART intervention delivery: who got what when
ID – site
Start 7
days?
Number
of SMART
visits
Average
visit time
(minutes)
New resources at each follow-upa
Number of
factsheets
received
Number of
goal-setting
sheets
received
Podcast
films
watched?
Intervention
delivered as
plannedb
Complete all
follow-up
visits?Week 2 Week 4 Week 6
1 – YKHB2 Yes 3 62 1, 5, 7, 10, 11 6, 11 2, 3, 4, 8, 9, 11 10 3 No A Yes
2 – YKHB2 Yes 3 60 1, 7, 8, 11 4, 9, 10, 11 2, 3, 5, 6, 11 10 3 Yes A Yes
3 – HANTS1 Yes 4 47 2, 3, 7, 11 10, 11 11 4 3 No A Yes
4 – HANTS1 Yes 5 44 2, 3, 8, 11 5, 11 11 4 5 No A Yes
5 – HANTS1 Yes 4 71 1, 2, 4, 8, 10, 11 3, 7, 11 11 7 4 No A Yes
6 – HANTS1 Yes 3 47 1, 2, 11 7, 8, 9, 11 11 5 3 No A Yes
7 – HANTS1 Yes 4 55 1, 2, 10, 11 8, 11 11 4 3 No A Yes
8 – HANTS2 Yes 3 62 2, 3, 5, 11 11 9, 10, 11 3 3 Yes A Yes
9 – HANTS2 Yes 4 52 2, 7, 9, 10, 11 11 11 4 4 Yes A Yes
10 – YKHB1 Yes 2 60 11 11 11 0 2 No A Yes
11 – YKHB2 Yes 3 45 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,
11
11 11 10 3 No B Yes
12 – YKHB1 Yes 3 60 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,
11
11 11 10 3 Yes B Yes
13 – YKHB1 No 3 60 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,
11
11 11 10 3 No B Yes
14 – YKHB1c Yes 4 22 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,
11
– – 10 4 No B No
15 – YKHB1 No 1 60 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,
11
– – 10 1 Yes C Yes
16 – YKHB2d Yes 2 70 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,
11
– – 10 1 No C No
17 –
HANTS2e
Yes 1 95 7, 8, 10, 11 – – 3 1 No C No
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TABLE 16 Pattern of SMART intervention delivery: who got what when (continued )
ID – site
Start 7
days?
Number
of SMART
visits
Average
visit time
(minutes)
New resources at each follow-upa
Number of
factsheets
received
Number of
goal-setting
sheets
received
Podcast
films
watched?
Intervention
delivered as
plannedb
Complete all
follow-up
visits?Week 2 Week 4 Week 6
18 – YKHB1f No 0 0 – – – 0 0 – D Yes
19 –
HANTS1
g
No 0 0 – – – 0 0 – D No
a Data from researcher follow-up CRFs: 1, managing pain with opioids; 2, contacts and further information; 3, getting hold of prescriptions; 4, organising medicines; 5, fitting opioids into
daily routine; 6, checking opioids are managing pain; 7, common concerns; 8, keeping on top of side effects; 9, pain diary; 10, medication chart; and 11, goal-setting sheet.
b A, received the intervention as planned, i.e. started within 7 days of baseline data collection, received at least a minimum of three SMART study nurse visits, received tailored staged
information provision, goal-setting and regular review and coaching; B, received the intervention as planned (minimum of three SMART study nurse visits + goal-setting + review and
coaching), but unclear if information provision was tailored to participants needs; C, received goal-setting, review and coaching as planned, but did not receive minimum of three SMART
study nurse visits or staged information provision; D, did not received any elements of the intervention.
c Participant withdrew from researcher follow-up after 14 days, but continued to use the goal-setting element of the SMART intervention with study nurse.
d Participant died after receiving two SMART study nurse visits.
e Participant died after receiving one SMART study nurse visit.
f Participant did not receive the intervention from their study nurse, but did complete all follow-up visits with a researcher.
g Participant died before receiving first SMART study nurse visit.
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on her caseload by telephone on a single day because of a SMART study visit. The extra time required for
SMART study nurse visits led the study nurses at the individual sites to discuss this impact with one another.
To what extent were each of the intervention elements implemented as planned?
Overall, the deliverability of the four-step educational approach was initially seen by the study nurses as
challenging and required practice. However, they perceived the delivery of the four steps in a therapeutic
conversational style, which enabled it to flow naturally and recognised them as being inherently part of
what specialist nurse practice looks like. Study nurses responded:
The four-step process sort of reflects the nursing process really doesn’t it? You know that’s what you
do, or what you should be doing. But I think having it in your head more concretely and having things
that you do at each of those steps just makes it more real.
H4CNS003
I followed this process . . . I found that kind of reflected pretty much what we do with that sort of pain
assessment and their usage of medication assessment that followed quite well anyway.
H4CNS001
Fully embedding the concept of supported self-management in end-of-life care took time and practice for
the study nurses. The reflective patient-led approach to the educational process challenged their desire
to go in and immediately ‘come up with solutions’ (H2CNS002). In addition, all the study nurses were
experienced palliative care clinicians and the standardised approach to the four steps challenged their
own working style which they had evolved. Consequently, the shift in thinking required for delivery of the
self-management ethos within the educational approach was accommodated more successfully by some
of the study nurses than by others. For example, one said, ‘I need to just take a little step back and let
the patient tell me what they want to do a little bit more’ (H2CNS002).
The deliverability of the individual elements of the four-step educational approach was mixed. The quality/
completeness of evidence for each step varied owing to poor completion of the study nurse CRFs, which
were intended to document what had been delivered by the study nurses at each SMART visit (Table 17).
Undertaking the needs assessment (step 1) was universally recognised by the study nurses as part of their
usual practice and did not present as a challenging aspect of the intervention. Table 17 shows that, based
on the study nurse CRFs and the presence of staged information provision and goal-setting (which were
predicated on having undertaken a needs assessment), all of the 17 participants who started using the
intervention received a needs assessment.
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FIGURE 9 Timing of SMART study nurse visits.
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Overall, step 2 (giving information supported by educational resources in a staged and tailored approach)
was adhered to for the majority of participants. A total of 10 out of 19 participants (52.6%) received the
educational resources as intended (see Table 16, group A), whereas four participants received all the
factsheets resources at the first SMART visit. It is unclear whether or not this latter method of information
provision was at the participant’s request; however, one study nurse responded that ‘I just handed
everything over’ (H4CNS001). This type of delivery may have negatively influenced the acceptability of the
factsheets for these participants. The following argument for giving all the factsheets on the first SMART
visit was put forward by one study nurse:
When somebody’s newly started on an opioid . . . you can’t kind of pre-guess what they’re going to
need. And to me the whole point of it is that you are giving them the tools to be able to self-manage
. . . they should have all of them [the factsheets] at the beginning so that they’ve got the information
there.
H4CNS001
TABLE 17 Evidence of the four-step educational approach
ID – sitea
Step
1: need assessmentb
2: staged information
provisionc 3: goal-settingd 4: review and coachinge
1 – YKHB2 Yes Yes Yes Yes
2 – YKHB2 Yes Yes Yes Yes
3 – HANTS1 Yes Yes Yes Yes
4 – HANTS1 Yes Yes Yes Yes
5 – HANTS1 Yes Yes Yes Yes
6 – HANTS1 Yes Yes Yes Yes
7 – HANTS1 Yes Yes Yes Yes
8 – HANTS2 Yes Yes Yes Yes
9 – HANTS2 Yes Yes Yes Yes
10 – YKHB1 Yesf Yes Yes Yes
11 – YKHB2 Yes Unclear Yes Yes
12 – YKHB1 Yesf Unclear Yes Yes
13 – YKHB1 Yesf Unclear Yes Yes
14 – YKHB1 Yes Unclear Yes Yes
15 – YKHB1 Yesf No Yes No
16 – YKHB2 Yes No Yes Yes
17 – HANTS2 Yes No Yes No
18 – YKHB1 No No No No
19 – HANTS1 No No No No
a IDs match IDs in Table 16, but are presented in order of those with most to least evidence of the four-step educational
approach; therefore, not in ascending order.
b Evidence based on CRFs completed by study nurses.
c Evidence based on follow-up CRFs completed by researchers.
d Evidence based on presence of goal-setting sheets in participants CRF at each follow-up time point.
e Evidence based on study nurse CRFs, or evidence of multiple goal-setting if study nurse CRFs were missing.
f Study nurse CRFs not completed; therefore, evidence based on presence of information resources together with
goal-setting sheets and support by researcher field notes.
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Table 16 shows that all of the 17 participants who started using the SMART intervention received a
goal-setting sheet on their first SMART visit (step 3, resource 11). Subsequently, of the 14 participants
who received the intervention and completed a 6-week follow-up visit (see Table 16, IDs 1–14), only one
did not receive continued goal-setting and regular review and coaching (step 4). The study nurses
universally perceived the goal-setting and regular review process as acceptable and deliverable. They
identified the goal-setting as a core component of the intervention and perceived value in it because it
formalised and evidenced their specialist practice. It also facilitated review and coaching as the previous
goals because they were there to ‘reflect back on’ (H4CNS003). Consequently, goal-setting often
became the mechanism by which participants were helped to focus on doing things for themselves
(i.e. implementing self-management strategies). Participants and carers also recognised the value of the
goal-setting process as focusing on their needs and motivating behaviour change:
That’s been helpful . . . I think it has made me a bit more explicit about setting goals and saying to
[CNS name] ‘I’d like to do this, can you help me do this?’
H3Pt002
If you set a goal, even if you don’t reach it, I still think it’s a good thing to do.
H4Pt013
Participants’ perceived disadvantages of goal-setting were related to having different expectations of the
process, ‘sometimes your perception of what they are going to write is just completely different to what
they come out with’ (H2CNS001). Some participants struggled to think what their goals would be in the
context of clinical depression or a degree of memory loss.
In addition to the goal-setting, the only other core factsheet resource was ‘contacts and further
information’ (resource 2), which the CNSs were asked to deliver to the trial patient on their first SMART
visit. Thirteen (68%) participants received this factsheet on their first SMART study nurse visit (see Table 16).
By the 6-week follow-up time point, a further two participants had received this core factsheet.
Overall deliverability of the intervention
A total of 14 out of 19 (74%) participants received the intervention as intended or partially as intended
(see Table 16, groups A and B). Evidence of the four steps of the intervention having been completed was
present for the majority of participants who started using the intervention (see Table 17). The end-of-life
context provided a complex set of circumstances within which study nurses had to deliver the intervention.
Consequently, not all participants were able to fully engage with all elements of the intervention; however,
overall the four-step educational approach appears to have been adhered to by the study nurses.
Acceptability of the intervention
Acceptability of the self-management support toolkit components
Overall, the participants found the factsheet resources to be easy to read, clear and not too long. In the
case of the few participants who received factsheets and did not read them or just scanned them, the
resources were usually read by their carer and were perceived to be of benefit to them. The factsheet
‘Contacts and further information’ was often poorly delivered (i.e. not completed by nurses), but
participants saw it as highly relevant and acceptable: ‘all the numbers you need are there, it’s a brilliant
idea’ (H1Pt015-C) and ‘it’s just reassurance you know, an easy reference, just in case’ (H2Pt007).
Other than the core resources, factsheets that were commonly delivered on the first visit were ‘Managing
pain with opioids’ (n = 11) and ‘Common concerns’ (n = 10) (see Table 16). Both were considered by study
nurses to be essential resources as they helped to address concerns and expectations, ‘I think that perhaps
all patients should have that information [common concerns factsheet] as a standard’ (H1CNS001). By the
end of 6-week follow-up, 10 participants had received all 10 factsheet resources (see Table 16).
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The medication chart (resource 10) was delivered to 14 participants (see Table 16); however, the frequent
non-completion of the medication chart by the study nurses meant that its use and benefit varied. Some
nurses provided and completed a simplified one-page medication chart, whereas others helped participants
to produce their own versions (either paper based or using a spreadsheet). A number of participants
indicated that the medication charts helped them to plan activities away from the home by preparing the
necessary medicines to take with them – something that they previously would not have engaged in.
Similarly, the medication chart also facilitated carer involvement as it allowed for pre-emptive planning for
deterioration of the participant (i.e. carers were able to familiarise themselves with the medication chart
and respond appropriately if the participant was unable to).
The pain diary (resource 9) was successfully delivered to 11 participants (see Table 16) who viewed it as
acceptable, with the majority using it regularly. Participants and carers responded during the end-of-study
interview that the pain diary formalised and recorded information about the timing, intensity of pain
and outcome of analgesia comprehensively. Participants also responded that it helped with managing
breakthrough opioid medication because it enabled them to monitor pain intensity rating throughout the
day. The study nurses universally saw the pain diary as a helpful tool to monitor pain and evaluate the
effectiveness of analgesic medication and non-drug pain relief strategies (e.g. distraction or hot bath).
Overall, participants reported that the pain diaries helped them to keep track of the effectiveness of their
medicines by recording when a pain episode occurred, what action was taken and the response. This had
the effect of relieving the pressure and anxiety of having to remember these details. In addition, it made
participants, carers and study nurses aware of the pattern of pain events throughout the day and
stimulated conversations around adjustments to medicines and pain management in general.
The podcast films were watched by five participants who perceived them to be acceptable and:
. . . reassuring . . . I think the information was very useful, because it did home in on the fact that
you’re in control . . . that came across very clear.
H2Pt019
Nevertheless, it was noted that the podcast films (as with some of the factsheet resources) would have been
of greater use earlier on in participant’s experience of managing pain with opioid medicines. For example:
I think that would be useful if I was at the start of the process, but now, with all the things that were
said in the DVD, I kind of already knew, especially the chap who was managing his prostate cancer,
I’ve been through the same process myself.
H3Pt002
Importantly, participants responded that they valued the authenticity of the subjects in the films (one patient
and two specialist palliative care nurses), particularly as they were sharing their experience and self-management
strategies. Only one participant who received the podcast films did not watch them, which was in the context of
untreated depression. Study nurses responded during the end-of-study interviews that they thought the podcast
films were helpful for participants and their carers, and having an alternative to paper-based information suited
some people well. However, overall the podcast films were not offered by the study nurses to all participants.
This may have been an issue of practicality; for example, one study nurse said that she forgot about them
because they were separate from the main file with the factsheet resources, whereas another noted that she
did not carry the DVD/memory sticks with them when she visited participants.
Finally, the goal-setting sheets were universally seen by participants, carers and study nurses as acceptable.
The study nurses responded during the end-of-study interviews that the goal-setting sheets formalised and
evidenced their specialists practice as well as facilitating the review and coaching of previously made goals:
I could actually say to you now, with the patients, I’m actually at this point with them . . . we’ve set
these goals and I’m off today to reflect on those and identify any other issue.
H4CNS003
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Participants also responded positively to the goal-setting, indicating that the process was manageable
and helped them to be more explicit about the things they wanted to achieve. It also helped stimulate
participants’ thinking around performing the tasks necessary for self-managing medicines such as:
. . . right this is what we’ve got to do now, and get this sorted . . . it’s made us more aware to help
things along.
H1Pt015
Completion rate for the goal-setting sheets was high: of the 52 SMART study nurse visits that occurred across
all participants, there was evidence of goal-setting (or review of goal-setting) at 44 (85%). In the majority of
cases, the goal-setting sheets were delivered and completed well, with appropriate patient-focused goals
set and action plans made to achieve the goals. One participant who withdrew from researcher follow-ups
(due to uncontrolled pain) continued to use the goal-setting sheets.
Overall, the patients, carers and CNSs always perceived some benefit to the SMST. The goal-setting
was the most frequently valued element, but often other elements were also liked (e.g. the pain diary).
The factsheets often reinforced information provided by the CNSs or that the patients already knew and
they stimulated patients and carers to ask further questions. If the factsheets were not read by the patient,
then they were often valued by their carer. The CNSs particularly valued the common concerns factsheet.
The podcast films were valued by those who had been provided with them.
Overall, there was a range of participant responses to the SMST as a whole from the overtly positive, ‘we’ll
treasure that’ (H1Pt001), through to more general, ‘it has helped me, definitely’ (H3Pt041); a minority of
patients did not fully engage with it. Generally, the study nurses viewed the SMST as of value particularly as
a resource to support verbal information provision and to refer back to when reviewing self-management
progress. For example:
It’s just a solid piece of evidence, rather than us just trying to explain things to patients and sort of jot
things down for them, they’ve actually got information that we can leave with them that they can use
. . . I’d like to be able to use these tools with other people that come onto my caseload. I think they
are very useful.
H4CNS003
To have all of this to give them, kind of backs up what we say, rather than it’s just you talking to the
patient, and then the minute you’ve left the house they’ve got nothing then to hold on to.
H4CNS001
However, given the complex end-of-life circumstances for some participants, not all were able to engage
with the intervention or benefited from it directly themselves. For example:
Unfortunately things have gone from bad to worse with him [study patient] deteriorating and
[name of carer] not being very well, I think it was just perhaps a bit too much.
H1CNS001
Acceptability of the four-step educational approach
The deliverability of the four-step approach was seen as acceptable to the study nurses, who did not
perceive that they needed any additional skills to deliver it; it was viewed as a normal part of the specialist
role. Still, study nurses perceived value in the explicit nature of the four-step educational approach as it
formalised and gave structure to supporting participants and their carers to self-manage medicines within
the complexity of the end-of-life context with frequent deterioration of health and depression.
All participants stated that they derived a benefit from the intervention, but the extent to whch the
participants were aware of, or acknowledged, the four-step approach varied. The acceptability of the
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delivery of the intervention and resulting benefit were increased for the participants and their carers
because of the almost universal value that they placed on contact with their study nurse (particularly when
face to face and in their own homes).
The second part of the four-step approach was provision of information tailored to patients’ needs.
Frequently, delivery of the SMST resources (i.e. the factsheets) by the study nurses was less than ideal,
which, as a result, had an impact on the acceptability and benefit of the resources, particularly when they
were not discussed or talked through, or when all the factsheets were given all together as a large file.
There was also difficulty in providing the intervention at the most appropriate time for participants (and
their carers) while they were well enough to engage in it, given the unpredictability of end-of-life context.
Overall, the four-step educational approach helped to stimulate suggestions for self-management
strategies and then enabled patients, carers and study nurses to determine which strategies worked for the
individual. In addition, the intervention as a whole (see Box 3) stimulated appropriate questioning by the
patient or carer to the CNS; for example, ‘it’s been easy to ask questions’ (H1Pt001). Participants who
were already effective self-managers prior to the trial felt that they would have used the materials more if
they had received them earlier (at their first contact with their CNS). For example:
I’ve been doing this for over a year. And a lot of the things in here I knew. And frankly, I’m a very
organised person, so I’ve got all the diaries, and I’ve got all the prescriptions, and they’re all online.
Whereas it takes a while to get to that stage, to figure out what you’re meant to be doing, how
you’re meant to be doing it.
H3Pt002
Completion of study nurse case report forms
Study nurses were asked to complete a brief CRF after each SMART visit, documenting what had been
delivered. Completion rates were high; study nurses’ CRFs were completed in 43 out of 52 SMART
intervention visits that were delivered across the whole feasibility study (83% completion rate). For SMART
study nurse visits for which study nurse CRFs were missing, information on the date of visit was gathered
from participant clinical records and evidence of the four-step educational process and the use of the
SMST tool resources (including whether or not goal-setting sheets had been completed) was gathered by
researchers at follow-up visits. For four participants [all from the same site in Yorkshire and the Humber
(YKHB1)] no study nurse CRFs were completed.
Participant self-reported outcomes
Exploratory analysis of participant self-reported outcomes
Descriptive statistics (mean and 95% CIs) of the participant self-reported outcome measures at each time
point and at 6 weeks compared with baseline (difference) are presented in Table 18 and summarised
overall by time point. Owing to the small number of participants taking part, further outcome summaries
by potential confounders such as disease state, age, sex, level of support and recruitment site, were
not undertaken.
This study was not powered to detect any changes in outcome measure score, and there was no change
in average pain scores; however, there was a slight reduction in interference from pain (–1.6, 95% CI
–2.8 to –0.4) and a modest increase (0.7, 95% CI 0.3 to 1.2) in self-efficacy scores (see Table 18). There
was no overall change in the intensity of common end-of-life symptoms (ESAS), health-related quality of
life [EuroQol-5 Dimensions (EQ-5D)] or satisfaction with information about medicines (SIMS).
Figures 10–12 present histograms of the change in average pain, pain interference and self-efficacy scores,
respectively. These histograms show that, for the majority of participants, average pain intensity worsened
over the study period (i.e. scores of > 0), whereas there was greater stability or improvement across the
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TABLE 18 Descriptive analysis of participant self-reported outcomes
Participant-
reported
outcome
Study time point
DifferenceaBaseline Week 2 Week 4 Week 6
BPI (scale 0–10)
Average pain 4.3 (3.1 to 5.6) 3.3 (2 to 4.6) 4.1 (2.4 to 5.7) 3.5 (2.3 to 4.8) –0.2 (–1.5 to 1.1)
Pain
interference
4.3 (3.1 to 5.5) 3.5 (1.8 to 5.2) 2.7 (2.4 to 5) 2.5 (1.4 to 3.6) –1.6 (–2.8 to –0.4)
Worst pain 6.1 (4.5 to 7.6) 5.3 (3.4 to 7.2) 5.9 (3.9 to 7.8) 5.4 (3.6 to 7.2) –0.1 (–1.5 to 1.4)
Least pain 2.8 (1.4 to 4.2) 2 (0.7 to 3.3) 2.7 (1.2 to 4.2) 2.5 (1.1 to 3.8) 0.1 (–1.1 to 1.3)
Present pain 2.9 (1.8 to 4.1) 2.7 (1.5 to 3.8) 3.5 (1.8 to 5.1) 3.7 (1.9 to 5.5) 0.8 (–0.8 to 2.4)
SES (scale 0–10)
Total score 7.1 (6.3 to 7.9) 7 (6.2 to 7.8) 7.5 (6.5 to 8.5) 7.7 (6.7 to 8.6) 0.7 (0.3 to 1.1)
ESAS (scale 0–10)
Total score 2.3 (1.7 to 2.9) 2.6 (1.6 to 3.6) 2.9 (2.3 to 3.5) 2.7 (1.9 to 3.5) 0.1 (–0.5 to 0.7)
EQ-5D (scale 0–1)
Health status 0.52 (0.4 to 0.63) 0.56 (0.44 to 0.68) 0.52 (0.4 to 0.63) 0.58 (0.44 to 0.7) 0.05 (–0.11 to 0.21)
SIMS (scale 0–17)
Total score 11.7 (9.7 to 13.8) 13.8 (11.4 to 16.2) 13.4 (11.4 to 15.4) 13.7 (7.5 to 20) 1.7 (–4.5 to 7.8)
a Differences were calculated as the mean difference between baseline and 6-week follow-up time points.
Notes
Data are presented as mean (95% CIs).
An intention-to-treat approach was taken, therefore the denominator at baseline was n = 19 and at all follow-up time
points was n = 15.
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FIGURE 10 Histogram of change in BPI average pain intensity scores. N.B. change scores calculated week 6 score
minus baseline score.
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board on BPI pain interference (i.e. scores of ≥ 0) and, largely, there were improvements for all participants
on the self-efficacy scale (i.e. scores of > 0). Table 19 presents the variability (SD) with 95% CI for
candidate primary outcome measures, along with the estimated effect size for the change in average pain,
pain intensity and self-efficacy at 6 weeks compared with baseline.
The number, proportion and 95% CI around the proportion of participants with clinically meaningful
reduction in average pain and pain interference are summarised in Table 20. These data show that at
follow-up weeks 2 and 6 there were more responders based on pain interference than average
pain intensity.
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FIGURE 11 Histogram of change in BPI pain interference score. N.B. change scores calculated week 6 score minus
baseline score.
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FIGURE 12 Histogram of change in SES score. N.B. change scores calculated week 6 score minus baseline score;
> 0 indicates improvement.
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Participant acceptability of self-reported outcomes
Generally, participants’ experience of completing the self-reported outcome measures was acceptable;
however, there were some limitations related to the wording of some questions given the end-of-life
context (e.g. ‘normal work’ and ‘enjoyment of life’ on the interference subscale of the BPI). A small number
of participants criticised the ‘duplicity’ (H4Pt001) of some questions, given the combination of five different
measures. Overall, there was dislike for the SIMS as many participants experienced difficulty remembering
specific information that they had received about their medicines over the preceding 2 weeks.
Overall, completion rates for the questionnaire packs were high: all questionnaires were completed by
participants with a researcher at each time point. The proportion of missing data at individual item level
was very low (Table 21) and did not prevent any summary scores from being calculated at any time point.
The proportion of missing data was < 3% for all participant self-reported outcome measures at all time
points, except for BPI at the week 4 follow-up (3.9%). The most commonly missing item on the BPI was
the final item about the extent to which pain interferes with enjoyment of life (missing in three cases
from the same participant); a number of participants responded that they felt that this question was
inappropriate for people approaching the end of life. Similarly, for the EQ-5D, one response to the final
item asking respondents to rate their overall health from best to worst was missing at all time points (from
the same participant in each case). The field notes kept by the researchers identified a general lack of
acceptability of this question by participants. One participant responded during the end-of-study interview,
‘it’s a stupid question to ask people in palliative care’ (H1Pt011-C), when asked specifically about this
response item. The SIMS was least liked by the participants; nevertheless the proportion of missing data
was extremely low.
TABLE 20 Responders based on reductions in average pain intensity and pain interference at each follow-up
Time point
Responders
BPI average pain BPI pain interference
Number of responders % 95% CI Number of responders % 95% CI
Follow-up week 2 4 26.7 7.8 to 55.1 6 40.0 16.3 to 67.7
Follow-up week 4 3 20.0 4.3 to 48.1 3 20.0 4.3 to 48.1
Follow-up week 6 3 20.0 4.3 to 48.1 7 46.7 4.3 to 48.1
Notes
The denominator at all follow-ups was n= 15.
Responders were classified as participants reporting a ≥ 2-point or ≥ 30% reduction in average pain score or a ≥ 1-point
reduction in pain interference at each follow-up time point compared with baseline.
TABLE 19 The SDs and 95% CIs for candidate primary outcome variables for a definitive trial
Time point
Candidate primary outcome variable, SD (95% CI)
BPI average pain BPI pain interference SES
Follow-up week 2 2.6 (1.9 to 3.8) 2.5 (1.9 to 3.7) 1.6 (1.2 to 2.4)
Follow-up week 4 2.4 (1.7 to 3.7) 3.1 (2.2 to 4.8) 1.4 (1.0 to 2.2)
Follow-up week 6 3.0 (2.2 to 4.7) 2.4 (1.7 to 3.8) 1.8 (1.3 to 2.9)
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Primary outcome measure for a definitive trial
The level of missing data for the BPI average pain, BPI pain interference and SES was negligible (see
Table 21). There were no ceiling or floor effects for the BPI average pain (maximum score = 10, reported
by n = 0; minimum score = 0, reported by n = 1). For BPI pain interference, no ceiling effects were found
(maximum score = 10, reported by n = 0); however, marginal floor effects were observed (minimum
score = 0, reported by n = 4). No floor or ceiling effects were found on the SES (maximum score = 10,
reported by n = 0; minimum score = 0, reported by n = 0). There was greater stability or improvement by
6-week follow-up across the board on BPI pain interference (i.e. scores of ≤ 0) compared with BPI average
pain intensity and, largely, there were improvements for all participants on the self-efficacy scale. Taking
account of the variability in participants’ change in scores from baseline to 6 weeks (based on the upper
limit of the 95% CI for the SD), a large effect size of 0.65 was observed on the SES and 0.46 on the BPI
pain intensity scale, whereas a negligible effect size of 0.05 was observed on the BPI average pain scale
(Table 22).
The results suggest that the SES and BPI pain interference scale are more responsive to change and should
be considered for the primary outcome for a definitive trial. Estimates of mean scores, variability and effect
sizes are provided in Tables 18, 19 and 22 to inform future sample size calculations.
TABLE 21 Missing data level from participant self-reported outcome measures
Study time point Outcome measure
Number of items overall
(all participants) Number of (%) missing items
Baseline (n = 19) BPIa 228 2 (0.9)
SESb 114 0 (–)
ESASc 190 3 (1.6)
EQ-5Db 114 2 (1.8)
SIMSd 323 0 (–)
Week 2 follow-up (n= 15) BPIa 180 4 (2.2)
SESb 90 1 (1.1)
ESASc 150 2 (1.3)
EQ-5Db 90 1 (1.1)
SIMSd 255 1 (0.8)
Week 4 follow-up (n= 15) BPIa 180 7 (3.9)
SESb 90 0 (–)
ESASc 150 4 (2.7)
EQ-5Db 90 1 (1.1)
SIMSd 255 0 (–)
Week 6 follow-up (n= 15) BPIa 180 5 (2.8)
SESb 90 0 (–)
ESASc 150 2 (1.3)
EQ-5Db 90 1 (1.1)
SIMSd 255 0 (–)
a A total of 12 items.
b A total of 6 items.
c A total of 10 items.
d A total of 17 items.
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Assessing contamination of non-study nurses
The survey assessing contamination of non-study nurses was sent to all non-study CNSs working at the
four recruitment sites (n = 37). The demographics and responses are summarised in Table 12. The overall
response rate was 41% (n = 15) and, like the study nurses, non-study nurses were all female, of a similar
age and had worked in specialist palliative care services for a similar length of time. However, fewer
non-study nurses were independent prescribers.
The responses to the non-study nurse survey are summarised in Table 23. A general awareness of the
presence of the SMART study was high among non-study nurses. Of the 15 respondents, only one (7%)
was unaware of the SMART study and, of the remaining 14 responders, nine (64%) were aware of what
the SMART study was about in a general sense. One non-study nurse responded: ‘not aware of what it
involves or spoken to my colleagues about it. Just from the title that it is a study about patients having
more control in managing their medication’ (NSN004).
TABLE 22 Summary statistics and estimated effect sizes for the difference in scores for candidate primary outcome
measures at 6 weeks compared with baseline
Outcome n
Difference at 6 weeks compared with baseline
Mean difference (95% CI) SD (95% CI)
Effect size
(mean/SD)
Effect size
(mean/SD upper limit)
BPI average pain 15 –0.2 (–1.5 to 1.1) 2.4 (1.8 to 3.8) 0.2/2.4 = 0.082 0.2/3.8 = 0.05
BPI interference 15 –1.6 (–2.8 to –0.4) 2.2 (1.6 to 3.5) 1.6/2.2= 0.73 1.6/3.5 = 0.46
SES 15 0.7 (0.3 to 1.1) 0.7 (0.5 to 1.1) 0.74/0.72 = 1.03 0.74/1.14 = 0.65
TABLE 23 Non-study nurse survey responses
Non-study survey questions n (%)
Aware of SMART study?
Yes 14 (94)
No 1 (6)
Aware of what the SMART study is about?
Yes 9 (60)
No 6 (40)
Discuss SMART study with a study nurse?
Yes 1 (6)
No 14 (94)
Influenced or changed practice?
Yes 0 (–)
No 15 (100)
Have you seen a SMART participant?
Yes 2 (13)
No 13 (87)
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In terms of direct communication about the study, only one respondent (7%) had discussed the SMART
study with one of the study nurses. Concerning contamination of non-study nurse usual practice, all
respondents indicated that their own practice was not influenced or changed as a consequence of working
in a team in which their colleagues were using the SMART intervention. Two respondents indicated that
they had each seen one SMART participant when covering for a study nurse: one during a hospital
admission and one in an outpatient clinic.
Adverse events
There were no serious adverse events attributed to the trial intervention or trial processes. Two participants
were admitted as inpatients (one to a hospice and one to a hospital) for symptom control.
Conclusions
In conclusion, the feasibility study of the SMART intervention was a single-arm trial in which 19 participants
were recruited over 4 months from four community palliative care services via 12 palliative care CNSs who
were trained in the delivery of the intervention. In total, 17 participants commenced the SMART intervention
with a trained study nurse and 15 were followed up at 2, 4 and 6 weeks following baseline assessment.
Through this study we have demonstrated that our research process, study nurse training schedule and
intervention delivery strategy are feasible and acceptable within a sample of community-based individuals
approaching the end of life, their carers and palliative care CNSs. A total of 74% of participants received
the intervention as intended (or partially as intended), with flexibility of delivery necessary to allow for the
complex circumstances of managing symptoms at the end of life. The follow-up rate was 79% at 6 weeks,
higher than follow-up rates observed in previous trials of similar community-based populations.
Although the analysis of participant self-reported outcome was exploratory, the data overall tended to favour
improvements in pain interference and self-efficacy over improvements in pain intensity. The results of the
feasibility study were used to determine which outcome should be considered as the primary outcome for a
future definitive RCT and to estimate the sample size required for such a trial. The next chapter demonstrates
the feasibility of conducting a health economic evaluation of the SMART intervention.
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Chapter 4 The SMART health economics:
feasibility of economic evaluation and preliminary
cost-effectiveness
Introduction
Before investment in new health-care interventions can be made, convincing evidence of the value for
money of those interventions must be provided. The SMART feasibility study included resources for health
economic research to be conducted that would help determine both the feasibility of an economic
evaluation in this patient group and setting and whether or not there is the potential for the SMART
intervention to be cost-effective.80
Aims and objectives
The overall aim of the health economic research was to establish the feasibility of an economic evaluation
of SMART and preliminary estimates of cost-effectiveness. Specific objectives were to:
l determine acceptability and completeness of resource use and utility measures in this setting
l establish the cost of the SMART intervention
l develop a decision-analytic model that would permit the generation of cost-effectiveness estimates
l employ the model to test effectiveness scenarios
l employ the model to estimate the value of further research.
Feasibility
The SMART feasibility study was used to test the acceptability of the data collection forms. Acceptability is
evidenced by the level of missing data. The completeness of the data collected in the outcome measures
pack was recorded using descriptive statistics, detailing the number and percentage of questionnaires
returned and the number and percentage of missing items within the returned questionnaires.
Resource use
Data collection forms to identify the health and social care services that individuals used were completed
by researchers using clinical records. The form, which was adapted from one used in the IMPACCT study,
is included in Appendix 3.
Quality of life (utility)
In order to calculate quality-adjusted life-years (QALYs), it is necessary to collect data on health state utility.
The EQ-5D is NICE’s preferred measure of health state. The feasibility of using the new EQ-5D-5L was
explored.81 The EQ-5D-5L formed part of the interview-administered questionnaire and was scored using a
newly developed UK tariff.82
The small sample size and absence of a control group meant that an economic evaluation based on
patient-level analysis of the data was not possible. Thus, estimates of cost-effectiveness were based on a
decision-analytic modelling (DAM) approach.
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Cost-effectiveness and decision-analytic model
We conducted a preliminary economic evaluation of the SMART intervention plus standard care compared
with standard care alone following the NICE reference case.83 Outcomes were expressed as QALYs and
costs calculated from the perspective of the NHS and Personal Social Services (PSS). A DAM developed for
the NIHR-funded IMPACCT project was adapted for use here. In the absence of trial data, the DAM allows
us to estimate the cost-effectiveness of the SMART intervention and explore, through sensitivity and
scenario analyses, the levels of effectiveness and costs that would yield acceptable value for money metrics
for the intervention. The DAM is a simplified representation of the patient pathway describing the major
health and cost events that occur over a relevant time period.
Model structure, cycle length and time horizon
The SMART DAM (Figure 13) was adapted from the IMPACCT DAM and is a Markov model with weekly
cycles that runs for a time horizon of 52 weeks. The model structure, time horizon, cycle length and
parameters were developed using the findings from a model literature review and expert and patient
opinion. The model was developed in line with current best-practice standards.84,85
The DAM comprises health states based on level of pain severity (no/mild pain, moderate pain, severe pain)
and death (see Figure 13). Within each of the pain health states, the occurrence of side effects (i.e.
constipation, drowsiness and nausea) was permitted.
In the DAM, a cohort of hypothetical patients (mean age 72.4 years) who have advanced cancer and pain
move (or transit) through the health states in accordance with specified transition probabilities. Each health
state has a mean cost and utility value associated with it so that the cohort members accrue QALYs and
costs as the 52 weeks pass. Patients can move between pain states and between pain states and death.
Side effects are not represented as separate health states.
SMART
Palliative
care + pain +
opioids
Moderate pain
Standard
care
Severe pain
Dead
No/mild pain
Side effects vs.
no side effects
Side effects vs.
no side effects
Side effects vs.
no side effects
FIGURE 13 Diagram of the SMART DAM.
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Model parameters
The model parameter values are described in Tables 19 and 21. They were derived from a number of
sources, including the IMPACCT patient survey data, data from the literature, analysis of palliative care
patient survival data and analysis of a previous advanced cancer trial.86
Cost and utility parameters
The model uses resource use and utility data collected from participants during the NIHR-funded IMPACCT
study. Between August 2013 and June 2014, 248 patients were recruited to the study and completed a
survey. Community-based patients with pain from advanced cancer who were aged ≥ 18 years were
eligible for the study. Patients with advanced cancer were defined as those patients with metastatic cancer
(histological, cytological or radiological evidence) and/or those receiving anticancer therapy with palliative
intent. Patients with pain were defined as those receiving analgesic treatment for cancer symptom-related
and/or therapy-related pain. Patients had to be able to complete the questionnaires and provide informed
consent to participate. Thirteen palliative care services across England recruited patients to the study.
The participants completed a resource use questionnaire capturing health-care use, pain rating scales, the
EuroQol-5 Dimensions, three-level version, and additional utility measures: the European Organisation for
Research and Treatment of Cancer 8 Domains (EORTC-8D)87 and ICEpop CAPability measure for Adults
(ICECAP-A).88
The resource use questionnaire asked participants to recall use of primary and community care (e.g. GP
visits and nurse contact) and secondary or hospital care (e.g. visits to accident and emergency and hospice
stays) in the previous 4 weeks. Unit costs were assigned to the data in order to estimate the average cost
of health and social care service use for the sample. Unit costs were obtained from national sources
including the Personal Social Services Research Unit (PSSRU) Unit Costs of Health and Social Care 2015,89
NHS Reference Costs 2014–201580 and the British National Formulary.90
Mean cost and utility estimates (with variance) were estimated for each of the model pain health states
(Table 24). Individuals were classified into pain health state using a 0–10 pain severity rating scale, where:
l 0–4 = no/mild pain
l 5–6 =moderate pain
l 7–10 = severe pain.
The impact of side effects (nausea, constipation and drowsiness) were estimated using a previous trial data
set that included EQ-5D, cost and side effect data. COUGAR II86 was a trial of chemotherapy compared
with active symptom control for those with refractory oesophagogastric adenocarcinoma.92 These data
were thought appropriate as the participants were at the end of life and had similar characteristics to
those in the survival estimation and IMPACCT survey samples.91 A regression model was run predicting,
in turn, EQ-5D and costs, and using side effect identifiers based on European Organisation for Research
TABLE 24 Utility parameter values
Parameter Mean SD Source
No/mild pain 0.526 0.282 IMPACCT patient survey91
Moderate pain 0.423 0.296 IMPACCT patient survey91
Severe pain 0.149 0.321 IMPACCT patient survey91
Decrement for nausea –0.084 0.028 COUGAR II trial data86
Decrement for constipation –0.052 0.027 COUGAR II trial data86
Decrement for drowsiness –0.222 0.022 COUGAR II trial data86
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and Treatment of Cancer – Quality of Life Questionnaire C30 (EORTC-QLQ C30) questions as predictors.
The beta coefficients on each of the predictors denote the utility decrement or cost impact associated with
each side effect. These were applied in an additive way in the model.
The development and implementation of the new tool were costed following consultation with the
SMART study researchers. In addition to the participant-completed data, the resources associated with
development and delivery of the SMART intervention were recorded based on routine data, such as
administrative records and participant records, as well as a detailed description of the intervention costs.
The costs of material development, printing and nurse training are included in Table 25.
Survival parameter
Although it was assumed that neither of the interventions compared in this evaluation influences mortality,
it was necessary still to estimate background survival in this population. The survival of the hypothetical
model cohort was estimated using a parametric regression, which was fitted to data gathered in another
IMPACCT workstream. The data (n = 4638, of whom 84% of patients had a cancer diagnosis and 16%
a non-cancer diagnosis) were retrospectively collected on all patient referrals to specialist palliative care
services in the city of Leeds, West Yorkshire, over a 2-year period (2012–14) and contained variables on
date of referral to palliative care, age, sex and date of death. The characteristics of the sample are
described in Table 26. There was no censoring of death and a Kaplan–Meier (K–M) curve was estimated
for the time between referral and death. Negative numbers were assumed to be errors and, where they
occurred, resulted in the cases being dropped.
A number of models were applied to the data, including exponential, Weibull and Gompertz. Visual
comparison of the modelled survival curve with the K–M curve and the Akaike information criterion were
used to judge model quality. Weibull had the lowest Akaike information criterion (16,891.5 vs. 17,760.15 for
exponential and 16,891.5 vs. 17,138.03 for Gompertz functions) and had good fit with the observed K–M
curve. Age and sex covariates were tested in the models but only age was found to be significant. The results
of the Weibull regression are shown in Table 27 and Figure 14. As the gamma factor was significant, the use
of the Weibull model is justified as this indicates a non-constant (and declining) hazard function. The same
TABLE 25 Cost parameter values
Parameter Mean (£) SD (£) Source
No/mild pain 531.49 1021.82 IMPACCT patient survey91
Moderate pain 720.55 1038.83 IMPACCT patient survey91
Severe pain 1089.12 1455.65 IMPACCT patient survey91
Increment for nausea 93.93 47.32 COUGAR II trial data86
Increment for constipation 33.23 46.60 COUGAR II trial data86
Increment for drowsiness 81.04 36.97 COUGAR II trial data86
Cost for SMART intervention 320.25 – SMART – see Table 33
TABLE 26 Sample for the survival analysis
Parameter n (%) (N= 4638) Mean SD Range
Female 2372 (51) – – –
Age (years) 4638 (100) 72.44 13.54 17–108
Survival (days) 4638 (100) 80.77 117.81 0–933
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risk estimates from this analysis were applied to all health states and the Markov model was relaxed to allow
these risk estimates to vary over time. The survival model estimates were permitted to vary in the probabilistic
sensitivity analysis following Cholesky decomposition for correlated regression parameters. During the
52-week model time horizon, 97% of the cohort were expected to have died. Survival was assumed to be
unrelated to pain, and thus the mortality rate was the same for all pain health states.
Transition probability parameters
Table 28 summarises the transition probabilities used in the model. The starting proportions of those in each
pain health state and of those with each of the three side effects were taken from the IMPACCT patient
survey, but allowed to vary in sensitivity analyses. Data from the feasibility study could not reliably inform on
the effectiveness of SMART as the study was not powered to do so. In the absence of effectiveness data
on the impact of the SMART intervention on pain and side effect management, we relied on expert opinion
on the likely effectiveness of the intervention (Professor Michael Bennett, University of Leeds) and on a
review of the literature. Given the uncertainty over the intervention effectiveness, we explored scenarios in
the model which assumed, for example, that the SMART intervention led to an overall reduction in the
proportion of people with side effects of 5% and a weekly reduction in pain status (from moderate and
severe to no/mild) of 1% per week. The baseline pain and side effect levels and pain progression were
assumed equivalent to those estimated in the standard care arm. To help inform model parameter
estimation, literature searches were conducted in June and July 2016 across the databases MEDLINE,
MEDLINE In-Process & Other Non-Indexed Citations, EMBASE and The Cochrane Library to identify economic
models of behavioural and educational self-management interventions for patients to manage pain and side
effects of medications at the end of life.
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FIGURE 14 Weibull estimated survival (weeks after referral to palliative care).
TABLE 27 Weibull survival analysisa
Parameter Coefficient SE z p> z 95% CI Hazard ratio
Gamma (_ln/p) –0.306 0.011 –27.220 0.000 –0.328 to –0.284 0.737
Constant –2.019 0.083 –24.330 0.000 –2.182 to –1.857 0.133
Age 0.005 0.001 4.640 0.000 0.003 to 0.007 1.005
p 0.737 0.008 0.721 to 0.753
1/p 1.358 0.015 1.328 to 1.388
SE, standard error.
a Survival per week from referral to palliative care.
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The change in pain status in standard care was modelled using the COUGAR II trial data set.86 In COUGAR II,
patients completed the EQ-5D measure at 3- and 6-weekly follow-ups during the trial, meaning that a
substantial number of longitudinal data were available for this group. The EQ-5D pain and discomfort item
response options were considered to be equivalent to the health states in the model defined by the numeric
pain scale categories. Thus, the EQ-5D responses ‘I have no pain or discomfort’, ‘I have moderate pain or
discomfort’ and ‘I have extreme pain or discomfort’ were assumed roughly equivalent to the pain rating
categories of 0–4, 5–6 and 7–10, respectively. Hence, by observing changes in EQ-5D pain item responses
over time, we were able to estimate the change in pain status over time at the end of life.
The EQ-5D pain item response was predicted in a multinomial regression with study week number and
survival included as covariates. Thus, the coefficient on the week covariate indicates the likelihood of change
in pain item response as time progresses, after controlling for survival. The results of the regression are
shown in Table 29 and indicate an increase in pain level over time, albeit a small one. Marginal effects were
used to estimate the transition probabilities for pain progression using the multinomial results. These results
inform only on the change in proportions over time (and not all the possible transitions between health
states), and the COUGAR data were insufficient to inform on all possible pain health state transitions.
Therefore, we assumed that transitions occurred only from the ‘no pain’ group to moderate and severe pain
groups. This background pain progression at the end of life was assumed to be the same in both arms, but
the scenario analyses allowed for improvements in health status in the SMART intervention arm.
Cost-effectiveness analysis
The economic evaluation follows the NICE reference case and hence a cost–utility analysis was conducted
with a cost per incremental QALY presented from UK NHS and PSS perspectives. The costs are reported
in 2015 prices and patient health is measured in terms of QALYs. Cost-effectiveness was assessed using
the incremental cost-effectiveness ratio (ICER) and net monetary benefit (NMB) values, and a range of
sensitivity analyses were conducted to explore the impact of key model assumptions and parameter
uncertainty on the results.
TABLE 28 Transition probability parameters
Parameter Mean (£) SD (£) Source
Background survival See Table 26 N/A Palliative care referral data
Starting proportions
No/mild pain 0.439 N/A IMPACCT patient survey91
Moderate pain 0.305 N/A IMPACCT patient survey91
Severe pain 0.256 N/A IMPACCT patient survey91
Nausea 0.212 N/A IMPACCT patient survey91
Constipation 0.331 N/A
Drowsiness 0.773 N/A
Pain progression See Table 26 N/A COUGAR II trial data86
Effectiveness
Standard care: pain 0 No change in pain progression – assumption
Standard care: side effects 0 No change in side effects – assumption
SMART intervention: pain –0.001 Weekly transitions: moderate to no pain and
severe to moderate – assumption
SMART intervention: side effects –0.05 Assumption
N/A, not applicable.
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The ICER is calculated by dividing the difference in mean costs between two arms by the difference in
mean QALYs between the two arms:
ICER =
CSMART − CUC
ESMART − EUC
=
ΔC
ΔE
, (1)
where CSMART and ESMART are the expected cost and effectiveness of the intervention (i.e. SMART) and CUC
and EUC are the expected cost and effectiveness of the usual care arm. The incremental cost and effect of
the SMART arm compared with usual care arm are represented by ΔC and ΔE, respectively. The NICE
willingness to pay per incremental QALY threshold [(λ) = £20,000] was used to define cost-effectiveness.
ICERs < £20,000 are usually indicative of cost-effectiveness. It was assumed that the NICE end-of-life
criteria were not met as these require an intervention to deliver an average increase in survival of 3 months
over usual care.
We account for parameter uncertainty in non-linear models by assigning probability distributions to each of the
input parameters and randomly drawing from these probabilities over the 10,000 Monte Carlo simulations.
This probabilistic sensitivity analysis allows the calculation of 10,000 ICERs and informs on the level of
uncertainty in the model. The probabilistic sensitivity analysis results were plotted on the cost-effectiveness
plane and NMB estimates used to generate the cost-effectiveness acceptability curve (CEAC).92 The CEAC
illustrates the probability that each intervention would be cost-effective given a range of willingness-to-pay
thresholds per incremental QALY.
The NMB was derived thus:
NMB = (λ × QALYs) − costs. (2)
TABLE 29 Pain progression over time
Model parameter
n 639
Log-ratio χ2(4) 30.99
Probability > χ2 0.0000
Pseudo-R2 0.0299
Log-likelihood –502.644
Pain parameter Coefficient SE z-value p-value Lower CI Upper CI
No pain (base)
Moderate pain
Week 0.0270 0.0092 2.9500 0.0030 0.0091 0.0450
Survival –0.0031 0.0006 –4.9600 0.0000 –0.0043 –0.0019
Constant 1.2037 0.1617 7.4500 0.0000 0.8868 1.5205
Extreme pain
Week 0.0524 0.0170 3.0800 0.0020 0.0191 0.0858
Survival –0.0029 0.0015 –2.0200 0.0440 –0.0058 –0.0001
Constant –1.6192 0.3482 –4.6500 0.0000 –2.3017 –0.9368
SE, standard error.
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Discounting was not required as all costs and benefits were experienced within 1 year. A half-cycle
correction was applied to account for the likelihood that model health state transitions occur half-way
through the model cycles. All analyses were conducted in Stata software (version 14) and Excel® (2013;
Microsoft Corporation, Redmond, WA, USA).
Feasibility results
Resource use
Full resource use data for 6 weeks were collected for 15 of the 19 participants (78.9%). Four participants
(21.1%) were lost to follow-up and, therefore, their patient records were not accessed. It was of note
that use of health-care services outside the GP practice, for example by the community team, was often
not recorded. Further investigation of how these services may be captured is required. Despite these
challenges, the researcher-completed outcome measure packs were completed.
There were 164 recorded instances of health-care service use for 15 participants over the 6-week study
period. As seen in Table 30, community nurse and palliative care CNSs were the services most
frequently accessed.
In order to calculate mean cost of care for each participant over the 6-week period, we assigned unit costs
to each service use (see Appendix 26 for unit costs). Cost data were completed for 15 participants. As seen
in Table 31, with unit costs applied to service use it can be observed that the main drivers of cost are GP,
CNS and district nurse home visits.
The questionnaire also included space to record prescribed medications. These data were collected for
the final 2 weeks for 15 patients and included only prescribed medications and not over-the-counter
medications and treatments the patient may have paid for themselves. These data have not been included
in the descriptive analysis.
Quality of life
In respect of assessment of quality of life, of the 19 participants in the study, 15 had complete information
for calculation of EQ-5D-5L. The four participants who were lost to follow-up had missing data for this part
of the questionnaire. Mean change from baseline to week 6 was 0.1079. Table 32 provides a summary of
the EQ-5D-5L.
TABLE 30 Recorded service use for 15 participants
Service Outpatient/day hospice Home Inpatient admission Telephone Total
GP 3 15 0 6 24
CNS palliative care 5 21 7 16 49
Doctor palliative care 3 2 0 4 9
Community nurse 20 29 0 8 57
Secondary care 7 0 3 0 10
Nurse other 6 3 0 6 15
Total 44 70 10 40 164
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Intervention costs
Intervention costs were calculated and included for SMART. The total intervention cost is estimated
at £320.25 per patient (Table 33). Development costs were also estimated; this included material
development (printing SMST resources), training sessions for nurses and researchers and time to deliver
intervention (Table 34).
Cost-effectiveness results
Results for the base-case cost-effectiveness analysis of SMART compared with usual care are presented in
the Table 35. Based on the model assumptions regarding pain progression and SMART intervention
impact, it can be seen that SMART is more effective and less costly than usual care. SMART can be said to
dominate usual care, indicating that there are cost savings to be made from the introduction of SMART.
TABLE 31 Mean resource use and costs
Service Type n
Number of
uses
Mean
cost (£) SD (£)
Minimum
(£)
Maximum
(£)
GP Outpatient/day hospice 1 3 132.00 0.00 132.00 132.00
Home 8 15 168.75 89.19 90.00 360.00
Telephone 4 6 40.50 15.59 27.00 54.00
CNS palliative care Outpatient/day hospice 3 5 62.10 21.51 37.26 74.52
Home 8 21 97.81 59.54 37.26 223.56
Inpatient admission 2 7 130.41 131.73 37.26 223.56
Telephone 8 16 33.06 17.67 16.53 66.12
Doctor palliative care Outpatient/day hospice 1 3 501.00 0.00 501.00 501.00
Home 2 2 167.00 0.00 167.00 167.00
Community nurse Outpatient/day hospice 4 20 186.30 80.49 74.52 260.82
Home 6 29 180.09 211.32 37.26 596.16
Telephone 5 8 26.45 9.05 16.53 33.06
Secondary care Outpatient/day hospice 7 7 167.00 0.00 167.00 167.00
Inpatient admission 1 3 501.00 0.00 501.00 501.00
Total cost (£) 536.07 513.04 90.00 1998.77
TABLE 32 THE EQ-5D-5L utility values by time point
Time point Observed Missing Mean SD Minimum Maximum
Baseline 19 0 0.564 0.227 0.122 0.927
Week 2 (follow-up 1) 15 4 0.679 0.196 0.193 0.942
Week 4 (follow-up 2) 15 4 0.603 0.206 0.184 0.942
Week 6 (follow-up 3) 15 4 0.672 0.223 0.108 0.942
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The results of the one-way sensitivity analyses conducted for SMART compared with usual care are given in
Table 36. Assuming that there was a 2.5% reduction in side effects and a 0.005% reduction in pain led to
a drop in QALY gain of 0.0041. This meant that costs for SMART were now higher than for usual care,
but with an additional health benefit of 0.0045 QALYs per patient. This results in an ICER of £11,977 per
additional QALY, which still indicates cost-effectiveness. Sensitivity analyses were conducted using different
utility values, the EORTC-QLQ C30 and the ICECAP-A quality-of-life measures. The results of both of these
analyses were similar, with SMART once again dominating standard care alone.
With costs of SMART increased 100%, it can now be seen that SMART becomes a more expensive
intervention. However, the ICER of £16,778 remains below the NICE cost per QALY threshold of £20,000.
One assumption that could be made is that nurse visits to the patient do not increase because of SMART.
This extra visit cost was removed, leading to an intervention cost of £49.15. This decrease in incremental
cost served to make SMART more cost-effective. With the costs of cancer for each pain severity group
halved, SMART becomes a more expensive intervention; however, again, with an ICER of £1830, this
remains below the NICE cost per QALY threshold.
TABLE 33 Intervention costs
Resource type Unit cost (£) Mean number of visits Time (minutes) Cost (£)
Sessions with CNSa 91 (per hour of
face-to-face contact)
3.25 55 271.10
SMART toolkit contents (see
Appendix 9 for more detail)
43.87 N/A N/A 43.87
DVD pressing 3.60 N/A N/A 3.60
Memory sticks 1.68 N/A N/A 1.68
Total 320.25
N/A, not applicable.
a Development costs were estimated. This included material development (printing and patient boards), training sessions
for nurses and researchers.
TABLE 34 Development costs of SMART
Itema Total cost (£)
Intervention toolkit folders 2293.55
SMART DVDs 949.44
Seven × nurseb training 3276.00
Trainer expenses 2220.00
Researcher preparation and delivery time 354.60
Total 9093.59
a See Appendix 26 for detail.
b Reference: Curtis89 page 17.
TABLE 35 Results of cost-effectiveness analysis SMART vs. usual care
Strategy
Total
cost (£) Total QALY
Incremental
cost (£)
Incremental
QALY ICER NMB (£)
Net health
benefit
SMART 8921 0.0473 –175 0.009 SMART dominates 5 0.0025
Usual care 9096 0.0387
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The uncertainty around the model results can be seen in Figure 15, the cost-effectiveness plane. The
results vary widely, with ICERs scattered across the cost-effectiveness plane. As the spread of ICER cloud is
greater vertically than horizontally, there appears to be greater uncertainty in the costs than in the QALYs.
The uncertainty around the cost-effectiveness is further represented in the CEAC in Figure 16. The CEAC
shows the likelihood that SMART will be acceptable to a decision-maker, given a particular threshold.
SMART has a 68.9% probability of being cost-effective at a £20,000 per QALY threshold, increasing to
78.3% at a £50,000 per QALY threshold.
Feasibility of conducting a cost-effectiveness evaluation of SMART
An economic evaluation was conducted to assess the feasibility of estimating cost-effectiveness of SMART
compared with usual care in patients at the end of life who receive opioids. The feasibility of a trial-based
evaluation was also explored. The evaluation consisted of an economic decision-analytic model, in which
cost-effectiveness was assessed for the remaining survival time of patients from a NHS and PSS perspective
over 1 year.
The costs of developing and implementing the SMART intervention are relatively modest and, in this
analysis, these costs are recovered in savings brought about by improved management of pain and opioid
side effects. Given the assumptions made relating to effectiveness, the SMART intervention led to cost
savings and yielded incremental QALYs in our base case and many of the deterministic sensitivity analyses.
These QALY gains are small, although this is to be expected as this population has a limited survival time in
which to benefit. In general, the results are robust to one-way parameter changes and SMART appears to
be cost-effective compared with standard care alone.
TABLE 36 Results of one-way sensitivity analysis
Sensitivity analysis Strategy
Total
cost (£)
Total
QALY
Incremental
cost (£)
Incremental
QALY s ICER (£)
Reducing effectiveness by
50%
SMART 9151 0.0432 55 0.0045 11,977
Usual care 9096 0.0387
Using ICECAP-A utility
values
SMART 8921 0.0847 –175 0.0055 SMART dominates
Usual care 9096 0.0792
Using EORTC utility values SMART 8921 0.1000 –175 0.0054 SMART dominates
Usual care 9096 0.0946
Increasing SMART
intervention costs by 100%
SMART 9241 0.0473 145 0.0086 16,778
Usual care 9096 0.0387
Assuming no extra visit costs
for SMART
SMART 8650 0.0473 –446 0.0086 SMART dominates
Usual care 9096 0.0387
Halving the costs of the
cancer for each severity
group
SMART 5073 0.0473 16 0.0086 1830
Usual care 5057 0.0387
Scenario where side effect
costs and utility decrement
are halved
SMART 8468 0.0670 –119 0.0068 SMART dominates
Usual care 8587 0.0602
EORTC, European Organisation for Research and Treatment of Cancer.
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The probabilistic sensitivity analysis highlights moderate uncertainty in the model as the SMART
intervention has a 69% chance of being cost-effective. Given the uncertainty around the cost-effectiveness
and data highlighted above, and as effectiveness parameters were based on plausible scenarios, the results
should be treated with caution. However, the results indicate that a low-cost intervention such as SMART
could be cost-effective in this population even if the impact on pain and side effect management were
modest and suggests that further research is warranted.
A full economic evaluation of patient-level data from a RCT is required to allow confidence in decision-
making. The feasibility aspects of this study suggest that this should be possible. Although missing data on
the utility measures were minimal, greater effort may be required in the collection of cost data and access
to centrally held health-care use records may be optimal.
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Chapter 5 Discussion and conclusions
We have shown that the evaluation of a supportive self-management intervention for patientsrequiring analgesia, and who are approaching the end life, is feasible.
Summary of specific feasibility study outcomes
Developed a construct of supported self-management in palliative care in relation to
analgesic medicines
This was derived through a synthesis of our existing research and literature reviews of patient needs,
behaviour change theory, existing interventions and ways to optimise the context in which HCPs can
provide support. The development of the supportive self-management concept included key contextual
factors in end-of-life care pain management, patients’ concerns about analgesia and the roles and
responsibilities of patients, carers and professionals that we represented on a continuum in relation to
self-management behaviours.
Developed and refined an intervention consisting of a self-management toolkit and a
four-step education approach
We explored and refined our concept of supported self-management with 11 patients, eight carers and
19 HCPs though interviews and focus groups, informing the development of our intervention. From these
data, we developed a four-step education approach that consisted of a needs assessment, including
capacity for self-management, provision of information, goal-setting and review and coaching. We
supported this approach with a self-management toolkit that comprised information factsheets, a pain
chart and medication diary, goal-setting sheets and two 5- to 6-minute podcasts. We mapped data from
our literature review and interviews against target behaviours and techniques to enhance self-efficacy to
ensure that the toolkit and education approach would address the needs of patients, would be based on
sound theoretical principles of enhancing self-management and would therefore be more likely to be
effective in practice.
Developed and delivered a brief training programme for clinical nurse specialists in
palliative care
The intervention was designed to be delivered to patients by community-based CNSs in palliative care.
We engaged an expert nurse educator to design and deliver the training, which modelled the four steps
within a clinical encounter and was based on a therapeutic conversational process between the specialist
nurse and patient. This training included reflection, experiential learning and the development of a
modelled self-management-focused conversation between two nurse educators.
Conducted a feasibility study of the intervention to inform the design of a future
randomised controlled trial
This tested the recruitment and follow-up rates, fidelity of treatment delivery and suitability of outcome
measures. We trained 12 CNSs from four UK hospices in the delivery of the intervention. During the
4-month study period, we identified 103 eligible patients from 417 who were screened. The most
common reasons for ineligibility were patients not treated with a strong opioid (53%) and expected
survival of < 6 weeks (19%). Of the 103 eligible patients, 37 (36%) were approached, of whom 19
(51% of those approached) agreed to participate and 15 completed the 6-week follow-up period. We
found that 13 out of these 15 patients received all components of the intervention. Most patients (13/15)
received a minimum of three visits during the 6-week study period. Rates of missing data for our outcome
measures were very low. Although we observed no changes in our measures of pain intensity, we did
observe improvements in our measures of interference from pain and in enhancing self-efficacy, which our
evidence synthesis and interview data highlighted as being more important outcomes to patients than pain
intensity alone.
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Acceptability of intervention
Through qualitative interviews with patients and CNSs who participated in our feasibility study, we were
able to understand the acceptability of the intervention and potential challenges within a large RCT.
Patients and carers perceived that they all derived some benefit to them from the SMST, but the degree
and nature of this benefit was variable and dependent on individual circumstances and preferences. The
goal-setting sheets were the most frequently valued element; however, there were often other elements
that were liked (e.g. the pain diary). The value of the factsheets to patients and carers appeared to be in
reinforcing information that they had already been provided with by their CNS. Nurses reported that,
although some patients found the concept of supported self-management more difficult to grasp, in
general they felt that the educational approach was in keeping with their usual practice. All of them
valued the training and materials. The busy and time-pressured reality of clinical practice for these specialist
nurses, who often managed large caseloads, meant that the delivery of the intervention per protocol
during the course of the trial varied. Patients perceived that the intervention was most effective when
nurses delivered the factsheets according to need, completed contact information sheets, reviewed
patients’ diaries and set goals. We assessed the potential for contamination of nurses not involved in the
study by those nurses who were. We found that, although there was a general awareness of the study,
there was no evidence that practice had changed or that the intervention was used by nurses who were
not involved in the study.
Health economic analysis
We estimated cost-effectiveness of the SMART intervention within this feasibility study using a DAM
approach because of the small number of patients and the lack of a control arm. We demonstrated that it
was feasible to collect information to inform a full economic evaluation within a definitive RCT. The
cost–utility analysis suggested that the SMART intervention appears to be cost-effective compared with
standard care alone and could lead to cost savings. The SMART intervention yielded QALY gains and cost
savings in our base case and many of the deterministic sensitivity analyses.
Success criteria and key learning points
Ultimately, we aimed to establish the acceptability and uptake of the SMART intervention and determine
the feasibility of evaluating this intervention within a definitive trial. In order to judge whether or not
we had achieved our aims, we agreed our success criteria beforehand (see Chapter 1, Success criteria).
Here we review the extent to which we have met these criteria.
Phase I
Establishment of patient and public involvement panel
This was achieved within 3 months of starting the SMART project. The PPI panel consisted of carers and
bereaved carers of patients who had received palliative care in the community. PPI panel members were
invited to quarterly PPI meetings as well as the biannual investigators meeting and Study Steering Group
meetings. PPI panel members were involved in reviewing our initial concept of self-management and
the components of our prototype SMART intervention prior to the modelling focus groups. A PPI panel
member reviewed participant study materials (e.g. information sheets) and contributed to interpreting the
results of the feasibility trial during the investigator meetings.
Development of a concept of usual care based on literature review and clinical
practice observations
This was achieved by reviewing the contextual policy literature on delivering end-of-life care in the
community (see Chapter 1) and during interviews with CNSs, GPs and consultant palliative care clinicians
working in hospice and community palliative care services (see Chapter 2).
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Development components of a prototype SMART intervention and delivery strategy
This was achieved throughout the first phase of the SMART project, during which the literature was
reviewed on supported self management of chronic diseases and end-of-life care. The literature scoping
work informed the theory-driven development of a prototype SMART intervention based on the theories of
self-efficacy and behaviour change that were best suited to the developing intervention.39,54
Phase II
Establish members of focus groups
Recruitment of patients, carers and HCPs to the Phase II focus groups was achieved through community
palliative care services. The Phase II methodology was amended to allow patients to take part in a
interview format if they were to unwell or preferred not to attend a focus group but still wished
to participate.
Development of refined intervention materials and delivery strategy
This was achieved through an iterative process involving patients, carers, HCPs, the research team, expert
advice from the study co-applicants, the PPI panel and the Study Steering Group.
Phase III
Recruit three participants per month per each site within 4-month recruitment period
The observed recruitment rate was 1.2 participants per month per site for 4 months. Our initial recruitment
strategy was an estimate based on the caseloads of all CNSs working within community services at the four
sites. We recruited approximately one-third of all full-time equivalent CNSs working within the recruitment
sites. The observed new referral rate was approximately what we had expected (4.2 patients per month
per site vs. 3 patients per month per site, respectively); however, we overestimated the proportion of patients
that we expected would be prescribed strong opioids for pain, which led to a screening failure rate of
53.5%. Therefore, to increase the recruitment rate to three participants per month per site, a future definitive
trial should consider recruiting all full-time equivalent CNSs within community palliative care services at each
of the sites and increase the range of the intervention (and consequently the eligibility criteria) to include
patients on weak opioids.
Feasibility of data collection
The overall level of missing data for the participant self-reported outcomes and the measures of health-care
resource use was very low. These findings indicate that the deliverability of data collection methodology
was feasible through face-to-face researcher visits. Data from our previous research (IMPACCT) indicate
that follow-up data collection rates would be far worse if data were not collected face to face. Participant
acceptability and preferences of the self-reported outcomes were assessed by evaluating the level of
missing data for each outcome measure and the post-study interviews with participants.
Estimating primary study end point
Owing to the low level of missing data, we were able to evaluate the variability in the participant
self-reported outcome measures across the follow-up time points. We identified that the BPI pain
interference scale and SES are the measures most likely to be sensitive to change over the defined
follow-up period. This fits with the mechanisms of impact of the intervention outlined in the logic model
presented in Chapter 2, which identified that the SMART intervention would lead to improvements in
participants’ self-confidence (self-efficacy) in managing analgesic medication and consequently reduce the
impact of pain on activities of daily living within the context of declining health. The self-efficacy scale was
most acceptable to participants (some participants did not like the final question on the BPI interference
scale) and demonstrated the largest potential effect size.
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Participant, carer and study nurse acceptability of the study experience
Participants and their carers universally indicate that their overall experience of the study was positive and
they had sustained use of the intervention resources over the 6-week follow-up time point. The study nurses
also indicated that the study process was acceptable; however, ongoing training and support throughout the
trial period were necessary to improve the fidelity of delivery of the intervention and a future definitive trial
should consider implementing a sustained programme of ‘top-up’ training sessions for study nurses.
Limitation of feasibility and considerations for a future definitive
randomised control trial
To inform the design of a future definitive RCT of the SMART intervention, we have identified the key
learning points and highlighted opportunities to address them.
Recruitment
Limitation
The feasibility study was limited by the lower than anticipated recruitment rate.
Solution
Extend the range of eligible participants to include people prescribed weak opioids. Research field notes
identified that many patients who were screened as ineligible because they were not prescribed strong opioids
were in fact prescribed weak opioids for pain. Recruited patients already taking strong opioids reported that
they would have benefited from the intervention before or at the point of commencing strong opioids.
Intervention content
Limitation
The content of the intervention was focused on strong opioids only.
Solution
Modify the content of the SMST resources and CNS training manual to include information about weak
opioids. This process should include further stakeholder input (i.e. patients, carers and HCPs) to ensure that
the content of the SMST resources remains relevant and acceptable to individuals prescribed weak opioids.
Intervention delivery
Limitation
The fidelity of intervention delivery was limited by the need for ongoing training and support throughout
the trial period.
Solution
Modify training and support for CNSs to ensure that the research process is more clearly articulated and
that the concepts of self-management and means to support this by nurses are better understood to
reduce variations in the fidelity of intervention delivery.
Trial support
Limitation
Sites where CRN support was not secured had lower recruitment rates.
Solution
Securing CRN support at each site to assist researchers with screening, recruitment, follow-up visits and final
data collection, and to assist study nurses with completion of CRFs relevant to the delivery of the intervention.
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Trial processes
Limitation
The process for recording withdrawal was not sufficiently detailed.
Solution
Clear reporting of withdrawal procedures with levels of withdrawal to capture patients who withdraw
from researcher follow-up (because of the burden of continuing with these visits), but continue to use the
intervention with the study nurse.
Outcomes and outcome measures
Limitation
The number of follow-up visits was considered burdensome for some participants.
Solution
Reduce the number of follow-up visits from three to two (weeks 3 and 6 following baseline). Data from
participant self-reported outcome measures indicated little change in the variables between weeks 2 and 4.
Based on the acceptability to participants and large potential effect size, we recommend that the primary
outcome measure for a further definitive trial would be the SES. Consider using interference from pain as a
second primary outcomes rather than pain intensity.
Trial design
Limitation
The feasibility trial did not have a control arm or assess the feasibility of randomisation processes.
Solution
Contamination of non-study nurses was low at participating sites; therefore, a parallel design could be
considered for this reason. However, this design would be feasible only if patients allocated to the control
arm were seen by untrained nurses and those allocated to intervention arm were seen by trained nurses.
Current services are delivered by nurses with geographically based caseloads and so their eligible patients
could be allocated to either arm. A cluster design with nurse as the cluster would lead to the most efficient
trial design, while accounting for nurses’ geographically aligned caseloads. If nurses within a service are
willing to be randomly allocated to either intervention or the control, then all eligible patients within a service
could still be considered for recruitment, maximising accrual rate while increasing the number of clusters of
participants. In addition, having intervention and non-intervention nurses within each site further minimises
between-site differences. Therefore, we recommend a cluster trial design at the level of the nurse for a future
definitive trial, as we have shown that there is little contamination of nurses within a site and it allows
participants to be seen by their geographically aligned nurse without having to cluster at the site level.
Furthermore, we recommend that a future definitive trial would have an internal pilot study to evaluate the
feasibility of randomisation processes and generate pilot data required to inform the sample size for a
definitive trial.
Conclusion
We have shown that the evaluation of a supportive self-management intervention for patients requiring
analgesia, and who are approaching the end life, is feasible. Our success criteria were largely met and, for
those that were not, we have identified clear means to succeed within a future trial through a detailed
process evaluation of our feasibility study. The key considerations in the design of future definitive trial
have been identified, which we believe is now feasible to undertake.
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Appendix 2 The content and form of previous
interventions to improve pain management
West CM, Dodd MJ, Paul SM, Schumacher K, Tripathy D, Koo P, et al. The PRO-SELF(c): Pain ControlProgram – an effective approach for cancer pain management. Oncol Nurs Forum 2003;30:65–73.58
PRO-SELF: a pain control programme for cancer pain management
Time period Intervention
Week 1 Nurses meet patients and family caregivers in their homes
Conduct an in-depth assessment session, identifying areas of knowledge deficit
Review answers to questions on the knowledge and attitude questionnaire
Review the PRO-SELF: pain control booklet and use the teaching guide to enhance information in the
booklet
Review baseline pain scores and pain pattern
Review pain medicines and drug administration schedule
Educate patients regarding optimal administration of pain medications, set up medicines in the dosette box
Instruct patients on how to complete a daily pain management diary
Review side effects checklist and discuss prevention and management of side effects
Educate patients on how to discuss with their HCPs the need for change in the pain management plan if
appropriate
Review how to contact nurses for pain management questions
Week 2 Nurses telephone patients and family caregivers
Review pain scores and medication use during the previous week
Reinforce teaching about use of analgesics, side effects management and concerns about addiction if
needed
Determine if patients had to see HCPs for pain management or if analgesic prescription changed during
the previous week
Answer questions about pain management
Week 3 Home visit: same as week 2
Week 4 Telephone call: same as week 2
Week 5 Telephone call: same as week 2
Week 6 Home visit: same as week 2
Fahey KF, Rao SM, Douglas MK, Thomas ML, Elliott JE, Miaskowski C. Nurse coaching to explore and
modify patient attitudinal barriers interfering with effective cancer pain management. Oncol Nurs
Forum 2008;35:233–40.59
Coaching intervention: nurse teaching to explore and address patient attitudinal barriers interfering with
effective cancer pain management.
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Four telephone calls over 6 weeks:
1. greeting – initiate call by listening and outlining plan for the session
2. current issue – consider and explore attitudinal barriers; promote patient’s recognition of attitudinal
barriers interfering with adequate pain management
3. problem – help patient describe and consider the nature and extent of problem that is interfering with
better pain management
4. problem impact – explore specifics about how the problem (and related beliefs and behaviours) is
affecting the patient
5. short-term goals – encourage identification of short-term goals and promote exploration of specific
behaviours that might help the patient reach goals
6. strategies – list strategies and options for overcoming the barriers
7. tasks – select tasks that will support the removal of attitudinal barriers, enhance self-confidence and
improve pain management
8. summary – summarise the discussion and allow for questions.
Ward S, Donovan H, Gunnarsdottir S, Serlin RC, Shapiro GR, Hughes S. A randomized trial of a
representational intervention to decrease cancer pain (RIDcancerPain). Health Psychol 2008;27:59–67.60
RIDcancer PAIN +: an intervention to decrease cancer pain.
Seven elements:
1. Patients asked to describe their beliefs about their pain in terms of cause, timeline, consequences and
control (assessment interview). The intervener listened carefully for mention of barriers to pain
management such as fears of addiction or concerns about side effects.
2. Gaps, confusions and misconceptions about reporting pain and using analgesics were identified
and discussed.
3. Creating conditions for change – patients discussed the losses that result from the misconceptions.
4. Intervener provided information to fill the gaps and replace confusions that had been identified. An
educational message had been prepared for each of the common attitudinal barriers (fatalism about
cancer pain management, exaggerated fear of addiction, worry about developing tolerance, concern
about side effects, fear of being a complainer and worry about masking changes in disease status).
The messages were developed from evidence in the literature and had been used previously.
5. Summary and discussion of the benefits of adopting this new information.
6. The patient created a plan for changing the way he/she managed pain.
The first six elements were covered in a single session that lasts from 20 to 80 minutes, depending on the
number of misconceptions that were identified.
7. Evaluation of coping plans – took place during follow-up telephone calls that occurred 2 and 4 weeks
after the first session. The intervener reviewed the plan with the patient to work out if the patient was
meeting their goals, to determine which coping strategies had been most useful and to revise the plan.
These follow-up calls lasted approximately 5–10 minutes.
Cagle JG, Zimmerman S, Cohen LW, Porter LS, Hanson LC, Reed D. EMPOWER: an intervention to address
barriers to pain management in hospice. J Pain Symptom Manage 2015;49:1–12.61
EMPOWER: an intervention to address barriers to pain management in hospice patients.
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
116
Components:
1. Staff training
i. an overview of barriers to pain management in hospice
ii. an in-depth discussion of common barriers and suggestions for addressing patient and family fears
and misconceptions
iii. instructions on use of the EMPOWER screen
iv. strategies to improve patient caregiver medication management
v. presentation of case examples
vi. distribution of written material outlining the components of the intervention.
2. The EMPOWER screen
i. Hospice nurses were instructed to screen family caregivers and, if possible, the patient, using the
EMPOWER screen during admission. The screen consisted of eight yes/no questions to identify
common concerns related to pain and pain management. The concerns included addiction, side
effects, pain as a sign of weakness, being perceived as drug seeking, being a bother, building a
tolerance, taking/giving too much and that the medicines would not work.
3. Tailored education using the EMPOWER brochure
i. If any of the eight barriers to pain management were identified, hospice staff gave the patient/
family member the EMPOWER brochure, which included evidence-based statements, and reviewed
its content. The statements were written to address common fears and misinformed beliefs while
aiding communication between patients, caregivers and hospice providers. For example, to address
concerns about tolerance the statements say –
– ‘It is normal for your body to adjust to the pain medication. Your dose can be increased if
necessary so the medication keeps working’
– ‘Using medication now will not prevent it from working in the future’.
ii. When no barriers were identified during the screen, families still received the brochure, but there
was no discussion of its content.
4. Follow-up
i. Staff were instructed to document patient and family concerns in the medical chart and discuss
identified concerns during team meetings.
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Appendix 3 Summary of learning Cancer Carer
Medicines Management
A Phase I/II feasibility trial of Cancer Carer Medicines Management:
an educational intervention for carer management of pain medication
in cancer patients at end of life (research data available to the team)
The Phase I systematic review and Phase II patient and carer interviews
Beliefs
l Evidence of beliefs that initially hindered, reduced or delayed pain control.
¢ Fears of addiction/dependency (not being able to come off it if started).
¢ Fears of having to rely on morphine.
l Patients self-managing to avoid ‘crises’ (i.e. pre-empting emergencies and seeking to avoid
hospital admissions).
l Fear of side effects (e.g. reluctance to increase baseline pain medicines for fear of drowsiness);
therefore, use of pro re nata medication instead.
l Concern about out-of-hours care and treatment.
l Common wish to take the minimum medication possible – often underpinned by rationale ‘so that they
can have more later’.
Skills
l Carer often acts as the person who reminds the patient to take medicines, helping when patients
become confused or forgetful, ensuring that medicines taken at appropriate times.
l Development of routines to suit home life (e.g. to prepare medicines in evening for next day or week).
Recurrent contextual issues
l Lack of in-depth conversations with patient and carer regarding pain medications across control group.
l Problems with 111 service in a crisis.
Value of intervention
l Most found some aspects of it helpful.
l Carers commented on the value of CCMM resources in the toolkit, particularly for information,
reassurance and supporting problem-solving.
l Some positive changes in medicines management (e.g. increased acceptance of the need for opiates),
knowledge being reinforced or enhanced, and behavioural change (e.g. responding more readily to
patients’ requests for pain relief and improved systems in place for giving and recording medicines).
Nurse data
l Only some aspects of the intervention were perceived as distinct from current practice.
l The toolkit (e.g. the information about opioids was seen as a new and useful resource).
l The structured conversational process was considered to be similar to nurses’ routine practice.
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l Value of having written materials about opioids and introducing more systematic techniques for
managing pain medication.
l Positive experiences of training helped nurse engagement.
l Nurses’ accounts emphasised the diversity of patient and carer circumstances, experiences and needs.
The adaptability of the intervention, the extent to which nurses could individualise its delivery was
perceived as crucial to its usefulness.
l Nurses did not fully exploit the adaptability of the toolkit. Although some nurses introduced the toolkit
resources selectively, there was a tendency to use the toolkit as a package that they gave to carers in
its entirety with the expectation that they would decide for themselves which tools would be useful.
l The focus on pain was seen by some nurses as limiting its usefulness. They argued that carers typically
managed multiple medications for a range of symptoms at end of life so broadening the intervention
to accommodate that would increase its applicability and acceptability to carers. Nurses were critical of
some written resources, which they felt should be comprehensive (all medicines for cancer) rather than
pain specific (e.g. the medicines chart).
l Most argued that introducing the intervention earlier in the course of a patient’s illness would be
easier, more appropriate and of greater benefit. They gave examples of carers who were unable to
engage with the intervention because they were overwhelmed and distressed.
l The nurses reported that the intervention had facilitated communication and relationship building.
l Most found value in the intervention and identified advantages in offering carers written information
about analgesics and simple formats for documenting pain and medication. Some thought the
intervention had influenced their practice: they would be more likely in future to include carers in
discussions and encourage them to keep records.
Carer need literature
Lau et al.93
l Interviews with informal caregivers (n = 23) and hospice providers (n = 22).
l Caregivers’ life experience and self-confidence facilitated medication management.
l Caregivers’ negative emotional states, cognitive and physical impairments, low literacy, other
competing responsibilities, as well as patients’ negative emotional states and complex medication
needs were limiting factors.
Kimberlin et al.94
l Focus groups and interviews with cancer patients (n = 22) and family caregivers (n = 16).
l Seven themes emerged suggesting improvements that are needed in the communication process.
These included (1) improving the process of information exchange, (2) increasing active participation
of patient and caregiver in the care process, (3) improving provider relationship-building skills,
(4) overcoming time barriers, (5) addressing fears regarding use of pain management medications,
(6) fostering appropriate involvement of family and caregivers in the communication process and
(7) improving co-ordination of care among providers.
Mehta et al.95
l Grounded theory study of family caregivers (n = 24).
l Derived an explanatory model of how family caregivers manage the pain of cancer patients at home
involving four main processes: ‘drawing on past experiences’; ‘strategizing a game plan’ (accepting
responsibility for pain management, establishing relationships with patients and health-care team
and seeking information on pain and pain management); ‘striving to respond to pain’ (including
implementing strategies for pain relief, determining the characteristics of pain and verifying the degree
to which pain relief strategies are successful); and ‘gauging the best fit’ (a decision-making process that
links all the processes, recognising parameters and limitations, and then joins the pieces together).
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Mehta et al.96
l Grounded theory study of family caregivers (n = 24).
l Family caregivers are not always well prepared and require appropriate support to ensure optimal
pain control.
l Understanding that family caregivers are continuously engaged in specific processes as they prepare
for and implement pain management strategies can help HCPs tailor their interventions.
Mehta et al.97
l Grounded theory study of family caregivers (n = 24).
l Caregivers assessed different types of pain and, therefore, were experimenting with different types of
interventions. Not all family caregivers were able to distinguish between the different pains afflicting
patients and, consequently, were not selecting the most appropriate interventions. This often led to
poorly managed pain and frustrated family caregivers.
Schumacher et al.98
l Transcribed interactions between intervention nurses and patients (n = 52) and their family
caregivers (n = 33).
l Describes the difficulties with pain management that patients and family caregivers bring to a nurse’s
attention during a teaching and coaching intervention. Found patients had difficulty in seven areas
when they attempted to put a pain management regimen into practice, namely (1) obtaining the
prescribed medication(s), (2) accessing information, (3) tailoring prescribed regimens to meet individual
needs, (4) managing side effects, (5) cognitively processing information, (6) managing new or unusual
pain and (7) managing multiple symptoms simultaneously. The findings suggest that the provision of
information about cancer pain management to patients and their family caregivers is not sufficient to
improve pain control in the home care setting.
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Appendix 4 Summary of learning IMPACCT
Meta-review
57 (of six reviews and two papers) describing the optimal components for an educational
intervention for advanced cancer pain using Michie et al.’s39 behaviour change wheel as theoretical
underpinning.
Information on pain management
l Providing education to patients approaching the end of life to self-manage their pain is known to
reduce pain.
l Include name and type of medication, routes of administration, around the clock/as needed, schedule
and dosing.
l Patients with cancer pain should routinely be provided with patient-based education to improve
knowledge on managing pain and analgesia.
l Provide consistent screening for misunderstandings about pain and analgesia prior to commencing
analgesic therapy. Address these aspects through clear advice and information.
l Written or audio-visual material supporting the advice should be given to the patient to take away.
Cognitive barriers to pain management
Includes concerns about tolerance, addiction, fatalism, religious fatalism, being a good patient, side effects
of medication are inevitable and unmanageable, masking signs of disease progression, distracting clinicians
from treating the disease, harming the immune system, injections and respiratory depression. Patients and
carers view pain as a referent for disease status (i.e. worsening pain =worsening disease). Morphine use
has particularly strong symbolism of addiction and tolerance and its introduction into a patient’s life is
seen/interpreted as a signal of impending death.
Information on how to implement self-management strategies
l It is not known which aspects of self-management education interventions are most effective (content,
timing, frequency, mode of delivery).
l Information and advice should be so that a lay person could improve his/her knowledge of
pain management.
l Behavioural instructions on how to perform the desired behaviour means skill building via instructions,
so that a lay person could actually perform desired pain management.
l Skills-based interventions showed greater effectiveness compared with education approaches in
reducing pain severity (not statistically significant, but considered a promising finding). Skills-based
interventions defined as ‘changing patients’ dysfunctional beliefs about pain and promote the use of
specific skills to manage it (e.g. distraction, relaxation). Specific components varied, targeting all three
attributes of knowledge, skills, attitudes of cancer pain and its management.
l Specialist nurses and pharmacists might be the most appropriate HCPs to deliver pain management advice.
Contextual factors that need to be addressed in an intervention to
support self-management of cancer pain
l Patient/carer level (intrinsic): psychological and physical capability to engage with an intervention;
reflective processes around planning and managing cancer pain.
l HCP level (extrinsic): appropriate education/training of the HCP to deliver education (the intervention)
to patients; the HCP requires protected time to deliver education (the intervention) to patients (written
material and face-to-face educational session of not less than 15 minutes); multidisciplinary involvement.
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Themes from qualitative studies
Control, knowledge, meaning of morphine, adherence, impact of pain and trust. Qualitative research
evidences indicates that patients constantly make a trade-off between the impact of pain against the
impact from analgesia on physical and cognitive function.
Intervention components are those activities that should be included in an educational intervention in
order to change the behaviour of individuals. The authors identified five out of the nine behaviour change
wheel intervention functions and suggest that these should be included in any educational intervention
promoting self-management of advanced cancer pain:
1. education, for example providing written information about pain management, including analgesic and
non-pharmacological approaches
2. training, for example providing instruction, demonstration and coaching of new skills (techniques for
managing daily drug regimes, relaxation techniques)
3. enablement and persuasion, for example overcoming cognitive and emotional barriers to pain
management through addressing concerns about tolerance or addiction
4. environmental restructuring and resources, for example incorporating the delivery of education for
self-management into the usual care provided by specific health professionals, such as specialist nurses,
primary care practice nurses and community pharmacists
5. modelling, for example patients talking to other patients about their successful use of various pain
management strategies.
APPENDIX 4
NIHR Journals Library www.journalslibrary.nihr.ac.uk
124
Appendix 5 Focus group topic guide/interview
guide: patients/carers
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Appendix 6 Card pack used in the patient/carer
interviews and focus group
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Appendix 7 Focus group topic guide/interview
guide: health-care professionals
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Appendix 8 Card pack used in the health-care
professional interviews and focus groups
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Appendix 9 SMART self-management support
toolkit factsheets
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Appendix 10 Topic guide for structured
patient podcast
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Appendix 11 Topic guide for structured
health-care professional podcast
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Appendix 12 Pain diary
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Appendix 13 Medication chart
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Appendix 14 Goal-setting sheets
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Appendix 18 Nurse self-management
conversation prompts
Supportive self-management in palliative care
. . . assessing, planning and implementing appropriate care to enable the patient to live until they die
and supporting the patient to be given the means to master or deal with their illness themselves.
Johnston et al.51
Conversational process
Phase of self-management
conversation
Approach/role
(Johnston et al.51) Skills Example
Orientation to
self-management
l Person centred
l Problem centred
l Moment centred
l Meaning centred
Emotion work: take account
of what is important to the
person, their identity, to their
previous experience and how
they are making sense of the
current situation66
Focus on maintaining
normality (Johnston et al.51)
Suspend concerns about time
the conversation will take
Assess: purpose to identify
l how a person is managing
their pain and their pain
medications (the
behaviours associated with
taking medicines for pain)
l what beliefs are influencing
their pain
medicine management
l their knowledge of their
pain medicines
l Facilitator Start with open question
focused on intention of
conversation Can you tell me how you have
been getting on with managing
your pain medicines?
Recognise and validate the
feeling expressed by the
patient It sounds as though this has
been really tough
It sounds as though you have
been working hard to try and
get on top of your pain
Use probing questions to find
out in more detail about how
the person is managing their
pain medicines – what they
are doing, how they are
understanding analgesics and
the beliefs influencing this
understanding
So one of the challenges you
are facing is . . . can you tell me
a little more about . . .
Are there other concerns that
are influencing how you are
managing your medications?
Check for other concerns and
repeat process of gathering
and reframing Can I just check whether you
have any concerns about taking
medications for your pain; for
example, many people worry
that they will get addicted to
If not already mentioned,
check whether or not person
has any concerns raised by
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Phase of self-management
conversation
Approach/role
(Johnston et al.51) Skills Example
the medicines or that if they
take them now they will not
work so well if the pain gets
worse, or some people have
worries that relate to their
own or a family member’s
experiences of taking pain
medicines in the past
beliefs about pain
medications (e.g. typical
fears about opioids such as
dependence and tolerance,
meaning of being on opioids,
etc.) and previous experience
of pain medications (such as
family members who have
taken opioids)
Ask patient to identify most
pressing concern(s)
So to summarise, the key things
influencing your ability to
manage your pain are (list a, b,
c, etc.)
Which of these is most
important for us to
address today?
Agree a plan for what to
discuss today – negotiate to
add a topic to the patient’s
list if you feel is it significant
to improving their pain
medicine management
OK let’s talk about that a bit
more X
If you need to add a topic:
‘Once we’ve done that I would
like to talk a bit more about Y
because I think this will also
help. Would that be OK?’
Inform: purpose
l to tailor information,
specific to the
identified concerns
l to provide information that
will positively alter
behaviour and address
beliefs to improve pain
medicine management and
pain relief
l Communicator
l Educator
l Problem-solver
Restate the issue to be
discussed
So the issue you have identified
as being most challenging is . . .
Normalise the issue
This is something that many
people have concerns about
Introduce the educational
resource relevant to this issue
I think this resource will be
helpful, let me go through it
with you/tell you about it . . .
Reinforce the information: key
points
This factsheet/podcast explains
that it is important to a, b, c
Check understanding/
response
How does this sound to you?
Does this information help
your concerns?
Address any remaining
concerns (may need to
reassess concerns and provide
other information)
If appropriate suggest ways of
monitoring pain (pain diary
and pain medication chart)
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Phase of self-management
conversation
Approach/role
(Johnston et al.51) Skills Example
Setting self-management goals:
purpose
l to draw up, together, a
plan that responds to the
concern(s) and that has the
potential to improve their
pain management
l Goal-setter
l Reporter
Begin to explore some
possibilities for positively
influencing pain management
Having gone through this
information, do you think there
are some things that you can
try which will help you to
manage your medicines/
pain differently?
Check out the things
suggested
Which of these ideas will be
realistic to try this week?
Are there things that will make
this difficult for you to do?
Refine the suggested plan
So just to recap, you are going
to (state what the patient is
going to do), because this will
help your pain by (state how
this behaviour is going to help
manage medicines or control
pain). If you do this you are
hoping that (state expectation
of action) by (state time frame)
Record suggested plan
Let’s just make a note of what
you are hoping to achieve in
the next week, so that we can
review how things have gone
when we next meet
Agreeing self-management
goals
l Advocate Remind patient of resources
available to support agreed
plan
Don’t forget that there are
some other things available to
support you with your plan. I’m
going to leave the fact sheet
with you so that you and your
family can read and refer to it,
in your own time. There are
other sources of reliable
information available on the
internet so I’ll leave you a list of
where to look. Also, if for any
reason the plan we have
discussed is not possible or your
pain increases then we would
want to know. (Then go
through who to telephone/
contact etc.)
Regular review l Monitor Make a plan to review So the last thing is to make a
date and time for us to review
the plan that you have made
and your pain management . . .
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Appendix 19 Making action plans
Making action plans with individuals
One of the most important self-management skills is goal-setting. Goals often need to be broken into
smaller, more achievable steps or tasks. Once a goal has been set, it needs to be decided how exactly it
can be achieved, by making an action plan.
An action plan should be time limited (i.e. 1 or 2 weeks) and be related to a goal that the individual really
wants to achieve. The individual should be able to achieve the action plan and the plan should be very
specific, specifying what, how much, when and how often.
Parts of a personal action plan
1. Something the individual wants to do.
2. Reasonable/achievable (something that the individual could expect to be able to achieve within
the week).
3. Action/behaviour specific.
4. Answer the questions: what, how much, when, how often.
Consider
l The specific steps needed to achieve the goal (include what, when, how, where and how often).
l The things that could make it difficult to achieve the goal.
l The plan for overcoming these challenges.
l Supports and resources needed to achieve the goal.
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Appendix 20 Aide memoire for researchers to
use with study nurses
Researcher aide memoire
Supporting the nurses in their use of the four-step educational approach:
Needs assessment
l What is your experience of asking patients how they are managing their pain medicines?
l How are you finding using the four-step conversational process?
Information provision
l Thinking about your experience of providing the intervention, are there parts of it that feel easier/more
appropriate to do than others?
l Could we do anything additional to support you in delivering the process? Are there any extra resources/
materials that might be of help to you?
Goal-setting
l Thinking about the process of goal-setting with study patients, what are the kinds of things patients
are prioritising? Do you feel that this prioritisation process is helpful in supporting self-management?
l Are you managing to use the goal-setting sheet at each visit? How are you finding this? What sort of
action plans are you developing with the patients (are they practical steps, action orientated, time
specified, barrier focused with strategies for overcoming these, etc.)?
Review and coaching
l I’ll be here next week; can we talk over these issues again to see if there are any changes or additional
things that would help you?
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Appendix 21 Framework for researcher
field notes
Ongoing supportive visits
Visits with CNSs – reinforcing the workshop session.
Needs assessment
l Response to how she/he is finding asking patients about their needs (beliefs, behaviours and
knowledge), resulting discussion, any researcher recommendations.
Information provision
l Response to how she/he is finding providing information, issues raised and researcher’s response,
when appropriate.
Goal-setting
l Response to how she/he is finding using the goal-setting sheet, resulting discussion
and recommendations.
Coaching
l Response to how she is finding the reviewing with the study patient(s), resulting discussion and
coaching of CNS by researcher.
Delivery and discussion of further training resources:
l For example, Johnston et al.’s51 self-management definition, self-management conversational prompts,
audio file of modelled self-management conversation, action-planning sheet.
Response of the CNS to the above process and trial delivery.
Any confounding factors?
l Lack of CNS availability/time?
l Lack of receptiveness? Is there an apparent reason for this?
Researcher reflexivity
l Should I have handled anything differently?
l What lessons can be learnt for the other CNSs or other patients in terms of delivery of the intervention
by the respective CNS?
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Appendix 22 Feasibility study interview guide
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
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o 
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o 
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• 
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Appendix 23 Non-study clinical nurse
specialist survey
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Appendix 24 Analyses of the feasibility study
qualitative findings
Thirteen patients and seven carers participated in 13 interviews at the end of their involvement in thefeasibility trial (Table 37). They were asked about their last main occupation and their highest
educational achievements (Table 38).
TABLE 37 Qualitative data sources obtained during the feasibility trial and the purpose for which they were used
in the process evaluation
Research design and processes The intervention
Deliverability, acceptability, perceived benefits and disadvantages of:
l eligibility criteria
l screening process
l recruitment
Data sources: CNS interviews and researcher field notes
Deliverability of four-step approach
Data sources: CNS interviews and
researcher field notes
Deliverability, acceptability, perceived benefits and disadvantages of:
l study period: 6 weeks
Data source: patient/carer interviews
Deliverability, acceptability, perceived benefits and disadvantages of:
l PROMs at four researcher visits
Data sources: patient/carer interviews and researcher field notes
Deliverability of SMST
Data sources: CNS interviews and
researcher field notes
Deliverability of:
l initial CNS SMART visit within 1 week of baseline visit by researcher
Data source: study mapping Excel spreadsheets
Deliverability of:
l CNS visits – as normal care but minimum of three face-to-face visits over
6-week study period
Data source: study mapping Excel spreadsheets
Acceptability of four-step approach
Data sources: CNS interviews and
researcher field notes
Deliverability, acceptability, perceived benefits and disadvantages of:
l training to deliver the intervention
¢ initial session and ongoing
Data sources: CNS interviews and researcher field notes
Acceptability of SMST
Data source: CNS interviews
Perceived benefits of four-step
approach
Data source: CNS interviews
Perceived benefits of SMST
Data sources: CNS interviews and
patient/carer interviews
continued
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All but one (n = 11) of the 12 study nurses participated in an interview at the end of the feasibility trial
(Table 39).
The Phase III qualitative data results have been presented in tabular form for clarity and brevity, within an
analysis framework designed for the study. The initial focus was on the findings regarding deliverability,
acceptability, perceived benefits and possible disadvantages of both the research design and the
intervention itself.99 In line with the recommendations of Moore et al.76 regarding process evaluation of
complex interventions, the final column of the analysis framework, and the ultimate higher level of
analysis, focuses on the mechanisms of action – the participant responses to the research design or
intervention, the mediating factors and the consequences (Tables 40 and 41).
TABLE 37 Qualitative data sources obtained during the feasibility trial and the purpose for which they were used
in the process evaluation (continued )
Research design and processes The intervention
Perceived disadvantages of
four-step approach
Data source: CNS interviews
Perceived disadvantages of SMST
Data source: CNS interviews and
patient/carer interviews
PROM, patient-reported outcomes measure.
TABLE 38 Phase III qualitative data sample: patient and carer interviews
Demographic data: patient and carer Phase III interview sample
Number of
interviews
n= 13
Thirteen patients, seven carers participated in dyad interviews with patient
Remaining six patients recruited to feasibility study – one admitted to hospice post trial, other five
withdrawal or loss to follow-up of the patient during course of trial
Last main (or current) occupation
Patients Car mechanic, care worker, coach trip business, education welfare officer, electrical engineer, fitters
mate, nurse, professor, publisher, secretary, senior lecturer, shop manager, vehicle inspector
Carers Anglican minster, architect, brick layer, care worker, nursery school worker, secretary, security worker
Number of
qualifications
Professional, vocational or other
work-related qualifications below
degree level
Professional, vocational or other
work-related qualifications at
degree level or higher
Patients 4 6 3
Carers 1 5 1
TABLE 39 Phase III qualitative data sample: CNS interviews
Demographic data: CNS Phase III interview sample
Number of interviews n= 11
Location n= 5 Yorkshire based (out of 6 study nurses); n= 6 Hampshire based (out of 6 study nurses)
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TABLE 40 The process evaluation of qualitative outcomes regarding the feasibility trial research design
Feasibility of research design
and processes
Findings from the data: deliverability, acceptability, perceived
benefits, disadvantages
Mechanism of action: participant responses to the research
design and processes, mediating factors, consequences
l Eligibility criteria l The eligibility criteria were initially seen by nurses as being acceptable by
being open and wide. However, in terms of delivery, the CNSs were
surprised by the relative lack of individuals who met the eligibility criteria.
Then, of those who did meet the eligibility criteria they were often those
with complex end-of-life needs where the individuals would have been
‘on their reserves to do it (take part)’ (H2CNS002)
l CNS responses:
It’s interesting that . . . there’s quite a lot of patients that aren’t
even on opioids
H1CNS002
Maybe 50% weren’t on opioids . . . I thought that would be
really easy actually! I was very shocked that it wasn’t
H2CNS002
I was surprised in a way that I didn’t have any patients that
would be applicable for the study . . . maybe, that shows how
complex the patients are that come to us, and how quickly
people who may possibly have been suitable deteriorated
H1CNS004
l Mediating factors: late referrals to specialist palliative care
services, resulting in many on their caseloads being close to
imminent end of life (< 6 weeks) and complex needs of others
l Consequences:
¢ Smaller numbers of theoretically eligible patients than
expected, and of those who were ‘eligible’ they often had
very complex needs
¢ Therefore, overall consequence was lower than
expected recruitment
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TABLE 40 The process evaluation of qualitative outcomes regarding the feasibility trial research design (continued )
Feasibility of research design
and processes
Findings from the data: deliverability, acceptability, perceived
benefits, disadvantages
Mechanism of action: participant responses to the research
design and processes, mediating factors, consequences
l Screening process l Deliverability and acceptability of screening process with CTA/CTP
generally seen as acceptable by the CNSs, but they were very aware that
they (and sometimes the CTA/CTP) were often not available when they
had said they would be for screening appointments
l CNS responses:
It was only tricky because of time
H1CNS002
l Mediating factors: the existing pressures on their role (CNS but
also CTA/CTP role) and the often high caseloads of the CNSs
l Consequences:
¢ Screening appointments frequently needed to be
rearranged/reattempted, meaning screening was missed on
some weeks
¢ One CNS stated that she found the screening onerous and
two CNSs said they would have preferred to screen with the
researcher (rather than having to deal with two people
regarding the study – CTA/CTP and researcher)
¢ Therefore, overall consequence was that screening was
regularly undertaken but not always on a weekly basis
l Initial approach of
eligible patients
l Deliverability of approaching ‘eligible’ patients often challenging [e.g.
patients already approached regarding drug trials, patients admitted to
alternative care settings (hospital, hospice and nursing homes)]
l CNS responses: approaching patients to introduce the study,
although challenging, was not an issue in itself for most
l Mediating factors: it was the circumstances around end of life
that were challenging [e.g. frequent admissions, complex
physical (often infections and sepsis) symptoms, psychological
and social issues]
l Consequences: the complex social/psychological issues at end of
life meant that the CNSs felt, for some patients, that they
‘couldn’t burden them with something else at that time’
(H1CNS002). Nonetheless, this was not inappropriate gate-
keeping, but rather challenging circumstances such as patients
caring for others
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Feasibility of research design
and processes
Findings from the data: deliverability, acceptability, perceived
benefits, disadvantages
Mechanism of action: participant responses to the research
design and processes, mediating factors, consequences
l Study period: 6 weeks l The study period was universally seen as ‘about right’ or ‘just right’ by
the patients and their carers
l The CNSs also appeared to agree on the acceptability and deliverability
of a 6-week study period
l Patient responses:
I think it’s just about right actually, you probably need that
length of time to get any results
H2Pt019
It seems to have gone quick
H1Pt001-C
l Mediating factors: the end-of-life context and many study
patients experienced uncontrolled symptoms (not just pain) and
infections during the course of the study
l Consequences: despite this, relatively few patients were lost to
follow-up during the 6 weeks
l PROMs at four time points l The patients, in interviews, all stated that it was acceptable completing
the PROMs battery at 2-week intervals over the 6 weeks (at four time
points). Some emphasised the importance of completing them face to
face with a researcher, ‘you gave us the comfort and support to go
through them’ (H1Pt001). A small number of patients criticised the
‘duplicity’ (H4Pt001) of some questions given the combination of five
different measures, or said that they were ‘long’
l Nevertheless, the researcher field notes captured some difficulties for
patients with the PROMs in the end-of-life context during the process of
data collection:
¢ BPI:
¢ % of relief from medicines – patients were frequently uncertain
how to answer this as they often stated that they were not
going to come off their medicines to find out the answer to this.
It was also difficult to answer in the context of complex
neuropathic pain with intermittent severe pain episodes such as
from trigeminal neuralgia
¢ ‘normal work’ and ‘enjoyment of life’ were seen as
inappropriate wording for end-of-life context
l Patient/carer responses:
‘I’ve learnt stuff’ by completing them
H4Pt013
I found them really useful . . . it put things more into perspective
H3Pt041
It’s the sort of questions you expect in something like this
H1Pt009
It’s made you focus on how you feel
H2Pt007-C
l vs.
Hang on a minute I’ve just answered that one
Some of the questions were a bit hard to answer
H2Pt019
continued
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TABLE 40 The process evaluation of qualitative outcomes regarding the feasibility trial research design (continued )
Feasibility of research design
and processes
Findings from the data: deliverability, acceptability, perceived
benefits, disadvantages
Mechanism of action: participant responses to the research
design and processes, mediating factors, consequences
¢ ESAS:
¢ anxiety and depression questions were sometimes sensitive areas
given high rates of clinical depression and use of antidepressants
¢ ‘well-being’ question often disliked given end-of-life context
¢ EQ-5D-5L:
¢ general lack of acceptability of question regarding how good/
bad health is today on scale of 1–100 ‘it’s a stupid question to
ask people in palliative care’ (H1Pt011-C)
¢ SIMS:
¢ general difficulty remembering what specific information about
medicines had been received over the last 2 weeks
‘The only one that confused you was the last one with the
1–100’ (how good or bad your health is today on the EQ-5D-5L)
H1Pt015-C
l Mediating factors: the study PROMs, although utilised in
palliative care studies, are not specifically worded for the
end-of-life context. The patients and carers were more positive
about PROMs completion in the interviews at the end of the
study than during the study, when completing them with
the researchers
l Consequences:
¢ Dichotomy between the value of the PROMs completion
process in itself for some patients (evaluating the impact of
pain and medications) vs. the inappropriate wording of
some questions, resulting in questions not being completed
¢ Therefore, overall consequence was that patients’
experience of PROMS completion was acceptable, but there
were some limitations related to the wording of questions
for the end-of-life context
l Four researcher visits l The patients and carers all stated that the frequency of researcher visits
(fortnightly) was acceptable and some really looked forward to
these visits
l Patient responses:
It’s been very nice you coming in
H2Pt019
It’s been lovely. I enjoy you coming . . . you’re so easy to talk to,
you ask the right questions
H1Pt009
l Mediating factor: the value of taking part in a research study,
seeing a researcher external to their care team and developing a
relationship over 6 weeks
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Feasibility of research design
and processes
Findings from the data: deliverability, acceptability, perceived
benefits, disadvantages
Mechanism of action: participant responses to the research
design and processes, mediating factors, consequences
l Initial CNS SMART visit within
1 week of baseline visit
by researcher
l CNS visits – as normal care but
minimum of three face-to-face
visits over 6-week study period
l In Hampshire, all study patients were seen within 6 days of recruitment
by their CNS for first study visit
l In Yorkshire, 8 out of 10 patients were seen within 7 days of recruitment
by their CNS for first study visit
l All study patients (who were not lost to follow-up) received three
face-to-face visits as a minimum over the 6 weeks (maximum number of
face-to-face visits by a CNS was five)
l Consequences: the SMART CNS visits followed their normal
pattern of care, enabling the minimum dose of the intervention
(three face-to-face visits over the study period) to be successfully
delivered to all study patients
l SMART CNS visits l The study nurses successfully delivered their visits and they were
acceptable as they matched their normal visiting pattern
l However, in relation to the acceptability of the extended length of the
visits, the nurses were very conscious of the extra time required for study
visits – approximately 30 minutes for first visit and 15 minutes for each
further visit, and the impact on their workload
l CNS responses:
We (one study CNS and another) talked about timekeeping a
lot, because in my first couple of SMART study appointments
they were really long, partly because the lady I had, it was quite
difficult to keep to time with them anyway
H2CNS001
l Mediating factors: the time-pressured nature of CNS role; this
was partially offset by the CNSs in the Wessex region being
reimbursed for their excess treatment costs (the extension of
their visits)
l Consequences:
¢ The nurses managed to successfully accommodate this
additional workload (which had been made clear from the
start of the study), without changes to their care patterns,
except for one (part time) study nurse who asked a
colleague to follow-up some patients on her caseload by
telephone on a single day because of a study visit
¢ The extra time required for visits led the study nurses at the
individual sites to discuss this impact with one another
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TABLE 40 The process evaluation of qualitative outcomes regarding the feasibility trial research design (continued )
Feasibility of research design
and processes
Findings from the data: deliverability, acceptability, perceived
benefits, disadvantages
Mechanism of action: participant responses to the research
design and processes, mediating factors, consequences
l Training to deliver
the intervention
l A bespoke training workshop was successfully delivered via two sessions
to all the study nurses by a skilled nurse educator
l Approximately half of the study nurses found the workshop session
acceptable. The response to the session was widely variable from the
overtly positive:
I wasn’t really sure what to expect really. I think it sort of got you into
thinking . . . about these four steps as a way of sort of addressing each
problem that you would have with the patient, and then . . . alongside
that introducing the individual appropriate tools. So I think for me it was
a good afternoon . . . Because I’m more of a reflective person . . . I’m not
the sort of person who likes to rush in, grab everything and rush out . . .
So for me, ‘just sort of go with the flow, and see how the afternoon
unfolded’, that was comfortable for me . . . whereas I think some of the
other members of the group there, I think they wanted the end at the
beginning . . . I was quite happy to go through that process. And I think
having gone through the process, I came away thinking ‘Right, I know
what I’m doing’
H4CNS003
I thought it was very good, very informative, gave us a good baseline to
work from and to understand the study
H4CNS001
Personally I found it really helpful. I would in a visuala way. I work with
imagery and I’m naturally predisposed to responding with emotion and
. . . other people don’t, so I know other people didn’t find that day
particularly helpful or aspects of it
H3CNS002
l To the less positive:
It was OK . . . it was relevant and it put it (the intervention) in a bit
more perspective
H4CNS002
l CNS responses:
¢ The general response was that the workshop covered
everything required for their study involvement
¢ However, some nurses felt that the session made the
four-step educational approach seem more complicated that
it actually was, rather than a normal part of everyday
specialist practice (which they all recognised once using it)
¢ Some CNSs perceived that the description of the four-step
educational approach and the stages of the therapeutic
conversational process, did not completely match and
overlay one another, causing them a degree of confusion
l Mediating factors:
¢ The workshop raised some anxieties ‘just give me the facts
I’m too busy for all this’ (H3CNS001) and ‘it made me think
– oh my goodness this is going to be quite intense and
hard’ (H1CNS002)
¢ Responses to the workshop varied with some liking the
thought-provoking/reflective nature of the session and
others desiring alternative approaches
l Consequences:
¢ The researchers clarified, where necessary, the four-step
educational process to the nurses via ongoing support
¢ The subsequent need to provide a modelled
self-management-focused professional conversation to the
study nurses was also apparent. This was audio-recorded
and provided to the CNSs, but only a few listened to it
¢ The overall consequence of the workshop was, however,
successful delivery and introduction of the nurses to the
research processes and the four-step educational process,
delivered by a conversational process
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Feasibility of research design
and processes
Findings from the data: deliverability, acceptability, perceived
benefits, disadvantages
Mechanism of action: participant responses to the research
design and processes, mediating factors, consequences
It was good and covered everything . . . it (the four step educational
approach) just needed to be clearer
H1CNS002
l And the more explicitly negative:
I found it quite frustrating, because I thought it’s not really my style . . .
like putting the cards out on the floor and all that . . . I would have been
happy for you just to tell us (about the four step educational approach)
. . . it’s not a process that we’re not familiar with
H3CNS001
I remember being a bit confused . . . the four things (four steps of the
educational process) weren’t quite the same as the other four things
exactly (in the conversational process)
H1CNS001
I felt the training we went on could have been shorter or it could have
been more in-depth about the key things we really needed to focus on,
which was about the goalsetting and things. I was a bit worried at the
beginning – for me! And I thought ‘is this really what we need . . . we
are all experienced CNSs, can’t we just focus on what . . . kind of
questions can be used?’ (in each step of the conversational process)
H2CNS002
That afternoon training where the lady was talking with pieces of paper
on the floor, was a bit of a wasted opportunity . . . 15 minutes into her
conversation I didn’t really know what she was talking about . . . she
was trying to get us to talk through our normal assessment, and then
apply that to self-management per patient. But for me . . . it wasn’t clear
enough what we were talking about until the end. So then you’re kind
of sat there wasting time where you’re making memories, wondering
what on earth is going on, rather than ‘I know exactly what we are
going to be talking about, and now I’m making memories, we are
enforcing the goals of this.’ . . . It was quite stressful really
H2CNS001
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TABLE 40 The process evaluation of qualitative outcomes regarding the feasibility trial research design (continued )
Feasibility of research design
and processes
Findings from the data: deliverability, acceptability, perceived
benefits, disadvantages
Mechanism of action: participant responses to the research
design and processes, mediating factors, consequences
I must admit, at first when I did the picture cards I sort of got lost with
‘where is this going, what’s this about?’ And I think that bit was quite
time consuming as well if I remember rightly
H1CNS003
I got confused with the training . . . I found it quite a lot of information
taking . . . the four steps weren’t the same (as the conversational process)
H1CNS004
l Some CNSs readily understood the self-management ethos, others were
more challenged by it. For those that understood the ethos there was
a perceived benefit of refocusing the professional conversation on
self-management of analgesia and related treatments which was
gained from the workshop and further support
l CNS responses: the self-management ethos required a shift in
thinking and emphasis by the nurses ‘I just had to remember
not to do my usual line of questioning around pain, around
background pain, breakthrough pain, focusing on descriptions
of pain, but more on their experience of the pain and their
experience of managing the pain’ (H2CNS001). ‘My practice
needs to be a more defined process of allowing them (patients)
to be independent in all ways, not just in goalsetting around
their medication . . . it’s a whole change of behaviour, I think,
by me’ (H3CNS002)
l Mediating factor: this refocusing challenged the professional
identity of these specialist palliative care nurses, where their
therapeutic role is measured by their effectiveness at
removing pain
l Consequences: it was harder for some nurses to adapt their
practice from ‘imposing views’ telling patients how to use their
opioids, to collaborative discussion focused on patients using
and developing their own self-management strategies as result
of information provision from the CNS
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Feasibility of research design
and processes
Findings from the data: deliverability, acceptability, perceived
benefits, disadvantages
Mechanism of action: participant responses to the research
design and processes, mediating factors, consequences
l The researcher field notes captured inherent difficulties in providing
ongoing support to the CNSs during the course of the trial:
¢ Difficulty making appointments to meet with CNSs, usually had to
be first thing at the start of their working day
¢ The CNSs were not always available when they said they would be
(due to extended/unexpected patient visits, over-running meetings,
their own illness, etc.)
¢ However, when they were available they were usually open in their
discussion of their study experiences and willing to be supported via
discussion and further training resources (yet this time was always
pressured or limited)
l Mediating factors:
¢ Nurses were time pressured, some were difficult to make
appointments with because of workloads
¢ Not all of CNSs visited their office before going out to visit
patients and none wished to make appointments at the end
of the day
¢ Visits to CNSs were also complicated by CNSs covering
weekend working and, therefore, having days off in the
week
l Consequences:
¢ The CNSs responded openly to being asked questions about
study experiences of needs assessment, information
provision, goal-setting and coaching. However, the limiting
factor was the lack of CNS availability and time. Over the
course of trial the CNSs were visited usually once a fortnight
depending on their availability. The original intention had
been weekly visits
¢ Therefore, the overall consequence was that the delivery of
follow-up support to the nurses was less than originally
intended
CTA, clinical trials assistant; CTP, clinical trials practitioner; PROM, patient-reported outcome measure.
a The nurses were asked to select pictures that represented elements of supportive self-management to them.
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TABLE 41 The process evaluation qualitative outcomes regarding the SMART intervention
Feasibility of intervention
delivery
Findings from the data: deliverability, acceptability, perceived
benefits, disadvantages
Mechanism of action: participant responses to and interactions with
the intervention, mediating factors, consequences
The four-step educational
approach:
l needs assessment
l information provision
l goal-setting
l review and coaching
l Deliverability of the educational approach to focus on supported
self-management required practice:
¢ perceived challenge of delivery of the four steps in a
therapeutic conversation, so that it flowed naturally and
covered all areas
l The educational approach itself was seen as acceptable as the
steps were noted to be inherently part of what specialist CNS
practice looks like
l CNS responses:
I think I needed to adjust my meetings with the patients, because I was
very much solving the problem. A couple of patients I was suggesting
things, rather than letting them tell me what their goals were, so I think
that changed . . . it took two or three interventions (visits) to realise that
H2CNS002
It’s not so much what we did but maybe how we did things, you
know, focusing differently . . . it made you focus on that subject
(self-management of analgesia) each time you saw them . . . It’s made
me think more about following that structure, which is good and seeing
how people respond
H1CNS002
It’s just re-learning a conversation
H2CNS001
The four-step process sort of reflects the nursing process really doesn’t
it? You know that’s what you do, or what you should be doing. But I
think having it in your head more concretely and having things that you
do at each of those steps just makes it more real
H4CNS003
I followed this process . . . I found that kind of reflected pretty much what
we do with that sort of pain assessment and their usage of medication
assessment that followed quite well anyway. The bit here about the needs
assessment and assessing their beliefs and knowledge, I kind of do that
anyway, but you thought about it more, because you were doing it as
part of this process; because obviously you need to understand from their
point of view, why they were taking the medication, because it might be
that you are going to tip it on its head when you were reviewing what
they’d done – when you went back to review your goal-setting
H4CNS001
I just think it has more meat on the bones . . . it’s a much more focused
way of practising
H4CNS001
A
P
P
E
N
D
IX
2
4
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry
w
w
w
.jo
u
rn
a
lslib
ra
ry.n
ih
r.a
c.u
k
2
7
2
Feasibility of intervention
delivery
Findings from the data: deliverability, acceptability, perceived
benefits, disadvantages
Mechanism of action: participant responses to and interactions with
the intervention, mediating factors, consequences
l Mediating factors:
¢ Fully embedding the concept of supported self-management in end
of life took time and practice, and challenged the desire of nurses to
go in and immediately ‘come up with solutions’ (H2CNS002)
¢ The structure of the four-step approach also challenged the CNSs
who were all experienced and therefore had their ‘own little style’
or ‘our sort of patter’ that they had already ‘evolved into’
(H2CNS002; H1CNS002)
¢ The nurses often wished to have delivered the four-step approach
more during the course of the study to have further practised their
delivery of it, for example to ‘five patients or something to sort of
get into it’ (H1CNS002)
¢ For some CNSs the ethos of supported self-management was easier
to adopt that for others. For some relinquishing control was easy
‘I don’t think we should have control’(H2CNS001) and it was all
about empowering patients
¢ In normal practice the nurses may not have discussed medicines
management at each visit ‘with a lot of the patients that we see, it’s
amazing that one week medication will be such a problem, it will
just be overtaking them. And then, with a few changes, then it
won’t be the big focus on their mind . . . I suppose if it wasn’t for
the study . . . you might have done it every second or third visit’
(H1CNS002)
l Consequences:
¢ The shift in thinking required for delivery of the self-management
ethos within the educational approach was accommodated more
successfully by some of the study nurses than others. For example,
‘I need to just take a little step back and let the patient tell me what
they want to do a little bit more’ (H2CNS002)
¢ All the nurses managed to deliver the educational approach via a
conversational process, as per normal therapeutic practice
continued
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TABLE 41 The process evaluation qualitative outcomes regarding the SMART intervention (continued )
Feasibility of intervention
delivery
Findings from the data: deliverability, acceptability, perceived
benefits, disadvantages
Mechanism of action: participant responses to and interactions with
the intervention, mediating factors, consequences
The SMST: all the factsheets l Deliverability and acceptability of the factsheets:
¢ staged and individualised provision of the factsheets worked
well for most CNSs, preventing the patients from
becoming ‘overwhelmed’
¢ for a minority (two study nurses) they delivered all the factsheet
resources at their first visit (despite training), ‘I just handed
everything over’ (H4CNS001), perhaps highlighting areas that
they felt were relevant. This type of delivery negatively
influenced the acceptability of the factsheets to the patients
– the argument made by the nurses for doing so was ‘when
somebody’s newly started on an opioid or indeed if you’re
very fresh to the patient, you can’t kind of pre-guess what
they’re going to need. And to me the whole point of
it is that you are giving them the tools to be able to
self-manage, but because you can’t guess which one
they’re going to need really, they should have all of them
at the beginning so that they’ve got the information there’
(H4CNS001)
l Perceived benefit of the factsheets:
¢ stimulated patients to ask further questions
l Patient/carer responses:
¢ Easy to read/look at, clear and not too long
Keep it like that, pamphlet form, I think more people will be able to
read it because it’s not too long
H1Pt015
The side effects one was interesting . . . it was mostly information
I know, but it’s good to sit and just read it through
H1Pt015-C
l CNS responses:
It’s good having them broken down (into sections), you can select what
you need out of them
H2CNS002
‘It’s nice to have the written back up’ to verbal information giving
H1CNS002
¢ They were universally perceived as easy to read – pitched at the right
level, spanning the spectrum of those with no medical knowledge
and those that did
I enjoyed using the factsheets
H2CNS001
¢ They were viewed as something new and beneficial that was not
available to them in their everyday practice
It’s good to go through the basics of the factsheets with them,
depending on time restraints, so that you’re pointing out the bits
that maybe relevant and show them, and talk around the bits on
the factsheet as well, with examples
H1CNS002
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Feasibility of intervention
delivery
Findings from the data: deliverability, acceptability, perceived
benefits, disadvantages
Mechanism of action: participant responses to and interactions with
the intervention, mediating factors, consequences
The way that the documentation was presented, it was very
professional looking, which sort of enabled the patient to take it
more seriously
H4CNS003
¢ That is, buy into it
She’s a very independent lady, so if she could manage to solve a
problem without contacting somebody, she wanted to do that, and
obviously the advice sort of gave her the ability to do that . . . she
knew . . . that the information was there
H4CNS001
When I did my next review she actually had half a dozen questions
from the factsheets . . . it was all relevant . . . it just took extra time
H1CNS001
l Mediating factors:
¢ Value of having written information to reinforce or act as a reminder
to verbal information provision
¢ Not all patients/carers value written information – ‘it’s really helpful
for the people who are going to read it’ (H3CNS001)
¢ Not always delivered appropriately. This was not just handing over
all the factsheets at once, for other CNSs the factsheets were not
always discussed with the individual or they were posted to the
individual (when the CNS forgot her master file of factsheets). One
patient received no factsheets during the course of the trial
l Consequences:
¢ Only one patient, on his request, received no factsheets during the
course of the study
¢ All other study patients received factsheets and, for those that read
them (the majority), they perceived a benefit from them (backing up
information that had been provided verbally and stimulating them to
ask further questions)
¢ For the few patients who received factsheets and did not read them
or just scanned them, the resources were usually read by their carer
and were perceived to be of benefit to them
continued
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TABLE 41 The process evaluation qualitative outcomes regarding the SMART intervention (continued )
Feasibility of intervention
delivery
Findings from the data: deliverability, acceptability, perceived
benefits, disadvantages
Mechanism of action: participant responses to and interactions with
the intervention, mediating factors, consequences
¢ For a minority of patients for whom the delivery was poor (e.g. not
discussed with the patient, all given at once, posted to the patient),
this negatively influenced the benefit of the resources. For some,
they were not utilised or read as a result
l Common concerns factsheet l Perceived benefit of the ‘common concerns when taking opioid
medicines’ factsheet
l Patient/carer responses:
I’m not so scared of it (morphine) now, because I know that I’m in
charge now. I know what happens if I do take too much, and I can
look for those signs within myself, and know where the limit is versus
pain . . . it’s opened my eyes a lot to it
H4Pt023
l CNS responses:
I think that perhaps all patients should have that information as
a standard
H1CNS001
¢ Felt that it helped to normalise patient and carer concerns
l Consequences:
¢ The perceived benefit of this factsheet was seen as great by the
nurses, patients and carers alike
¢ The nurses felt that it helped them to focus to a greater extent on
patients’ fears regarding opioids and to ‘unpick things more’
(H4CNS003)
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Feasibility of intervention
delivery
Findings from the data: deliverability, acceptability, perceived
benefits, disadvantages
Mechanism of action: participant responses to and interactions with
the intervention, mediating factors, consequences
l Contact factsheet l Deliverability and acceptability of the contact factsheet:
¢ Often poor delivery of the factsheet (non-completion by
the nurses)
¢ However, the acceptability of the factsheet was seen as high
by patients
l Perceived benefit of the contact factsheet to be limited due to
frequent non-completion
l Patient/carer responses:
All the numbers you need are there, it’s a brilliant idea
H1Pt015-C
It’s just reassurance you know, an easy reference, just in case, I’ve got
those contact details there in a handy sort of leaflet
H2Pt007
l CNS responses:
I like the idea of it to help get all those numbers together, because it’s
really confusing for them
H2CNS001
l Mediating factors:
¢ Such as the goal-setting sheets, this was the only other core
component of the SMST that the study nurses were asked to ensure
that all the study patients had and completed (on their first study
visit). Despite this, although the patients often had this factsheet in
their folder, it was commonly uncompleted by the nurses
l Consequences:
¢ As a result of the often non-completion of this factsheet by the
nurses, it was often not used by patients
¢ Nonetheless, all patients and carers liked the idea of it
¢ There is a potential need for further development of the factsheet to
outline ‘a next step of the decision tree’ (H2CNS001), i.e. a flow
chart of who the best contacts are in specific circumstances/
situations to help patients make these often complex decisions
continued
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TABLE 41 The process evaluation qualitative outcomes regarding the SMART intervention (continued )
Feasibility of intervention
delivery
Findings from the data: deliverability, acceptability, perceived
benefits, disadvantages
Mechanism of action: participant responses to and interactions with
the intervention, mediating factors, consequences
l Medication chart l Deliverability and acceptability of the medication chart:
¢ The deliverability of the medication chart was limited by the
frequent non-completion of the chart by the nurses
¢ However, the delivery of the study chart was designed to
allow flexibility to meet individual patient/carer needs
¢ Therefore, some nurses provided and completed an
alternative for patients, which suited the individual better
(e.g. a simpler one-page chart)
¢ Some patients produced their own charts – completing the
study version themselves or producing their own versions,
often based on a hospice discharge chart or using Excel
spreadsheets
¢ Patients, or their carer, all saw having a current up-to-date
version of a medication chart in their home as acceptable and
of value
l Perceived benefit of the study medication chart limited due to
frequent non-completion:
¢ Nonetheless, it often stimulated the use of alternatives
l Patient/carer responses:
From a carer’s point of view it’s a good thing to have it in the house . . .
if there came a point when I couldn’t do it myself, then it would be very
useful for (carer’s name)
H2Pt019
It’s handy, you can see straight away . . . what they’re all for
H1Pt001
It made me more organised. (Carer’s name) found it useful, because if
I’m drowsy or unwell, he’s known what time I take it, when I take it,
and what it’s used for
H3Pt002
¢ The charts helped some plan activities away from the home and what
medications to take with them
l CNS responses:
It would have been another job for me to do . . . it didn’t occur to me to
actually fill it out because I was thinking it was for them to do
H1CNS001
l Mediating factors:
¢ One patient filled it out himself as a distraction from his depression
¢ Despite frequent poor delivery, it facilitated carer involvement and
allowed for pre-emptive planning for deterioration of the patient
(i.e. the respective carers knew there was a medication chart if they
needed to administer them)
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Feasibility of intervention
delivery
Findings from the data: deliverability, acceptability, perceived
benefits, disadvantages
Mechanism of action: participant responses to and interactions with
the intervention, mediating factors, consequences
l Consequences:
¢ The medication chart was often not completed by the nurses, there
appeared to be an assumption (despite training) that patients could
complete the study chart themselves
¢ Nonetheless, its supply often stimulated adaptations or the use of
alternatives, for example a one-page chart by the CNS that could be
viewed simply at a glance, the use of Excel spreadsheets by patients,
patient adaptation of a chart that had been supplied on discharge
from the hospice
¢ When a version existed, it was valued as a reference for carers
¢ It was also viewed as particularly valuable in the context of opioid
induced drowsiness where patients could not remember details of
the medications and if they had already taken them (so the ability to
cross off doses on the study chart was valued for this reason)
¢ There was an additional perceived benefit if a patient had an
unexpected hospital admission. For example, ‘Everyone I showed
them to [at the hospital], they said ‘oh what a great idea . . . that’s
saved us so much work’ (H3Pt022)
l Pain diary l Deliverability and acceptability of the pain diary:
¢ Successfully delivered to 15/19 participants
¢ For those that received the diary they viewed it as acceptable
and used it
l Perceived benefit of the pain diary as a decision-making aid for
nurses and patients:
¢ For patients, it helped justify/stimulate the use of
breakthrough analgesia where pain scores increased
¢ For nurses, it helped facilitate adjustment of doses
l Patient/carer responses:
¢ Formalised and recorded information more comprehensibly
¢ It also helped with decision-making (e.g. if the pain rating increased
then it helped to encourage the use of breakthrough analgesia)
That pain diary is helpful, because for me I can look back and see
how the day . . ., because you forget from day to day
H2Pt019
And (CNS name) found it useful too when I was able to say what I’d
taken, what pain relief, what pain I was in, how long did it take for
me to make the pain manageable
H3Pt003
I don’t know if I would have been able to create my own form to
suit my needs. It’s great to have something like that available
H2Pt007
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TABLE 41 The process evaluation qualitative outcomes regarding the SMART intervention (continued )
Feasibility of intervention
delivery
Findings from the data: deliverability, acceptability, perceived
benefits, disadvantages
Mechanism of action: participant responses to and interactions with
the intervention, mediating factors, consequences
¢ Stimulated some patients/carers if not using the diary to note down
breakthrough doses of opioids
¢ Motivated other patients to use alternative versions of a pain diary
(e.g. Macmillan) or develop their own (i.e. to engage in their own
self-management activities as a result)
l CNS responses:
¢ Universally seen as helpful by the CNSs as allowed them to evaluate
the effectiveness of the medications more easily
¢ Enabled patients to formally record their experiences and what was
happening to them
l Consequences:
¢ It helped patients keep track of the effectiveness of their medicines
¢ It relieved the pressure on patients to remember these details (when
breakthrough doses had been taken and responses to the medication)
¢ It made patients, carers and CNSs observant of the patterns of pain
throughout the day and stimulated thinking regarding what could
and should be adjusted in the medication regime
l Podcast films l Deliverability and acceptability of the podcast films:
¢ The films were offered to eight participants to watch – five
patients watched them during the follow-up period
l Perceived benefit of the podcast films:
¢ Those that did receive them watched them (with the
exception of one patient)
¢ These patients found them to be acceptable and have benefit
l Patient/carer responses:
Reassuring . . . I think the information was very useful, because it did
home in on the fact that you’re in control . . . that came across very clear
H2Pt019
I think that would be useful if I was at the start of the process, but now,
with all the things that were said in the DVD, I kind of already knew,
especially the chap who was managing his prostate cancer, I’ve been
through the same process myself
H3Pt002
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Feasibility of intervention
delivery
Findings from the data: deliverability, acceptability, perceived
benefits, disadvantages
Mechanism of action: participant responses to and interactions with
the intervention, mediating factors, consequences
¢ The patient in the podcast discussing how he managed the supply
issues related to his medicines was seen as particularly beneficial. It
stimulated one study patient to use exactly the same system to keep
track of his medicines and their supply, ‘it’s how he does it, it just
makes so much sense . . . in fact, it was very short and was a big
disappointment wasn’t it when it finished!’ (H4Pt023)
¢ The information reaffirmed what was already known from the
factsheets, but it was more easily absorbed in the form of the short
podcasts
l CNS responses:
I do think that the videos were very good
H1CNS002
You need an alternative to paper . . . you shouldn’t exclude anyone
H4CNS002
l Mediating factors:
¢ Predominantly not offered by the CNSs, but often the patients said
that they would have watched them had they been offered
¢ This may have been an issue of practicalities – either that the nurses
forgot about them and therefore did not offer them or forgot to
carry them with them in their master files
¢ Authentic value of patients sharing their own experiences and
self-management strategies, seen as something that specifically related
to the viewers. For example, ‘He’s just an ordinary guy, he’s gone
through this, this is what he’s doing in his words and how he’s dealing
with it, and you can make that relate then to yourself’ (H4Pt023-C)
¢ Only one patient who received them had not watched them but this
was in the context of untreated depression
l Consequences:
¢ They were seen as beneficial by the few that were offered them
¢ The patient podcast, because of its authenticity and the value of
hearing the experiences and strategies of others in a similar situation,
was particularly valued
continued
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TABLE 41 The process evaluation qualitative outcomes regarding the SMART intervention (continued )
Feasibility of intervention
delivery
Findings from the data: deliverability, acceptability, perceived
benefits, disadvantages
Mechanism of action: participant responses to and interactions with
the intervention, mediating factors, consequences
l Goal-setting sheets l Deliverability and acceptability of the goal-setting process
and sheets:
¢ Universally delivered and completed for all study patients
¢ The completion of the sheets at each CNS visit illustrates the
acceptability of the sheets to the nurses
¢ In the majority of cases the sheets were delivered and
completed well, with appropriate-patient focused goals set
and action plans to achieve the goals
l Perceived benefit of the goal-setting process and sheets when
delivered well (focused on the patient’s goals):
¢ Value to CNSs
– formalising and evidencing specialist practice, ‘I could
actually say to you now, with the patients, I’m actually at
this point with them . . . we’ve set these goals and I’m off
today to reflect on those and identify any other issue’
(H4CNS003)
– Also facilitated review and coaching, as the previous goals
were there to ‘reflect back on’ (H4CNS003)
¢ Value to patients – It’s ‘looking at it from a different angle,
what they (patients) want to achieve’ (H1CNS001)
¢ Perceived potential disadvantage/harm of goal-setting if not
patient generated – ‘sometimes your perception of what they
are going to write is just completely different to what they
come out with’ (H2CNS001)
¢ Two patients appeared to find the goal-setting
documentation (as opposed to the discussion of it with the
CNS) wearisome, but this was in the context of depression
l Patient/carer responses:
That’s been helpful . . . I think it has made me a bit more explicit about
setting goals and saying to (CNS name) ‘I’d like to do this, can you help
me do this?
H3Pt002
I’ve found it quite manageable to think, look at that, and then think
about what I’ve achieved
H2Pt019
I think it’s a really good idea to try and make yourself do things
H1Pt001
Setting a goal . . . I think is a must
H4Pt013
¢ The goal-setting was beneficial as is stimulated thinking such as
‘right this is what we’ve got to do now, and get this sorted . . . it’s
made us more aware to help things along’ (H1Pt015) (e.g.
constipation related to opioid usage)
¢ They were often something that study patients wished to continue
with after the study
l CNS responses:
That was actually very useful, and I think that’s one thing I would take
away and carry on with, just from the focus of actually what you would
like to achieve this next week or two weeks. That is quite a useful angle
to look at things from . . . It was actually quite good getting them
(patients) to think about what they could do to help themselves
H1CNS001
To write those weekly goals is a completely new change in practice for
me. But I liked it. I think it was really useful, and you know, they liked it
as well, the patients and carers
H2CNS001
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Feasibility of intervention
delivery
Findings from the data: deliverability, acceptability, perceived
benefits, disadvantages
Mechanism of action: participant responses to and interactions with
the intervention, mediating factors, consequences
l Mediating factors:
¢ The goal-setting sheets, along with the contacts factsheet were the
core components of the SMST, to be completed at every visit.
However, unlike the contacts factsheet they were universally
completed by the nurses
¢ Some patients struggled to think what their goals would be in the
context of clinical depression or a degree of memory loss
¢ Even where the goal was not achieved there was a recognition that
the process of setting goals was useful in itself (perhaps because it
focused on defining small practical and achievable steps towards the
overall goals), ‘If you set a goal, even if you don’t reach it. I still think
it’s a good thing to do’ (H4Pt013)
l Consequences:
¢ Goal-setting often became the mechanism by which patients were
helped to focus on doing things for themselves (i.e. to implement
self-management strategies)
Because you make a realistic goal, and then you make a change,
because they’re aiming for a realistic goal I think the patient
adhered to the change a little bit better. And then you see some
progress, so even if some things, we did . . . roll on a goal (over the
weeks) . . . we would see some improvement that gives people some
positivity that they’ve made a change, they can look on paper what
their goal was . . . it keeps patients real because they forget how
things were a week ago and actually you’ve made a change and
it’s better
H2CNS001
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TABLE 41 The process evaluation qualitative outcomes regarding the SMART intervention (continued )
Feasibility of intervention
delivery
Findings from the data: deliverability, acceptability, perceived
benefits, disadvantages
Mechanism of action: participant responses to and interactions with
the intervention, mediating factors, consequences
l The SMST in its entirety l Deliverability and acceptability of the SMST as a whole:
¢ This was a complex picture given the end-of-life context so
not all patients fully engaged with the SMST, additionally
complicated by the fact that the resources were frequently
not delivered as ideally desired
l The perceived benefit of the SMST as a whole:
¢ There was always some benefit, just that the level of benefit
was widely variable, of the SMST to the patient and carer
(but also additionally to the CNS):
– The goal-setting was the most frequently valued element
– There were often other elements that were also liked
(e.g. the pain diary)
– The factsheets often reinforced information provided by
the CNSs or that the patients already knew
– If the factsheets were not read by the patient they were
often valued by their carer
– The CNSs particularly valued the common concerns
factsheet
– The podcast films were valued by those who had been
provided with them
l Patient/carer responses:
¢ Range of responses from ‘we’ll treasure that’ (H1Pt001) and ‘it has
helped me, definitely’ (H3Pt041) to a minority of patients who did
not fully engage with it
¢ All patients used the goal-setting, but it was a core component of
the SMST
¢ The SMST appeared to become onerous, and therefore not fully
used, in the context of clinical depression
¢ For two patients, the resources were seen as ‘a bit too nice and tidy
actually. I thought ‘I will just scrawl all over them and make a mess
of them’. That’s probably why I’ve not used them to be honest,
because of my scatty writing’ (H3Pt002). For the other patient, she
ended up transcribing notes she had already written neatly into her
pain diary
l CNS responses:
It’s just a solid piece of evidence, rather than us just trying to explain
things to patients and sort of jot things down for them, they’ve actually
got information that we can leave with them that they can use . . . I’d
like to be able to use these tools with other people that come onto my
caseload. I think they are very useful
H4CNS003
To have all of this to give them, kind of backs up what we say, rather
than it’s just you talking to the patient, and then the minute you’ve left
the house they’ve got nothing then to hold on to
H4CNS001
I’d seen him once or twice and his wife became quite poorly, and so
then actually kind of utilising their folder was, they didn’t do it really.
And not because they didn’t want to . . . they hadn’t had the time . . .
when they’d wanted to
H4CNS001
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Feasibility of intervention
delivery
Findings from the data: deliverability, acceptability, perceived
benefits, disadvantages
Mechanism of action: participant responses to and interactions with
the intervention, mediating factors, consequences
Unfortunately things have gone from bad to worse with him (study
patient) deteriorating and X (carer) not being very well, I think it was just
perhaps a bit too much
H1CNS001
l Mediating factors:
¢ The complexity and illness of end-of-life patients meant that not all
patients benefited from the SMST themselves; however, the
resources were viewed as of value to others within the respective
families/households
¢ Frequently less than ideal delivery of the resources by the CNSs. This
had a major impact on the acceptability and benefit of the resources
as a result – particularly when they were not discussed or talked
through, and when all the factsheets were given all together as a
large file
¢ Difficulty given the unpredictability of end of life in providing the
intervention at the perfect time for patients (i.e. while they are well
enough to engage in it)
l Consequences:
¢ Overall, the SMST helped to provide suggestions for self-management
strategies and then evidence for patients, carers and CNSs as to
which strategies worked for the individual
¢ The SMST also stimulated appropriate questioning by the patient/
carer to the CNS. For example, ‘it’s been easy to ask questions’
(H1Pt001)
¢ Patients who were already effective self-managers prior to the trial
felt that they would have used the materials more if they had
received them earlier (at their first contact with their CNS). For
example, ‘I’ve been doing this for over a year. And a lot of the
things in here I knew. And frankly, I’m a very organised person, so
I’ve got all the diaries, and I’ve got all the prescriptions, and they’re
all online. Whereas it takes a while to get to that stage, to figure
out what you’re meant to be doing, how you’re meant to be doing
it’ (H3Pt002)
continued
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TABLE 41 The process evaluation qualitative outcomes regarding the SMART intervention (continued )
Feasibility of intervention
delivery
Findings from the data: deliverability, acceptability, perceived
benefits, disadvantages
Mechanism of action: participant responses to and interactions with
the intervention, mediating factors, consequences
l The four-step educational
approach and the SMST (i.e.
the intervention in its entirety)
l The deliverability of the intervention was seen as acceptable to
the CNSs who did not perceive that they needed any additional
skills to deliver it (i.e. it was viewed as a normal part of the
specialist role):
Not different from my normal job . . . I think it would be different
for a general nurse to do it, definitely
H1CNS001
¢ Yet ‘you learn from it and it just makes you do your things a
little better’ (H2CNS002) and ‘it just makes you think about
things more’ (H1CNS002)
l Perceived benefit of the intervention:
¢ Delivered within the complexity of delivery at end of life with
frequent deterioration of condition and depression
l Patient/carer responses:
I think it’s made us more aware that you must take your tablets, you
must take the Movicol [magrogol; Movicol®, Norgine Ltd, UK] and your
medication regular, and you know, keep everything under control . . . I
just issue them [the medicines], you know give them to [patient’s name]
as and when. I’m quite happy and confident to do it
H1Pt015-C
It’s felt easier for me to manage the medications, to try and understand
and ask questions
H4Pt023
¢ For those that were already effective self-managers of their analgesia
prior to the study and had been seeing their CNS for a matter of
months – ‘I’ve got the same level of understanding and nothing’s
changed there’ (H2Pt007), but the intervention stimulated more
questioning regarding the side effects of the medications
l CNS responses:
The study allowed them (the patient and carer) to think more broadly
about how they manage pain
H4CNS001
It was almost as if I was handing her responsibility for her regime, if you
like. So I was allowing her to have, she was making a much more
informed choice about what she took, when she was to take it, why she
was taking it. And also leverage in terms of parameters of medications,
so it wasn’t just ‘right take this at 6 o’clock’ it was ‘well actually you
could maybe try doing this, or you could try doing that’ and allowing her
to make those choices based on the literature
H3CNS002
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Feasibility of intervention
delivery
Findings from the data: deliverability, acceptability, perceived
benefits, disadvantages
Mechanism of action: participant responses to and interactions with
the intervention, mediating factors, consequences
l Mediating factors:
¢ Many patients already had pre-existing relationships with their CNSs
and had great confidence and trust in them and their abilities
¢ The confidence derived by patients and carers was in the face of
often complex medication regimes and decision-making processes
¢ Not all patients appeared to really benefit from the intervention – for
these the issue appeared to be one of timing, ‘I think it kind of came
too late’ (H3CNS001)
¢ For others suffering with depression the value of the intervention
was lessened as a result
l Consequences:
¢ All patients stated that they derived a benefit from the intervention
via face-to-face contact with their CNS (in the form of the four-step
educational process, although it varied as to how much the patients
knew about and acknowledged this process)
¢ The acceptability of the delivery of the intervention and resulting
benefit was increased for the patients and carers because of the
almost universal value that they placed in contact with their CNS
(particularly when face to face and in their own homes); for
example, ‘She’s very efficient when she comes, she’s probably here
an hour and we don’t stop talking, mainly about the meds and why
I’m doing all that. So that’s absolutely brilliant’ (H2Pt007)
¢ A minority of patients did not really engage with the SMST, but for
these patients their carer often did and they received a benefit from
the SMST
¢ Overall, the intervention was stated to generate confidence in the
patients, and carers, in their ability to manage their medicines, ‘My
understanding has increased a lot . . . I feel . . . happier with the
medication I’m on and how it works . . . I don’t think I’m on my own
being scared of taking a lot of medication . . . it’s put me at ease’
(H4Pt023); ‘And the confidence. You know now if I go to the
doctors, I would ask questions about medications and things’ (H4Pt023)
¢ The intervention facilitated patients appropriately adjusting doses of
medications, especially laxatives, and administering analgesia within
prescribed ranges (e.g. prophylactic use of breakthrough analgesia
prior to activities at the lower end of the range, compared with use of
breakthrough analgesia when in pain at the higher end of the range)
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Appendix 25 Definition of self-management and
professional roles
Johnston et al.’s definition of supported self-management in palliative care:51
Assessing, planning, and implementing appropriate care to support the patient to be given the means
to master or deal with their illness or its effects. Supported self-management in advanced disease, by
nurses, can, empower people to acknowledge the impact of their condition on their life, and enable
them, where possible, to face the range of challenges they may have, and identify areas where they
need further support, help or care. Therefore, for individuals it’s about being provided with the means
to master or deal with problems rather than relinquish them to others.
Johnston et al.51
Johnston et al.’s related professional roles:51
Self-Management Support: Professional Roles
1. Advocate – To support self-management and the right of palliative patients to receive appropriate
medicines to meet their symptom control needs
2. Educator – To provide instruction regarding medicines to allow patients to self-manage
3. Facilitator – To promote relationships between healthcare professionals and patient/carer to enable
effective access to and use of medicines
4. Problem Solver – To use expertise (underpinned by robust needs assessment) to work out whether
current medicines and dosages are appropriate, or whether they should be altered
5. Communicator – To facilitate communication between individuals e.g. encouraging a patient to
discuss their pain with their carer
6. Goal Setter – To identify specific goals that the patient wishes to achieve, and the methods to
achieve the goals. This is motivational and enhances self-management performance
7. Monitor – To observe and constantly re-assess self-management of medicines over time. This
requires evaluation of an individual’s capacity to self-manage vs. their willingness to engage
and compliance
8. Reporter – To gather information and report it e.g. at multidisciplinary team meetings
Johnston et al.51
These extracts are reproduced from Johnston et al.51 © Johnston et al.; licensee BioMed Central Ltd. 2014.
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Appendix 26 The SMART intervention costs
TABLE 42 The SMART toolkit content unit costs
SMART toolkit contents: unit title Quantity Pages Cost (£) Unit cost (£)
Goals folder 50 4 164.79 3.30
NCR sets 300 4 120.26 0.40
Folder (with insert and spine) 50 1 435.70 8.71
Checking opioid medicines are managing pain 50 4 116.64 2.33
Pain diary 50 4 116.64 2.33
Common concerns 50 4 116.64 2.33
Contacts and further information 50 4 116.64 2.33
Keeping on top of side effects 50 4 116.64 2.33
Organising opioid medicines 50 4 116.64 2.33
Fitting pain control into my daily routine 50 8 218.24 4.36
Getting prescriptions and obtaining medicines 50 8 218.24 4.36
Managing pain with opioid medicines 50 8 218.24 4.36
Medicine chart 50 8 218.24 4.36
Total SMART folders 2293.55 43.83
NCR, no carbon required.
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